The efficacy of Nopales (Opuntia Spp) on Lipoprotein Profile and Oxidative Stress among Moderately Hypercholesterolemic Adults by Pereira Pignotti, Giselle A. (Author) et al.
  
The efficacy of Nopales (Opuntia Spp) on Lipoprotein Profile and Oxidative Stress 
among Moderately Hypercholesterolemic Adults 
 
by 
 
Giselle Adriana Pereira Pignotti 
 
 
 
 
 
A Dissertation Presented in Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
Approved November 2013 by the 
Graduate Supervisory Committee: 
 
Sonia Vega-López, Chair 
Glenn Gaesser 
Colleen Keller 
Gabriel Shaibi 
Karen Sweazea 
 
 
 
 
 
 
 
 
ARIZONA STATE UNIVERSITY 
 
December 2013
i 
 
ABSTRACT 
Background: Evidence about the purported hypoglycemic and hypolipidemic effects of 
nopales (prickly pear cactus pads) is limited. Objective: To evaluate the efficacy of 
nopales for improving cardiometabolic risk factors and oxidative stress, compared to 
control, in adults with hypercholesterolemia.  Design: In a randomized crossover trial, 
participants were assigned to a 2-wk intervention with 2 cups/day of nopales or 
cucumbers (control), with a 2 to 3-wk washout period. The study included 16 adults (5 
male; 46±14 y; BMI = 31.4±5.7 kg/m2) with moderate hypercholesterolemia (low density 
lipoprotein cholesterol [LDL-c] = 137±21 mg/dL), but otherwise healthy. Main outcomes 
measured included: dietary intake (energy, macronutrients and micronutrients), 
cardiometabolic risk markers (total cholesterol, LDL-c, high density lipoprotein 
cholesterol [HDL-c], triglycerides, cholesterol distribution in LDL and HDL subfractions, 
glucose, insulin, homeostasis model assessment, and C-reactive protein), and oxidative 
stress markers (vitamin C, total antioxidant capacity, oxidized LDL, and LDL 
susceptibility to oxidation). Effects of treatment, time, or interactions were assessed using 
repeated measures ANOVA. Results: There was no significant treatment-by-time effect 
for any dietary composition data, lipid profile, cardiometabolic outcomes, or oxidative 
stress markers. A significant time effect was observed for energy, which was decreased in 
both treatments (cucumber, -8.3%; nopales, -10.1%; pTime=0.026) mostly due to lower 
mono and polyunsaturated fatty acids intake (pTime=0.023 and pTime=0.003, respectively). 
Both treatments significantly increased triglyceride concentrations (cucumber, 14.8%; 
nopales, 15.2%; pTime=0.020). Despite the lack of significant treatment-by-time effects, 
great individual response variability was observed for all outcomes. After the cucumber 
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and nopales phases, a decrease in LDL-c was observed in 44% and 63% of the 
participants respectively. On average LDL-c was decreased by 2.0 mg/dL (-1.4%) after 
the cucumber phase and 3.9 mg/dL (-2.9%) after the nopales phase (pTime=0.176). Pro-
atherogenic changes in HDL subfractions were observed in both interventions over time, 
by decreasing the proportion of HDL-c in large HDL (cucumber, -5.1%; nopales, -5.9%; 
pTime=0.021) and increasing the proportion in small HDL (cucumber, 4.1%; nopales, 
7.9%; pTime=0.002). Conclusions: These data do not support the purported benefits of 
nopales at doses of 2 cups/day for 2-wk on markers of lipoprotein profile, 
cardiometabolic risk, and oxidative stress in hypercholesterolemic adults. 
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CHAPTER 1 
INTRODUCTION 
1.1 Background  
Cardiovascular disease (CVD) continues to be the leading cause of death and 
morbidity among Americans (1). In 2008, one of every three deaths in the United States 
was attributed to CVD. In that same year, the total cost (direct and indirect) of CVD and 
stroke was estimated to be $297.7 billion, costing more than any other diagnostic group 
(2). CVD has a multi-factorial etiology with several potentially modifiable risk factors, 
and may be prevented with adequate changes in lifestyle. The American Heart 
Association (AHA) has published recommendations to promote cardiovascular health and 
prevent CVD that includes seven cardiovascular health behaviors or factors (smoking 
status, body mass index, dietary intake, physical activity, and levels of blood pressure, 
blood glucose, and total cholesterol) (3).  
Epidemiological studies have shown that risk factor modification can significantly 
reduce the risk of CVD incidence and mortality. In fact, 44% of the decline for coronary 
heart disease mortality in the United States from 1980 to 2000 was attributed to 
reductions in major risk factors (4). Although CVD mortality has declined over the past 
years, only 8% of US adults had a low risk profile for CVD during 1999-2004 (5). 
Likewise, the prevalence of meeting all seven CV health behaviors or factors at ideal 
levels as recommended by the AHA was only 2% in 1988-1994 and 1.2% in 2005-2010. 
In addition, only one in five adults followed two or more of the five dietary 
recommendations (consumption of fruits and vegetables ≥ 4.5 cups/d, fish ≥ two 3.5-oz 
servings/wk, fiber-rich whole grains ≥ three 1-oz–equivalent servings/d, sodium < 1500 
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mg/d, and sugar-sweetened beverages ≤36 oz/wk), while less than 1% followed four or 
more components of a healthy diet. Therefore, considerable improvement in CV health 
behaviors and factors remain to be achieved in order to significantly reduce CVD 
mortality (6).  
The metabolic syndrome (MS) is a cluster of metabolic abnormalities associated 
with increased risk for diabetes and CVD (7). Its components are abdominal obesity, low 
high density lipoprotein cholesterol (HDL-c), fasting hyperglycemia, 
hypertriglyceridemia, and hypertension; three out of five abnormal components qualify a 
person for the MS (8). The prevalence of MS in the United States was 34% from the 
combined 1999-2006 National Health and Nutrition Examination Survey (NHANES) 
data. Mexican Americans presented the highest rates, 37% of men and 43% of women 
had MS (9). Identifying individuals with the MS may help improve cardiovascular health 
through a more intensive intervention focusing on lifestyle risk factors (10). 
It is well established that dietary quality is an important contributor to chronic 
disease prevention (11). The intake of fruits and vegetables among most Americans is 
lower than the recommended five daily servings; in 2007 only 24% of Americans reached 
the suggested intake (12). Similarly, the average intake of total fiber in 2007-2008 was 
15.9 g/day, which is well below the recommended Adequate Intake (25 to 38 g/day or 14 
g/1,000 kcal/day) (13). This is of particular concern considering that dietary fiber, 
especially soluble fiber, is suggested to decrease cholesterol, blunt glycemic response, 
increase satiety and is associated with lower CVD risk (14).  
Elevated low density lipoprotein cholesterol (LDL-c) is associated with 
atherosclerosis development and increased CVD risk (15). The excessive uptake of 
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oxidized LDLs by macrophages in the arterial wall gives rise to foam cells and fatty 
streaks inducing the production of several pro-inflammatory molecules that can result in 
atherosclerotic lesion (16). Therefore, one of the mechanisms underlying the 
development and progression of atherosclerosis is increased oxidative stress. Oxidative 
stress is caused by an imbalance involving the production of reactive oxygen species 
(ROS) and impaired antioxidant capacity (17). The increased production of ROS results 
in cellular damage, and particularly affects endothelial cells (17-19). The production of 
ROS and antioxidant capacity can be modified to some extent by dietary factors 
(nutrients, phytochemicals and fatty acid composition). Studies have shown that dietary 
patterns characterized by low saturated fat, total fat, and cholesterol intake; and rich in 
fruits and vegetables are inversely associated with oxidative stress (20, 21).  
A recommended approach to reduce LDL-c is increasing soluble fiber intake 
(pectin, mucilages, and gums) (22). Incorporating food items that are a good source of 
fiber could potentially improve other biomarkers of cardiometabolic disease risk. In a 
recent crossover study, the addition of 102 g of oat bran per day (6 g/day of soluble fiber) 
for two weeks resulted in greater reduction in total cholesterol (14% vs. 4%), non-HDL 
cholesterol (16% vs. 3%) and triglycerides (21% vs. 10%) in comparison to a low fiber 
diet (23). 
A less explored approach to using a functional food to improve cardiometabolic 
disease risk is the consumption of nopales (prickly pear cactus pads from the Opuntia 
species). Nopales are vegetables low in fat, high in total fiber and soluble fiber (0.9 g/100 
g), and a good source of vitamin A, β-carotene, vitamin C, and phenolic compounds (24, 
25). Nopales are easily available in Hispanic food markets in the US (25). In a pilot study 
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conducted by our group, Mexican Americans who reported consuming nopales had a 
mean intake of roughly once per week (3.8 servings/month); 18% of this subgroup 
reported intake of up to 2.5 servings/week (375 g/week) (unpublished observations). 
 Because of their fiber content, nopales are commonly regarded among Mexicans 
as a medicinal plant for glycemic and cholesterol control. However, the literature 
documenting their purported hypocholesterolemic potential is scarce. A study conducted 
in healthy, obese and diabetic subjects showed that the consumption of 300 grams a day 
of nopales (2.7 g/day of soluble fiber) for 10 days led to significant reductions in total 
cholesterol (14%) and triglycerides (24%). In addition, a decrease by 22% in glucose 
levels was observed in diabetic subjects (26). Similar results were observed with the 
consumption of 250 g a day of prickly pear in hypercholesterolemic or hyperlipidemic 
individuals (27, 28). Besides the hypocholesterolemic effects, prickly pear has shown to 
lower oxidative stress as indicated by decreases in isoprostanes (plasma, serum and 
urinary), malondialdehyde, ratio of reduced to oxidized glutathione (GSH/GSSG) and 
conjugated dienes lipid hydroperoxide (27, 29). Comparable studies evaluating the effect 
of nopales cactus pads, instead of cactus fruit (prickly pear), on oxidative stress are not 
available.  
 
1.2 Purpose of Research 
In light of the high CVD morbidity and mortality, the promotion of simple 
interventions to improve serum lipids and decrease oxidative stress are warranted to help 
prevent chronic diseases. Given the unique composition and potential benefits of nopales, 
their use may be an ideal approach as an adjunct therapy for the reduction in 
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cardiometabolic risk factors. Therefore, the aim of this study was to evaluate the efficacy 
of a 2-week intervention with nopales pads for the reduction of established CVD risk 
factors (serum lipids) in comparison to a control food with lower antioxidant and fiber 
content (cucumber) among adults with moderate hypercholesterolemia in a randomized 
controlled crossover trial. Because limited data exists on the effects of nopales 
supplementation on other factors associated with cardiometabolic risk, an exploratory 
assessment of biomarkers of insulin sensitivity, inflammation (high sensitivity C-reactive 
protein [hsCRP]) and oxidative stress (LDL oxidizability and total antioxidant capacity) 
was also conducted.   
 
1.3 Hypotheses 
1.3.1 Central Hypothesis: Nopales intake (2.5 g/day of soluble fiber) versus control will 
improve the lipid profile in adults with moderate hypercholesterolemia as indicated by 
total cholesterol, LDL-c, HDL-c, triglycerides, LDL subfractions and HDL subfractions.  
Specific Aim 1: To explore the effect of nopales intake (2.5 g/day of soluble fiber)  on 
the lipid profile (total cholesterol, LDL-c, HDL-c, triglycerides, LDL subfractions and 
HDL subfractions) in adults with moderate hypercholesterolemia. 
1.3.2 Exploratory Hypothesis 1: Nopales intake (2.5 g/day of soluble fiber)  versus 
control will improve cardiometabolic risk factors associated with insulin sensitivity and 
inflammation in adults with moderate hypercholesterolemia as indicated by fasting 
glucose, insulin resistance, hsCRP, and blood pressure. 
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Specific Aim 2: To explore the effect of nopales intake on cardiometabolic risk factors 
(fasting glucose, insulin resistance, hsCRP, and blood pressure) in adults with moderate 
hypercholesterolemia. 
1.3.3 Exploratory Hypothesis 2: Nopales intake versus control will improve oxidative 
stress status in adults with moderate hypercholesterolemia as indicated by LDL oxidation, 
oxidized LDL, total antioxidant capacity and plasma vitamin C. 
Specific Aim 3: To explore whether nopales intake affects oxidative stress status (LDL 
oxidation, oxidized LDL, total antioxidant capacity and vitamin C) in adults with 
moderate hypercholesterolemia. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Cardiovascular Disease 
It is estimated that one in three American adults over 20 years of age have one or 
more types of CVD. More than 2 million Americans have a heart attack or stroke each 
year which over 800,000 die or one death every 39 seconds (2, 30). Despite a 30% 
decrease in heart disease death rates between 2000 and 2010, CVD continues to be the 
leading cause of death among Americans, with 24% of all deaths being from CVD in 
2010 (1). It was estimated in 2008 that the sum of direct and indirect costs of CVD and 
stroke was $297.7 billion (2). As the population ages, it is projected that in 2030 40.5% 
of the US population will have some form of CVD, compared to 37% in 2010. As a 
consequence, it is estimated that by 2030 direct costs will reach $818 billion and indirect 
costs $276 billion (31).  
Changes in lifestyle may prevent CVD as this is a multi-factorial disease with 
potentially modifiable risk factors. With the main goal to promote cardiovascular health, 
and prevent CVD and stroke by 20%, the AHA released the “Strategic Impact Goals for 
2020 and Beyond” report. This report comprises a set of health metrics that evaluate 
seven cardiovascular health behaviors or factors: 1) smoking status; 2) body mass index; 
3) healthy diet; 4) physical activity; 5) blood pressure; 6) blood glucose; 7) total 
cholesterol. Each category is classified into poor, intermediate and ideal. For the healthy 
diet factor, the report proposes the assessment of dietary quality based on the 
consumption of 5 dietary components: 1) fruits and vegetables ≥ 4.5 cups/d; 2) fish ≥ two 
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3.5-oz servings/wk; 3) fiber-rich whole grains ≥ three 1-oz–equivalent servings/d; 4) 
sodium < 1500 mg/d; 5) sugar-sweetened beverages ≤ 36 oz/wk). The information based 
in these metrics will help the AHA monitor changes in cardiovascular risk and focus in 
areas of greatest concern (3).  
According to NHANES data, the prevalence of meeting all seven AHA health 
metrics at ideal levels was only 2% in 1988-1994 and 1.2% in 2005-2010. In addition, 
only 20% of adults followed at least two dietary recommendations, while less than 1% 
followed four or five components of a healthy diet. Meeting a greater number of 
cardiovascular health metrics was associated with a decrease in mortality. In a fully 
adjusted model, those who met six or more health metrics had 51% lower risk of all-
cause mortality and a 76% lower risk of CVD mortality in comparison to those meeting 
only one health metric (6). Similar results were observed by Ford et al. using NHANES 
data (1999-2002). Meeting at least five heath metrics was associated with a 78% reduced 
risk in all-cause mortality and 88% reduced risk in circulatory system diseases mortality. 
Those with a healthy eating score classified as ideal had a 49% risk reduction in all-cause 
mortality in comparison to a poor healthy eating score (32). These epidemiological 
studies have shown how risk factor modification can significantly reduce all-cause and 
CVD mortality. In fact, 44% of the decline of coronary heart disease (CHD) mortality in 
the United States from 1980 to 2000 was attributed to reductions in major risk factors (4).  
Considerable improvement in CV health behaviors and factors remains to be achieved, 
and change in dietary factors is one of the components that can significantly reduce CVD 
mortality.  
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This chapter will discuss dietary interventions to promote cardiovascular health 
with an emphasis on fiber and antioxidants from food. First, an overview of lipoprotein 
metabolism and oxidative stress will be provided to highlight how disturbances in these 
systems can influence CVD risk.  
 
2.2 Cholesterol Metabolism 
Cholesterol is essential for cellular functions such as bile acid synthesis, cell 
membrane structure, and as a precursor of adrenal steroids, gonadal steroids, and vitamin 
D. Its structure is composed of one hydroxyl group, four hydrocarbon rings and a 
branched hydrocarbon chain forming cyclopentano phenanthrene (33, 34). Cholesterol is 
synthesized in most tissues and can also be acquired through the diet. Cholesterol is 
carried in lipoprotein particles as cholesteryl ester and free cholesterol (33, 35, 36). 
Dietary and pharmacological interventions are able to interfere with cholesterol synthesis, 
catabolism and absorption, consequently impacting circulating cholesterol levels (35). 
2.2.1 Cholesterol Synthesis 
The cholesterol synthesis or mevalonate pathway starts with Acetyl coenzyme A 
(Acetyl CoA). The third step of the pathway involves 3-hydroxy-3-methyglutaryl 
coenzyme A (HMG CoA) reductase, the rate limiting enzyme for cholesterol synthesis 
that converts HMG CoA into mevalonic acid. Phosphate groups are incorporated into 
mevalonate at the expense of ATP producing isopentenyl pyrophosphate, when 
rearranged, results in the formation of dymethylallyl pyrophosphate. The addition of 
dimethylallyl pyrophosphate and isopentenyl pyrophosphate forms farnesyl 
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pyrophosphate. The combination of two farnesyl pyrophosphate forms squalene that once 
oxidized and rearranged produces lanosterol. After 19 reactions lanosterol is converted to 
cholesterol (34, 37). This process is energetically expensive, therefore cholesterol 
biosynthesis is tightly regulated. For instance, an increase in dietary cholesterol intake 
will down regulate hepatic cholesterol synthesis (37).  
As the pool of cholesterol in the liver increases, the release of sterol regulatory 
element binding protein (SREBP) is inhibited. SREBP is involved in the transcription of 
genes involved in cholesterol metabolism, such as the LDL receptor and cholesterol 
biosynthesis enzymes, including HMG CoA reductase. Therefore, suppressing the release 
of SREBP will down-regulate LDL receptor expression and cholesterol biosynthesis. 
Down-regulation of LDL receptor causes LDL to be retained in plasma (38). At the same 
time that SREBP stimulates LDL receptor, expression it also enhances lipid synthesis, the 
balance between these opposing effects will influence circulating cholesterol 
concentrations (39).  
2.2.2 Cholesterol Catabolism 
Another pathway contributing to the maintenance of cholesterol homeostasis is 
the catabolism in the liver of cholesterol into bile acids, which are important emulsifiers 
involved in the process of lipid digestion (40). The first reaction involved in the classic 
pathway of bile acid synthesis is the hydroxylation of cholesterol by cholesterol 7α-
hydroxylase (CYP7A1) encoded by the gene CYP7A1. Similar to HMG CoA reductase, 
CYP7A1 is a rate limiting enzyme. Bile acids exert a negative feedback on their own 
synthesis by inhibiting the expression of CYP7A1, again showing a tight regulation on 
cholesterol homeostasis. Whether dietary cholesterol inhibits or induces the expression of 
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CYP7A1 is still under debate, as a large variability in the response is observed depending 
on the animal model used (40).  
Once released from the gallbladder, bile acids enter the enterohepatic circulation 
and can be either reabsorbed in the intestines or excreted in feces. One of the main 
mechanisms underlying the LDL-c lowering effect of fibers, plant sterols and some drug 
therapies is the interruption of the enterohepatic circulation of bile acids by inhibiting 
absorption. To counterbalance fecal bile acid loss, a higher proportion of cholesterol is 
converted into bile acids, leading to a decrease in LDL-c concentration (34, 40). Although 
the intraluminal cholesterol available for absorption is derived from both diet 
(exogenous) and bile (endogenous), the majority of cholesterol is derived from bile. In 
fact, the diet is thought to contribute with only 200 to 600 g per day of cholesterol to the 
intraluminal pool, while 800–1200 g per day of cholesterol is derived from bile (35, 41). 
Therefore inhibiting bile acid reabsorption can significantly impact hepatic cholesterol 
homeostasis.  
2.2.3 Cholesterol Absorption 
Dietary cholesterol is a lipid with a variable proportions of free and esterified 
cholesterol. Cholesteryl ester (10 to 15% of dietary cholesterol) requires hydrolysis by 
cholesterol esterase to a non-esterified form, as only free cholesterol is absorbed in the 
intestinal lumen (41). Due to its hydrophobic nature, free cholesterol needs to be 
incorporated into bile salt micelles which act as carriers and solubilizers prior to 
absorption (35, 36). Besides free cholesterol, micelles also carry triglycerides, 
monoacylglycerides, phospholipids, and fatty acids (36).  
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Micelle absorption in the proximal jejunum occurs by passive diffusion and 
protein-mediated processes. The Niemann-Pick C1-like 1 protein (NPC1L1) is the main 
transporter identified for cholesterol absorption. Other carriers involved in cholesterol 
absorption include the scavenger receptor B-I, and CD36 (35, 42). NPC1L1 is located at 
the brush-border membrane of the enterocyte, and its inhibition decreases the absorption 
of cholesterol and other sterols. In contrast to the NPC1L1 action, two ATP-binding 
cassette transporters (ABCG5 and ABCG8) are involved in cholesterol and plant sterols 
efflux back to the intestinal lumen (42). This results in limited cholesterol and phytosterol 
absorption, causing excretion of unabsorbed sterols (42, 43). Once cholesterol enters the 
enterocyte, it undergoes a re-esterification process by acyl-coenzyme A:cholesterol 
acyltransferase 2 (ACAT 2) forming cholesteryl esters. About 70 to 80% of the 
cholesterol that reaches the lymph is esterified. While non-esterified cholesterol is more 
likely to be transferred back to the intestinal lumen via ABCG5 and 8, cholestereryl ester 
is incorporated into nascent chylomicrons and is released into the lymph, indicating that 
ACAT 2 is involved in an important step of cholesterol absorption. (33, 44). 
Dietary factors may reduce cholesterol absorption through different mechanisms. 
Plant sterols (phytosterols and stanols) compete with cholesterol for limited micellar 
solubilization and interfere with transporter-mediated processes of cholesterol uptake (35, 
45). While dietary fiber can bind to bile acids in the intestines and increase fecal 
excretion (35). This last mechanism will be further explained later in this chapter. 
According to the National Cholesterol Education Program Adult Treatment Panel III 
Report, 2 g/day of plant sterols and 5 to 10 g/day of viscous fiber reduces LDL-c by 6 to 
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10% and 3 to 5% respectively (46). Therefore dietary interventions are a major 
component of primary risk prevention of CVD (47). 
2.3 Lipoproteins  
Lipoproteins are three-dimensional structures that carry lipids and protein in 
plasma and are fundamental for lipid transport in the circulation. The structure of 
lipoproteins consists of a hydrophobic core comprised of cholesteryl esters and 
triglycerides, surrounded by a monolayer of phospholipids, unesterified cholesterol and 
apolipoproteins (Apo As, Apo Bs, Apo Cs, Apo D and Apo E). Lipoproteins are 
heterogeneous according to particle size, density, shape, content and function. The major 
lipoprotein classes according to physical-chemical characteristics are high-density 
lipoprotein (HDL), low-density lipoprotein (LDL), intermediate-density lipoprotein 
(IDL), very low-density lipoprotein (VLDL), and chylomicrons (33).  
Lipoproteins are dynamic in nature and constantly exchange molecules (lipids and 
apoproteins) among each other altering their physical and chemical properties (33). This 
remodeling process involves the cholesteryl ester transfer protein (CETP) and the enzyme 
lecithin cholesterol acyl transferase (LCAT) (48). CETP transfers cholesteryl ester in 
exchange for triglycerides from HDL to LDL and other Apo B-containing lipoproteins 
(48, 49). LCAT is involved in the esterification of cholesterol in HDL particles promoting 
cholesteryl ester migration into the HDL core and further cholesterol efflux from tissues 
into HDL. This is important to cholesterol transport from the peripheral tissues to the 
liver (48, 50). 
 
14 
 
2.3.1  Lipoprotein Metabolism 
Chylomicrons are the largest lipoproteins (75 – 1200 nm) and have the lowest 
density (0.95 g/dL) (33). They are synthesized in the intestine and require Apo B-48 to be 
assembled and secreted by mucosal cells into the lymph (38). They can also have other 
apoproteins including C-I, C-II, C-III, A-I, A-II and E (33). Chylomicrons acquire 
apoproteins, and free and esterified cholesterol mainly from HDL particles. Their main 
function is to transport dietary fat, mainly triglycerides (90% of its content) to the liver. 
While in circulation, triglycerides from chylomicrons are hydrolyzed by lipoprotein 
lipase (LPL) producing chylomicron remnants, a process that is activated by Apo C-II. 
The chylomicron remnants are quickly removed from circulation via a LDL-like receptor 
protein in the liver that can recognize Apo E and Apo B (33, 51). The half-life of 
chylomicrons in healthy subjects is short, approximately 4.8 hours (52).  
Endogenous cholesterol is transported from the liver to the cells by Apo B 
containing lipoproteins (VLDL, IDL, and LDL). First, VLDL is synthesized in the liver 
and requires Apo B-100 for its assembly and secretion (51). This is a large lipoprotein 
(30-80 nm) with a low density (0.95 – 1.006 g/dL) (33). Besides one non-exchangeable 
Apo B-100, VLDL has Apo C-I, II and III and Apo E, mostly acquired from HDL 
particles. This lipoprotein carries mostly triglycerides (50 to 60%) to extrahepatic tissues 
and is the main carrier of triglycerides in the fasting state. The triglycerides in its core are 
converted to free fatty acid and mono/diglyceride as is hydrolyzed by LPL, allowing the 
uptake of free fatty acids by peripheral tissues (51, 53). This causes VLDL to become 
denser and smaller, giving rise to IDL (25-35 nm; 1.006 – 1.019 g/dL). This lipoprotein 
has a short half-life and is removed from circulation when recognized by LDL receptors 
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in the liver via Apo B and E (33, 51). Impaired clearance of chylomicron remnants may 
prolong the circulation time of VLDL particles due to a decrease in the availability of 
lipoprotein lipase (LPL), which hydrolyses triglycerides (53).   
When IDL is not taken up by the liver, triglycerides in its core are further 
hydrolyzed by hepatic lipase (HL) and LPL producing LDL, the major cholesterol carrier 
in the circulation (51). The residence time of VLDL is approximately 3.6 hours and about 
50% is converted into LDL, whereas the residence time of LDL is nearly 3.6 days (52). In 
comparison to VLDL, LDL has smaller size (18-25 nm) but higher density (1.019 – 1.063 
g/dL) (33). Because it is derived from VLDL, its major protein is apo-B-100, its lipid 
core contains mainly cholesteryl ester and unesterified cholesterol (38). LDL particles are 
removed from circulation by LDL-receptors in the liver.  
Lastly, HDL is the lipoprotein smallest in size (5-12 nm) and highest in density 
(1.063-1.21 g/dL) (33). Apo A-1 is its main protein (about 60%), in addition to Apo A-II, 
Apo A-IV, Apo CI-III, and Apo E. This is the only lipoprotein that does not carry Apo B 
(54). Nascent HDL is generated from Apo-AI secreted in the liver and intestines and is 
poor in cholesterol, but acquires phospholipids and free cholesterol quickly from extra-
hepatic tissues. (49). 
HDL is known to have anti-atherogenic actions, the main one being related to 
reverse cholesterol transport (49). In this process, HDL mediates the efflux of cholesterol 
from foam cells of extrahepatic tissues back to the plasma and eventually to the liver. 
This represents a critical step in the prevention or reversal of atherosclerosis (55). ATP 
binding cassette A1 (ABC1) is a transporter that, in combination with lipid poor apo-A1, 
promotes the efflux of free cholesterol from macrophages and extra hepatic tissues 
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forming nascent HDL. Free cholesterol is esterified by lecithin-cholesterol 
acyltransferase (LCAT), producing mature HDL particles. HDL particles become larger 
through the uptake of free cholesterol from macrophages and endothelial cells by 
ABCG1-mediated cholesterol efflux.  Cholesteryl ester from the core of HDL can be up-
taken by the scavenger receptor B1 (SR-B1) in the liver or transferred to apo-B 
containing lipoprotein in exchange for triglycerides in a process mediated by CETP (51, 
55). Cholesterol in the liver can be recycled, used to produce sterols or excreted from the 
body in bile (38). 
2.3.2  LDL Heterogeneity and Small, Dense LDL Particles 
It is well known that an increased LDL-c concentration is highly correlated with 
CVD (56). However, lipoproteins are heterogeneous according to particle size, density 
and composition. Therefore, there is increasing attention to the relationship between 
lipoprotein subfractions and CVD risk (57).  
Several approaches can be used to classify LDL particles. When based on their 
density, they tend to be grouped into large LDL particles (>213 Å), which are less 
atherogenic, and small, dense LDL particles (<212 Å). For individual subfractions, 
generally seven major LDL subclasses are identified. LDL-1 is the largest and least 
dense, and LDL-7 is the smallest and most dense. (58). In addition, the LDL is 
recognized to have three different phenotypes: phenotype A is characterized by a 
predominance of large LDL particles; phenotype B is characterized by small LDL 
particles; and an intermediate phenotype is a mix of patterns A and B (59). Phenotype B 
is often associated with increased triglycerides and decreased HDL-c concentrations, a 
condition also known as atherogenic lipoprotein phenotype (60). 
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It is recognized that small, dense LDL particles are more atherogenic than larger 
buoyant LDL particles. Small, dense LDL has been associated with numerous chronic 
diseases. In a case control study, type 2 diabetes has been associated with a twofold 
increase in the frequency of LDL phenotype B in comparison to healthy controls (61). 
Similarly, patients with metabolic syndrome showed significantly higher concentrations 
of small, dense LDL than individuals without this syndrome. Additionally, the 
concentration of cholesterol in small, dense LDL was directly related to the number of 
components of metabolic syndrome (62). Results from the Stanford Five-City Project 
showed significant smaller LDL peak particle diameter in patients with coronary artery 
disease (CAD, 26.2 ± 1.0 nm) compared with age, gender and ethnicity matched-controls 
(26.7 ± 0.9 nm) (63). In the Quebec Cardiovascular Study, after 5 years of follow-up, a 
2.2-fold increased risk of ischemic heart disease was observed in men with smaller LDL 
particle size (<256 Å) compared to those with larger LDL particles (64).  After 13 years 
of follow-up, the same study showed that this relationship was attenuated, especially if 
follow-up was longer than 7 years, indicating that small dense LDL phenotype may be a 
better predictor in the short term (65). 
Alterations in the VLDL-IDL-LDL pathway as a result of diet, chronic disease or 
genetics will affect the LDL phenotype (66). For instance, insulin resistance or defects in 
adipose tissue can lead to an increase in free fatty acid levels, causing a greater uptake of 
free fatty acids by the liver. Consequently, the liver increases triglyceride and VLDL 
production and decreases Apo B hydrolysis (66, 67). An overproduction of VLDL is 
generally followed by an overproduction of IDL and LDL (66). As a result of the 
increased pool of triglyceride-rich VLDL, a greater exchange of triglycerides in VLDL 
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for cholesteryl ester in LDL takes place, mediated by CETP, producing cholesterol-
depleted and triglyceride-enriched LDL. Subsequently, the triglyceride-enriched LDL is 
hydrolized by hepatic lipase and LPL, producing small, dense LDL particles. This 
process is generally accompanied by an exchange of cholesteryl ester in the HDL core for 
triglycerides leading to a triglyceride-enriched but cholesteryl ester-depleted HDL, which 
is more rapidly up-taken by the liver (51, 66, 67). The decreased removal of postprandial 
triglyceride-enriched lipoproteins (chylomicrons and chylomicron remnants) further leads 
to the formation of small, dense LDL because chylomicrons compete with VLDL for 
LPL, increasing the residence time of VLDL in the circulation (67). 
There are several mechanisms that explain the atherogenic properties of small, 
dense LDL. The LDL receptor has a lower affinity for small, dense LDL compared to 
larger LDL particles, resulting in longer residence time in plasma for the former particles. 
In contrast, the small, dense LDL has a greater affinity for the scavenger receptor 
involved in the formation of foam cells and atherosclerosis (67). Additionally, the 
prolonged residence time and lower vitamin E content causes small, dense LDL particles 
to be more susceptible to oxidation and glycation (67, 68).  Also, these particles can enter 
the arterial wall more readily and their high affinity for proteoglycans results in 
prolonged residence time in the vascular wall (68). Lastly, small dense LDL particles 
promote endothelial dysfunction by stimulating the production of plasminogen activator 
inhibitor I (PAI-I) and thromboxane A2 (67, 68).  
Although small, dense LDL has been consistently related to CVD risk, most 
studies have not confirmed this LDL subfraction as an independent risk factor for CVD 
(69). Krauss et al. has pointed out that studies using the gradient gel electrophoresis 
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method have been more consistent in showing the benefits of assessing LDL subfractions, 
even after adjusting for other covariates (70). Nonetheless, the National Cholesterol 
Education Program Adult Treatment Panel III (NCEP ATP III) has included increased 
small, dense LDL as an emerging CVD risk factor (71).  
2.3.3 HDL Heterogeneity 
Having increased levels of large HDL particles may be an indicator of efficient 
reverse cholesterol transport due to the ability to carry more cholesterol in their core. 
Studies have shown an inverse relationship between low levels of large HDL particles 
and CVD risk (72-74). In the Framingham Offspring Study, patients with CHD had 
significantly lower concentrations of very large HDL and higher levels of very small 
HDL when compared to all healthy controls or low-HDL-c matched controls. In addition, 
the amount very large HDL had the strongest inverse association with CHD showing that 
for each mg/dl of very large HDL increase there was significant decrease in coronary 
heart disease (CHD) odds ratio by 26% (72). Similarly, among patients with low HDL-
cholesterol concentrations as their primary lipid disorder in the Veterans Affair HDL 
Intervention trial (VA-HIT), having low levels of large HDL particles was a better 
predictor of CAD risk than HDL cholesterol concentrations (73). Recent results from a 
long follow-up study have demonstrated that both large and small HDL particles were 
inversely related to CHD risk; however a greater CHD risk reduction was associated with 
large HDL (74).  
Besides the large HDL particles, some studies have acknowledged that small HDL 
particles may be inversely related to CHD risk while other studies have found no 
significant differences between HDL subfractions and CVD risk (75-77). Another study 
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using the VA-HIT follow-up data observed that the small HDL subclass, which 
constituted the majority of the total HDL particles in the sample studied, was associated 
with lower CHD risk (76). In the Caerphilly Study, total HDL-c and small HDL-c, but not 
large HDL-c, were inversely associated with CHD risk incidence. However, total HDL-c 
alone was a better predictor than both subfractions (75). Results from the Women’s 
Health Study showed that women with CVD had significantly smaller HDL particles. 
However, HDL subfractions (large, medium or small) did not confer additional 
predictability for CVD. The best predictor of CVD was the total/HDL cholesterol ratio 
(77).  
Some of the conflicting results described above might be explained by the fact 
that the multiple biological activities of HDL may be related to specific subfractions of 
HDL, as recently reviewed by Camont et al. (2011). Anti-oxidative activity has been 
linked to small, dense HDL that showed an increased ability to protect LDL from 
oxidative damage. It is suggested that the composition of small HDL has diminished 
sphingomyelin and free cholesterol. This confers increased fluidity to the lipid surface of 
the small HDL, facilitating the incorporation of oxidized lipids. The anti-inflammatory 
activity of HDL is also associated with small HDL, which seems to be related to 
differences in phospholipids composition. Phospholipids with variable fatty acid chain 
length and unsaturation differ in their ability to inhibit inflammation. Some of the effects 
includes inhibition of monocyte activation and adhesion to the endothelium and 
inhibition of adhesion molecule expression in endothelial cells. Both large and small 
HDL particles are associated with antithrombotic activity. Large HDL is involved with 
inhibition of platelet aggregation and small HDL presents an anticoagulant activity. In 
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addition, the vasodilatory activity is associated with large HDL which attenuates the 
production of thromboxane A2, a vasoconstrictor. Finally, cholesterol efflux from 
macrophages can be mediated by ABCA1 and is related to small, dense HDL, which also 
activates LCAT. The large HDL promotes cholesterol efflux from macrophages thorough 
ABCG1 and SR-B1 (78). 
 
2.4 Oxidative Stress 
Oxidative stress has been implicated as the underlying cause in the development 
and progression of atherosclerosis (79). The process of oxidative stress takes place when 
the generation of ROS exceeds the protective capability of the antioxidants defense. This 
process can be induced by hyperglycemia, free fatty acids and insulin resistance. ROS are 
highly reactive due to their atomic structure containing one or more unpaired electrons 
such as the superoxide anion (O2
-), hydrogen peroxide (H2O2), hydroxyl radical (OH
-) 
and peroxynitrite (OONO-). The increased production of ROS results in protein, lipid and 
DNA damage, and particularly affects endothelial cells (19). The antioxidant defense is 
composed of non-enzymatic compounds, such as vitamins (A, C, and E) and minerals 
(copper, zinc, and selenium), and enzymatic mechanisms like superoxide dismutase 
(SOD), catalase and glutathione peroxidase (18, 19). 
ROS have important biological functions by assisting the immune system, 
mediating cell signaling and playing a critical role in apoptosis (80). However, substantial 
evidence shows that excess ROS formation is associated with chronic diseases such as 
diabetes and CVD. Davi et al., have reported significantly higher oxidative stress in 
patients with Type 1 and Type 2 diabetes by approximately twofold in comparison to age-
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matched controls (81). In a case-controlled study, Monnier et al., observed a higher 
production of 8-iso prostaglandin F2, a marker of oxidative stress, in patients with 
diabetes compared to healthy controls, as well as a significant relationship between 
glucose fluctuations and oxidative stress activation (r=0.86, p>0.001) (82). In addition, 
markers of oxidative stress are higher in subjects with CHD, and might be employed to 
evaluate the status of chronic heart failure (HF) (83). According to Nagayoshi et al., in a 
study that evaluated oxidative stress in subjects with and without CHD, increased levels 
of urinary 8-hydroxy-2´-deoxyguanosine, and in vivo oxidative DNA damage were 
associated with the severity of HF and the progression of atherosclerosis (84). 
2.4.1  Reactive Oxygen Species Sources 
Enzymes from numerous cells have the ability to constantly produce low levels of 
ROS. These enzymes, including nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase, xanthine oxidase and uncoupled nitric oxidase synthase (NOS), are tightly 
regulated under normal conditions. Under certain disease conditions, such as 
atherosclerosis, diabetes, and hypertension, excessive superoxide production takes place 
(85-87).  
NADPH oxidase is an important source of superoxide in endothelial and smooth 
muscle cells. This enzyme helps regulate intracellular signaling cascades. However, the 
over-stimulation of NADPH oxidase by angiotensin II, thrombin, platelet-derived growth 
factor, TNF-α and sheer stress causes an increase in superoxide production (85, 86). The 
xanthine oxidase is present in circulation and endothelial cells, producing superoxide and 
hydrogen peroxide stimulated by cytokines (87). This enzyme seems to be a major 
contributor to oxidative stress in ischemia and reperfusion injuries (85). Another source 
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of superoxide is the mitochondrial transport chain. The increase in the electron donors 
flux into the electron transport chain can be stimulated in endothelial cells by angiotensin 
II, oxidized LDL, protein kinase C, and high glucose and free fatty acids levels. Once the 
voltage across the mitochondrial membrane reaches the critical threshold, the electron 
transfer is blocked causing the electron to be donated to an oxygen molecule, thus 
producing superoxide (85, 87). Lastly, increased NOS is involved in ROS production in 
endothelial cells. Nitric oxide (NO) is an endothelium-derived relaxing factor with anti-
atherosclerotic properties. NO has the capability to inhibit platelet aggregation, 
proliferation of smooth muscle cells, and the expression of adhesion molecules. These 
processes are involved in the development and progression of atherosclerosis. Increased 
NOS may indicate a limited capacity of the enzyme to produce NO (87). Under certain 
conditions, NO can be converted to various reactive nitrogen species, such as 
peroxynitrite. The uncoupling of NO is associated with atherosclerosis, 
hypercholesterolemia, diabetes and hypertension (86).  
2.4.2 Antioxidant Sources 
Antioxidants are molecules or systems that can delay or inhibit a biological target 
against oxidative damage. The antioxidant defense system is composed of enzymatic and 
non-enzymatic mechanisms that work in synergy with each other to counteract free 
radicals (18, 88, 89). Mechanisms of action include catalytic removal of ROS, binding of 
proteins to pro-oxidant metal ions, protection against protein damage, and reduction of 
free radicals by electron donors (88, 90).  
The major enzymes involved in the antioxidant defense system are SOD, catalase 
and glutathione peroxidase. SOD converts superoxide into hydrogen peroxide, reducing 
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the chance of peroxynitrite formation from the reaction with nitric oxide. This enzyme 
utilizes transition metals such as copper, zinc and manganese, as cofactors in its active 
sites. Subsequently, catalase converts hydrogen peroxide produced by SOD into water 
and oxygen, preventing the formation of hydroxyl radical. Glutathione peroxidase (GSH-
Px), which is selenium dependent, also removes hydrogen peroxide by coupling its 
reduction with the oxidation of GSH (reduced form of glutathione) to GSSG (oxidized 
form of glutathione). Glutathione is important for the regeneration of vitamins C and E 
(18, 88, 90, 91). 
The human diet has several compounds known for their antioxidant properties 
such as ascorbate (vitamin C), tocopherols (vitamin E), carotenoids, and polyphenols 
(88). Minerals, such as selenium, copper, zinc, and manganese act as cofactors for 
antioxidant enzymes (90). Ascorbic acid is a water-soluble vitamin found in fruits and 
vegetables, especially citrus fruits, peppers, kiwi, cherries, melons, tomatoes, leafy 
greens, broccoli, cauliflower, brussels sprouts, and kale. Ascorbic acid is able to scavenge 
oxygen and chelate pro-oxidant metal ions such as Fe2+ and Cu2+. When ascorbic acid is 
oxidized by ROS it is transformed into dehydro-ascorbate, which can be recycled back 
into ascorbic acid by the enzyme dehydro-ascorbate reductase (88). Ascorbic acid is also 
capable of regenerating tocopherol from the tocopheroxyl radical generated in LDL 
particles from inhibiting lipid peroxidation (92). Tocopherols are lipid soluble vitamins 
found in vegetable oils (soybean, sunflower, olive oil), wheat germ, nuts, and some green 
leafy vegetables (88). The most active form of vitamin E is α-tocopherol. Its main 
function is to inhibit lipid peroxidation by scavenging peroxyl radicals and preventing 
further reactions (88, 93). Carotenoids are lipid soluble vitamins present in fruits and 
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vegetables, such as carrots, tomatoes, citrus fruits, spinach and corn (88). Their 
antioxidant properties are related to the ability to scavenge radicals and quench singlet 
oxygen atoms (94). Polyphenols (flavonoids and phenolic acids) are a group of 
compounds known for their water soluble antioxidant properties. Over 8,000 different 
polyphenolic compounds have been described and are found in plant foods and their 
products, such as chocolate, green tea, berry and wine (91, 95). The antioxidant effects of 
polyphenols are related to free radical scavenging activities, through which free radicals 
are converted to a relatively harmless form, and to the chelation of pro-oxidant metal ions 
(96). 
In summary, the most common non-enzymatic antioxidant mechanisms are: (1) 
free radical scavenging activity; (2) chelation of pro-oxidant metal ions such as Fe2+ and 
Cu2+, preventing Fenton reactions; (3) quenching singlet oxygen; (4) breaking the free 
radical chain reaction; and (5) reducing local oxygen concentrations (97). In addition, 
there is evidence of indirect antioxidant effects. One example is that polyphenols can up-
regulate endogenous antioxidant enzymes such as SOD, catalase and glutathione 
peroxidase. Another mechanism is the modulation of cell signaling of inflammatory 
pathways such as the down-regulation of nuclear factor-kappa B (NF-κB), which will 
inhibit several cytokines. Finally, changes in chromatin remodeling through the activation 
of histone deacetylase will inhibit the expression of pro-inflammatory genes (98, 99). 
There is an increasing interest in the Total Antioxidant Capacity (TAC) which 
accounts for the cumulative action of all antioxidants available in plasma and body fluids. 
This measurement provides information on the antioxidant capacity of known and 
unknown compounds and their synergistic effects. Different methods have been 
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developed to measure the TAC, including total radical-trapping antioxidant parameters 
(TRAP), oxygen radical absorbance capacity (ORAC), trolox equivalent antioxidant 
capacity (TEAC), and ferric reducing ability of plasma (FRAP) (100).  
2.4.3  Oxidized LDL 
Oxidative stress causes damage to several biological components including lipids, 
protein and DNA. Of particular importance is the lipid oxidation that occurs in LDL, 
producing oxidized LDL (OxLDL). Lipid peroxidation has been shown to initiate and 
accelerate the atherosclerotic process (17, 101, 102). Increased OxLDL concentrations 
are associated with several chronic diseases such as CVD (101, 103), type 2 diabetes 
(104, 105), and metabolic syndrome (106).  
In a cross-sectional study OxLDL was positively correlated with acute coronary 
syndrome severity. In a sequence of highest to lowest OxLDL concentrations were 
individuals with acute myocardial infarction, followed by unstable angina pectoris, stable 
angina pectoris, and healthy control (101). Similarly, Weinbrenner et al. observed that 
individuals with stable CHD had 67% higher concentrations of OxLDL compared to sex-
matched healthy controls (103). In diabetic patients, OxLDL was positively related to 
diabetes duration. An OxLDL concentration of those with prolonged diabetes was almost 
two times higher compared to newly diagnosed patients, even with LDL-c maintained at 
a desirable level (105). Results from the Coronary Artery Risk Development in Young 
Adults (CARDIA), a population-based 15-year follow-up study, showed that increased 
OxLDL was significantly associated with incidence of Metabolic Syndrome. Individuals 
in the upper quintile of OxLDL were 3.5 times more likely to develop Metabolic 
Syndrome than individuals in the first quintile. When evaluating each Metabolic 
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Syndrome components individually, central obesity, hyperglycemia, and 
hypertriglyceridemia were associated with increased OxLDL (106). 
The process of LDL oxidation is progressive and causes the formation of mildly 
to extensively OxLDL (107). Monocytes migrate into the subendothelial space where 
they can differentiate into macrophages that are able to incorporate lipoproteins. OxLDLs 
are readily taken up by macrophages due to their increased affinity to receptors such as 
the scavenger receptor A1 (SR-A1), CD36, and the lectin-like oxidized low-density 
lipoprotein receptor (LOX-1) (16, 108). This leads to the accumulation of cholesterol in 
the macrophages, which eventually results in foam cell formation. Fatty streaks are 
formed by the accumulation of foam cells in the subendothelial space, leading to 
endothelial inflammatory response and atherosclerotic lesion development (16). OxLDL 
contributes to the formation of a fibrous cap over the fatty streak and stimulation of the 
fibrous cap rupture (109). In addition, OxLDL induces toxic effects in all stages of 
atherosclerosis including endothelial cell apoptosis, increased expression of adhesion 
molecules, impairment of eNOS activation, and increased formation of platelet clots 
(107, 109). For those reasons, OxLDL is more pro-atherogenic than native unmodified 
LDL. Therefore, strategies to decrease LDL oxidation may prevent the development and 
progression of atherosclerosis (109, 110).  
2.5 Dietary Interventions and Cardiovascular Disease Risk 
Dietary quality contributes to chronic disease prevention and diet is an important 
modifiable risk factor (3, 11). The Dietary Guidelines for Americans (111) and the AHA 
(47) recommend increased intakes of fruits, vegetables and whole grains. However, the 
intake of fruits and vegetables among most Americans is lower than the recommended 
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five daily servings. For example, in 2007 only 24% of Americans reached the suggested 
intake (12). Similarly, the mean intake of total fiber in 2007-2008 was of 15.9 g/day, well 
below the recommended Adequate Intake (25 to 38 g/day or 14 g/1,000 kcal/day) (13). 
The health benefits of fruits and vegetables can be partially explained by the presence of 
antioxidant vitamins, phytochemicals and fiber. Therefore, the impact of dietary 
interventions on cardiovascular outcomes with an emphasis on naturally occurring dietary 
fibers and antioxidants will be further discussed. 
2.5.1  Dietary Fiber 
Dietary fibers are oligosaccharides, polysaccharides and lignin that are resistant to 
digestion and absorption in human’s small intestine (112). The main sources of dietary 
fiber in the human diet are fruits, vegetables, cereal products, and legumes. Dietary fiber 
can be categorized according to its chemical and physical properties, particularly water 
solubility. Soluble fiber, also known as viscous fiber, causes gel formation and 
fermentation. Examples of this type of fiber include pectin, β-glucans, gums, and 
mucilages. Lignins, cellulose, and hemicellulose are examples of insoluble/nonviscous 
fiber (113). 
Observational studies have shown an association between fiber intake and lower 
CVD incidence and mortality (114-117). In a population-based cohort study in which 
older (>65 years of age) men and women free of chronic disease at baseline were 
followed for almost 9 years, cereal fiber intake was associated with a 21% lower risk of 
incident CVD comparing the highest with the lowest quintile intake. However the same 
relationship was not observed with fiber provided by fruits and vegetables (114). Similar 
results were observed for mortality risk by the National Institutes of Health–American 
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Association of Retired Persons Diet and Health Study, during a 9 year follow-up. Dietary 
fiber intake was significantly associated with a lower risk of all-cause mortality, showing 
a 22% risk reduction for men and women in the highest fiber intake quintile compared to 
the lowest quintile. In addition, higher dietary fiber intake was associated with lower 
cardiovascular mortality risk by 24% in men and 34% in women. However, when 
evaluating specific sources of fiber, only grains were consistently associated with lower 
risk of total and cause-specific mortality (115). Bellavia et al. evaluated the dose-
response relationship between fruit and vegetable intake and all-cause mortality during a 
13-year follow-up study. Not consuming fruits and vegetables was associated with a 53% 
higher mortality rate than consuming five or more servings a day. Those consuming at 
least one fruit a day lived 19 months longer than those not consuming fruits, but 
consuming more than one fruit a day was not associated with additional survival. 
Whereas individuals consuming three vegetables a day lived 32 months longer than 
individuals not consuming vegetables (116). A meta-analysis of eight cohort studies 
ranging from 8 to 19 years of follow-up evaluated the relationship between fiber intake in 
healthy participants and first hemorrhagic or ischemic stroke. The results indicated that 
increasing dietary fiber intake by 7g/day is associated with a 7% risk reduction of 
primary stroke. However, not enough scientific evidence was available to clarify if a 
specific food source and/or type of fiber is more beneficial for stroke prevention (117).  
Observational studies have also assessed the relationship between CVD risk 
factors and dietary fiber intake (118-121). In a prospective cohort study following pre-
menopausal women, fiber consumption of at least 22 g/day was associated with lower 
total cholesterol (-8%) and LDL cholesterol (-8%) levels, but not triglycerides and HDL-c 
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(121). Another cohort study with postmenopausal women showed that higher intakes of 
cereal fiber was associated with a smaller declines in minimum coronary artery diameter, 
a measure of progression of CAD. Other sources of fiber did not present beneficial effects 
(119). A baseline assessment from the PREDIMED trial (Prevención con Dieta 
Mediterránea) of men and women at high cardiovascular risk showed a modest but 
significant association between intima-media thickness (IMT) and total dietary fiber 
intake (p=0.03). However, the only specific food group inversely associated with IMT 
was fruit intake (p=0.007) (120). In a study including participants free of heart disease, 
the progression of atherosclerosis evaluated according to IMT was inversely associated 
with the intake of total fiber and viscous fiber, but not nonviscous fiber. Pectin, a type of 
viscous fiber which is mainly present in fruits and vegetables, presented the strongest 
inverse association (118). Nonetheless, it is important to notice that a major limitation of 
observational studies is the reliance on dietary self-report; additionally they do not 
provide information on causality. 
Randomized controlled trials (RCTs) can provide valuable information regarding 
the effect of different types of fiber on CVD risk factors. According to a meta-analysis of 
RCTs conducted by Brown et al. (1999), soluble fiber showed to be more effective at 
reducing cardiovascular risk factors. An increase in soluble fiber intake by 3 g/day is 
associated with a 5 mg/dL decrease in total cholesterol and LDL-c (122).Although a 
small change, this could reflect a 4% reduction of coronary heart disease incidence. In 
addition, similar effects were observed from the different types of soluble fiber (oat, 
psyllium, and pectin) (122). Two types of soluble fiber, psyllium and β-glucan, have been 
approved for health claims related to CVD by the Food and Drug Administration (FDA) 
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(123). The assumption is that consuming four servings a day of foods rich in β-glucan 
(1.78 g/serving) and psyllium (0.75 g/serving) reduces CVD risk. A randomized 
crossover study including 68 hyperlipidemic adults tested the effects of a diet high in 
psyllium and β-glucan (8 g/day) in comparison to a control low fat diet on serum lipid 
risk factors. Modest improvements in total cholesterol (-2%, p=0.001) and triglycerides (-
5%, p=0.001), but not LDL-c (-1%, p=0.064) were observed in the high fiber diet 
compared to control (123). In 367 hypercholesterolemic individuals the consumption of 
oat β-glucan cereal significantly lowered LDL-c from 4.7% to 6.5%. A higher molecular 
weight (MW) oat β-glucan was more efficient at reducing LDL-c than lower MW due to 
its increased viscosity (124). Barley is another source of β-glucan that has been studied 
for its effects on blood lipids. In a 10-week RCT, barley β-glucan of high and low MW (3 
g/d and 5 g/d) were administered to 155 hypercholesterolemic individuals. LDL-c was 
reduced by 9% with 3 g/day of both high and low MW barley β-glucan, and by 13% to 
15% with 5 g/day of low and high MW barley β-glucan respectively (125). The long-term 
(26 weeks) effect of psyllium husk fiber as an adjunct diet therapy to the AHA step 1 diet 
was evaluated in 248 individuals with hypercholesterolemia. In comparison to control, 
the psyllium group presented 4.7% lower total cholesterol and 6.7% lower LDL-c after 
26 weeks of intervention (126). As noted by Brown et al., simultaneous changes in the 
diet associated with the displacement of other nutrients (i.e. saturated fat, cholesterol) by 
fiber rich sources can confound the relation between fiber intake and blood lipids 
concentrations (122). 
The mechanisms by which soluble fiber can reduce blood cholesterol levels are 
related to some of its characteristics such as viscosity and fermentability. The 
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hypocholesterolemic effect of soluble fiber is primarily due to its ability to disrupt the 
enterohepatic circulation of bile salts and cholesterol by binding them in the intestinal 
lumen, which results in reduced absorption and consequently increased fecal excretion. In 
response, the liver up-regulates bile acid synthesis through the uptake of free cholesterol 
from the circulation. In turn, this causes a concomitant decrease in LDL-c concentrations 
(127-129). Another mechanism of action of soluble fiber is caused by the reduction in 
insulin secretion due to delay in gastric emptying and decreased absorption of glucose 
and other macronutrients. This leads to decreased insulin response as a consequence of 
lower postprandial glucose concentrations. The lower insulin response results in the 
inhibition of HMG-CoA reductase and consequently decreased hepatic cholesterol 
synthesis (128, 130). Lastly, soluble fiber undergoes bacterial fermentation in the colon, 
producing short chain fatty acids (SCFA) particularly acetate, propionate and butyrate. 
The ratio of propionate to acetate may affect lipid metabolism. Propionate has been 
shown to reduce hepatic cholesterol synthesis by inhibiting HMG-CoA reductase and by 
reducing acetate availability and incorporation into serum lipids (128, 129). 
2.5.2  Dietary Antioxidants 
 
Adequate fruit and vegetable intake is associated with a lower risk of several 
chronic diseases including CVD and type 2 diabetes (131-133). In part, this may be due 
to the antioxidant properties of several compounds commonly found in fruits and 
vegetables, including carotenoids, vitamins A, C, E, and polyphenols (87, 134). It has 
been demonstrated that the consumption of antioxidant-rich fruits and vegetables 
increases overall antioxidant status (135). The process by which the mobilization of 
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antioxidants counterbalance excessive ROS formation is fundamental to avoid redox 
balance pro-oxidant conditions (19). As previously explained, antioxidants work in 
synergy with each other and against ROS through different mechanisms such as 
inhibiting lipid peroxidation and hydroperoxide formation, and scavenging free radicals 
(18).   
A report by Miller, showed that a diet high in fruits and vegetables and low in fat 
caused a decline in oxidative stress and increased antioxidant capacity measured by 
isoprostanes and oxygen radical absorbing capacity (ORAC) respectively (136). 
Similarly, in a study that evaluated the Dietary Approaches to Stop Hypertension (DASH) 
diet, which is rich in fruits and vegetables, consumption of the diet for four weeks was 
associated with a 23% increase in the antioxidant capacity (FRAP) among obese 
hypertensive patients. However, the same association was not observed in lean 
normotensive participants (137). Whereas in a crossover intervention including 33 
healthy adults, food selection based on high antioxidant content for two weeks increased 
plasma α-tocopherol, but not plasma TAC. Nonetheless, improvements were observed in 
CRP levels and liver function (alanine aminotransferase, gamma-glutamyltranspeptidase, 
and alkaline phosphatase) (138). 
Polyphenols are one of the main dietary antioxidants with a total intake estimated 
to be ten times higher than that of vitamin C (139). Flavonoids are the most common 
group of plant polyphenols with an estimate daily total intake of 1 g/day. Commonly 
consumed flavonoid-rich foods includes cocoa, tea, highly colored fruits and vegetables 
and its derivate (i.e. grapes, berry, red wine) (140). In a large prospective study including 
older men and women, intakes of flavonoid in the highest quintile were associated with a 
34 
 
22% lower CVD mortality risk. Individual flavonoids, such as anthocyanidins, flavan-3-
ols, flavones, flavonols, and proanthocyanidins, were also associated with lower CVD 
mortality risk (141). Similar results were observed in the Women’s Health study with 16 
years of follow-up. Flavanones and anthocyanidins were inversely associated with CHD 
and CVD mortality, but not stroke mortality. When analyzing specific foods, apples, 
pears and red wine were associated with lower CHD and CVD mortality. Whereas 
grapefruit intake was associated only with reduced CHD mortality, and chocolate and 
strawberries to reduced CVD mortality (142).  
Randomized controlled trials have been conducted in order to test the effects of 
specific flavonoid-rich foods on oxidative stress and other CVD risk factors. Baba et al. 
randomly assigned 25 individuals to a either placebo or 26g of cocoa per day for twelve 
weeks. The intake of cocoa powder increased the lag time of conjugated dienes 
production indicating a lower susceptibility to LDL oxidation in comparison to the 
control group. However, oxidized LDL was not significantly reduced after the 
intervention (143). In a randomized crossover study, 23 individuals were fed two diets 
(four weeks each) with similar macronutrient composition, fiber and caffeine intake. One 
of the diets was supplemented with cocoa powder and dark chocolate (CPDC diet). 
Antioxidant capacity, measured by ORAC, increased by 4% and LDL oxidation lag time 
increased by 8% in the CPDC diet (144). In another randomized crossover trial, the acute 
consumption of dark chocolate bar, liquid cocoa and a cocoa-free placebo was evaluated 
in 45 overweight adults. Flow-mediated dilation (FMD) was improved by 4.3% after dark 
chocolate bar consumption and by 5.7% after sugar-free cocoa consumption (145). 
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In vitro studies with tea, a rich source of the flavonoids catechins, have shown to 
inhibit LDL oxidation and platelet aggregation (146). In vivo, Hirano-Ohmori et al. 
measured serum malondialdehyde-modified LDL (MDA-LDL) and 8-epi-prostaglandin-
F2α (8-epi-PGF2α), measures of oxidative stress, after a consumption of 7 cups a day of 
green tea for two weeks in 22 healthy males non-smokers. At the end of the green tea 
period the MDA-LDL concentrations were significantly decreased. However, the 8-epi-
PGF2α was not significantly altered after the intervention (147). This is consistent with a 
crossover study that evaluated the effects of green tea, black tea, and hot water with 
caffeine (1000ml/day) for seven days each on urinary F2-isoprostane excretion, a 
measure of lipid peroxidation. No change in isoprostanes was observed after the green or 
black tea intervention (148). In another study, green tea consumption by 14 healthy 
individuals showed an acute effect by decreasing FMD by 3.7% (p=0.02), however no 
changes were observed for inflammatory markers (CRP, IL-6) or antioxidant capacity 
(TAC) (149). 
Grapes are a good source of flavonoids, such as catechin, quercetin, and 
anthocyanins. Therefore Stein et al. evaluated the intake of grape juice for 14 days in 
adults with coronary artery disease. A significant improvement in FMD and a reduction in 
LDL susceptibility to oxidation were observed after the grape juice period even after 
adjustments for lipid lowering and antioxidant therapies (150). Another study compared 
the effects of grape juice and α-tocopherol for two weeks on markers of oxidative stress 
in healthy individuals. Both interventions had similar effects and significantly increased 
ORAC and LDL lag time to oxidation. However, neither α-tocopherol nor grape juice 
intake significantly changed urinary F2-isoprostane concentrations after two weeks of 
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intervention (151). In contrast, in a double-blind crossover trial older adults consuming 
one cup of either tart cherry juice or placebo for 14 days observed significantly lower F2-
isoprostanes after the cherry juice phase in comparison to placebo (152). Pignatelli at al. 
randomly assigned healthy individuals to drink red or white wine with the same alcohol 
percentage for 15 days. A significant decrease in urinary PGF2α was observed in both 
wine groups; however, it was more pronounced in the red wine group. Plasma 
polyphenols was higher in the red wine group. In addition, at the end of the intervention 
an inverse correlation between excretion of PGF2α and polyphenols was observed (153). 
A randomized cross-over study, Estruch et al. assigned healthy men to consume wine or 
gin for 28 days. The wine group presented a significant reduction in plasma SOD activity 
and MDA levels in comparison to the gin group.  In addition, there was a significant 
decrease in the lag time of LDL oxidation and in oxidized LDL concentrations (154).  
A meta-analysis of randomized controlled trial data showed that the consumption 
of some flavonoid-rich foods was associated with lower cardiovascular risk factors. 
Chocolate and cocoa were associated with improved FMD acutely (4%), and systolic (-
5.9 mm Hg) and diastolic (-3.3 mm Hg) BP after chronic intake. On the other hand, black 
tea intake caused an acute increase in systolic and diastolic BP independent of caffeine 
content. Chronic green tea consumption was associated with reduced LDL-c 
concentrations (-8.9 mg/dL). In addition, the authors emphasized that there is limited data 
from high quality intervention trials to assess potential efficacy of other flavonoid-rich 
sources such as grapes and wine on CVD risk factors; therefore more studies are 
warranted (155). 
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2.5.3  Effects of Nopales (Opuntia spp) and Prickly Pear Intake 
Nopales are the prickly pear cactus pads from the Opuntia species.  They are a 
traditional and popular food in Mexico with a total yearly production of 600,000 tons 
(25). They are low in fat and high in total (2.0 g/100 g) and soluble fiber (0.9 g/100 g). 
Moreover, they are a good source of vitamin A (443 IU/100 g), β-carotene (242 mg/100 
g), vitamin C (5.3 mg/100 g), and phenolic compounds (8-9 mg/100 g) (24, 25). 
According to a study evaluating the availability of culturally specific fruits and 
vegetables in Chicago, approximately 23% of grocery stores carry cactus pads (156). 
Prickly pear cactus pads are commonly used as a medicinal plant for glycemic and 
cholesterol control among Mexicans. When evaluating the use of complementary and 
alternative medicine among diabetic patients of different ethnicities, 33% of Hispanics 
reported the use of prickly pear cactus as an adjunct therapy for diabetes (157). 
The literature documenting nopales’ hypocholesterolemic effects is scarce. Most 
published studies have focused on cactus fruit (prickly pears) (27-29) rather than the 
more commonly consumed pads (nopales). In two separate studies with 
hypercholesterolemic or hyperlipidemic individuals, prickly pear intake (250g/day) 
lowered total and LDL-c by about 10% (27, 28). The effects were greater with a longer 
supplementation period (eight weeks vs. four weeks). In addition, in hyperlipidemic 
subjects the consumption of prickly pears led to an 11% decrease in both fasting blood 
glucose and insulin (28). The only study evaluating the effects of actual cactus pads 
(nopales) on lipids and glycemia is a 1983 study from Mexico that included 8 healthy, 14 
obese, and 7 diabetic subjects from 26 to 65 years of age who consumed broiled nopales 
(300 g/day for ten days) before the three main meals. In this study there was a significant 
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reduction in total cholesterol by 14%, triglycerides by 24% relative to baseline in all 
subjects, and fasting glucose by 22% in diabetic subjects (26). Another study evaluated 
the postprandial glucose response in subjects with type 2 diabetes after the consumption 
of three types of Mexican breakfasts with and without nopales. The incremental area 
under the curve for glucose was reduced by 20 to 48% in all breakfasts containing 
nopales compared to the same breakfast without nopales (158).  
Some studies evaluating the effects of cactus fruit have also investigated its 
effects on oxidative stress. In a study with young individuals suffering from familial 
heterozygous isolated hypercholesterolemia, consumption of prickly pears for four weeks 
was associated with lower oxidative stress as measured by an 8%, 6% and 9% decrease in 
plasma, serum and urinary isoprostanes, respectively (p<0.05) (27). In a shorter study 
(two weeks) with healthy adults, prickly pear intake (250g) significantly improved 
markers of oxidative stress relative to vitamin C supplementation (75 mg), resulting in 
lower malondialdehyde (-74%), F2-isoprostanes (-29%), ratio of reduced to oxidized 
glutathione (GSH/GSSG; 49%), and conjugated dienes lipid hydroperoxide (-40%) (29). 
Studies evaluating the effect of nopales cactus pads on oxidative stress are not available.  
More recent studies incorporated nopales into the diet as a supplement and 
showed disparate effects on markers of CVD. Guevara-Cruz et al. evaluated the intake of 
a drink containing dehydrated nopales, chia seeds, oats and soybean protein in 
participants with metabolic syndrome. Triglyceride levels were reduced by 15% and CRP 
levels by 18% in the intervention group; however, no changes were observed for total 
cholesterol, HDL-c, LDL-c, glucose and insulin (159). In a crossover study, healthy 
participants consumed tortillas made with ground nopales and bars with prickly pear fruit 
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jam twice a day for three weeks each. Increased levels of trolox-equivalent antioxidant 
capacity (TEAC; 11%), polyphenols (8%), and vitamin C (25%) were observed after the 
nopales tortillas phase. While only vitamin C (25%) was increased after the prickly pear 
bar phase. After the nopales tortilla phase and prickly pear phase decreases in 
malondialdehyde (MDA; 25% and 12%), glucose (18% and 13%) and LDL-c (17% and 
7%) were observed respectively. The consumption of nopales tortilla also showed 
reductions in total cholesterol (9%) and triglycerides (10%) (160).  
Despite the purported benefits, little is known about potential risks associated 
with consumption of prickly pear cactus.  There is documentation of adverse effects 
among patients with type 2 diabetes taking prescription medication concomitantly with 
prickly pear cactus. According to a study by Bush et al., out of 804 diabetic patients, 15% 
used herbal medicine. Potential adverse interactions were observed in 40% of the herbal 
medicine users. Eight cases were of hypoglycemia caused by nopales intake (161). A case 
of a 58-year-old male with type 2 diabetes treated with metformin and glipizde have been 
described. The patient reported consuming prickly pear cactus daily for two months and 
four cases of hypoglycemia were observed during that time, with blood glucose reading 
ranging from 49 to 69 mg/dL (162).  
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CHAPTER 3 
METHODOLOGY 
3.1 Study Design 
In this randomized crossover trial, participants were randomly assigned to 
supplementation for two weeks with 2 cups/day of nopales (280 g; intervention) or 
cucumbers (266 g; control), divided into two 1-cup daily doses for each of their two main 
meals.  After a two- to three-week washout period, participants received the alternative 
treatment for an additional two weeks (Figure 1).  Participants were asked to refrain from 
making any additional changes to their usual diet throughout the duration of the entire 
study. The study was approved by Arizona State University’s Institutional Review Board 
(Appendix A). 
 
3.2 Participant Selection 
 The sample was comprised of 27 adults (18 - 70 y) with moderate 
hypercholesterolemia (LDL-c ≥ 120 mg/dL). Participants were excluded as follows: (a) 
use of hypolipidemic medications; (b) regular physical activity ( ≥ 30 min /day for ≥ 5 
days/week), (c) presence of known chronic diseases (e.g., diabetes, CVD, cancer, 
hepatitis, inflammatory conditions, gastrointestinal disorders); (d) consumption of > 4 
servings/day of fruits and vegetables; (e) following a restrictive diet (e.g., carbohydrate 
restriction, veganism) or having any condition likely to require specialized dietary 
modifications; (f) use of supplements (antioxidants, fiber and botanicals); (g) latex 
allergy; (h) fear of needles; (i) breastfeeding, pregnancy, or intent to become pregnant; (j) 
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unwillingness to comply with study protocol; or (k) participation in other research 
studies. Subjects interested in participating in the study were pre-screened by a 
questionnaire to identify those that met the inclusion criteria (Appendix B).  
Potential participants who met the inclusion criteria signed a screening consent 
form (Appendix C) in which they agreed to be involved in the screening process. They 
attended a screening blood draw after a 12-hour fast to verify the presence of moderate 
hypercholesterolemia (LDL-c ≥ 120 mg/dL). The entire protocol was explained to 
individuals who met all inclusion criteria and participants provided written consent for 
the full study prior to enrollment (Appendix D).  
Figure 2 shows the Consort flow diagram for the present study. A total of 277 
subjects were assessed for eligibility of which 75 were eligible and agreed to be screened 
for moderate hypercholesterolemia. Of those, 30 participants were eligible for the study, 
of which three individuals decided not to participate and 27 participants provided written 
consent to participate. After providing informed consent, but prior to baseline data 
collection, four participants were no longer interested in the study and did not participate 
in any study procedures. Twenty three participants started the intervention and 16 
completed the study. The reasons for dropping out included dislike of the study food 
(nopales, n=3), lack of time (n=1), lost to follow up (n=2), and accident non-related to the 
study (n=1). 
  
 
4
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Figure 1. Study Flow Chart 
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Figure 2. Nopales Study CONSORT 2013 Flow Diagram (08-09-13) 
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44 
 
3.3 Test Foods 
The test foods (nopales and cucumbers) were purchased from local groceries 
stores (Ranch Market and Food City). Fresh cucumbers were given to participants along 
with measuring cups and instructions. Cucumbers were distributed once a week since 
they last about 7 to 10 days. Participants were advised to: (1) keep the cucumbers in the 
refrigerator; (2) wash, peel, and cut into 1 inch cubes before measuring 1-cup 
(approximately 130 g); (3) season and prepare according to personal preferences. The 
nopales were purchased already cleaned (thorns removed) and chopped, and were cooked 
in the Nutrition Metabolic Kitchen according to the following standard procedure. After 
thorough rinsing under cold running water, the nopales were cooked in boiling water for 
ten minutes and placed in ice to cool down. Nopales were packed in bags containing 140g 
each (equivalent to 1 cup) and then refrigerated before being distributed to the 
participants. Nopales were distributed once a week (14 bags/week) and participants were 
instructed to place them in the refrigerator or freezer until needed for consumption. 
Recipes for preparing the study foods in diverse ways were distributed to improve 
adherence. Participants were instructed to consume half of the daily test food contents 
with each of their two main meals. The selected dose (280 g/d) is equivalent to two cups 
of cooked nopales. Cucumber (2 cups/day or 266 g/day) was chosen for the control 
intervention because although it is similar to Nopales in weight and volume, it has a 
lower content of soluble fiber (0.2 g/100 g vs. 0.9 g/100 g) and antioxidant micronutrients 
(Table 1) (24). 
To monitor compliance and whether participants maintained their usual dietary 
habits, participants were asked to complete a 3-day food record (Appendix E) prior to the 
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beginning and during the last week of each intervention phase. In addition, they were 
asked to keep a tally of servings of test foods per day (Appendix F). The 3-day food 
records were checked carefully for completeness and the data were analyzed using 
Nutrition Data System for Research (NDSR) software (University of Minnesota, 
Minneapolis, MN) (24). Dietary variables of interest were estimates of total energy 
intake, percentage of energy provided by macronutrients (carbohydrate, fat and protein, 
and different types of carbohydrate and fat), and antioxidant micronutrients (carotenoids, 
vitamins A, C and E) consumed by the participants. 
 
Table 1. Nutritional characteristics of test foods  
 Nopales (cooked) 
100 g              280 g 
Cucumber (raw) 
100 g               266 g 
Energy (kcal) 15 42 15 40 
Carbohydrates (g) 3.28 9.18 3.63 9.66 
Fat (g) 0.05 0.14 0.11 0.29 
Protein (g) 1.4 3.92 0.65 1.73 
Total Fiber (g) 2.0 5.6 1.1 2.9 
Soluble fiber (g) 0.9 2.5 0.2 0.5 
Vitamin A (IU) 443 1240 105 279 
Vitamin C (mg) 5.3 14.8 2.8 7.5 
β-carotene (µg) 242 678 45 120 
α-carotene (µg) 47 132 11 29 
    Source: NDSR, 2012 
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Before and after each intervention phase a likert-type scale survey was 
administered to assess gastrointestinal symptoms (abdominal pain, increased bowel 
movements, bloating, flatulence, fullness and increased liquids; Appendix G). In addition, 
after each intervention, a likert-type scale survey was used to evaluate the acceptability 
and satisfaction of test foods (appearance, consistency/texture, flavor and overall 
satisfaction; Appendix H). 
 
3.4 Blood Collection 
Fasting blood samples were collected at the beginning and end of each dietary 
intervention period on two separate days at least one day apart to account for day-to-day 
variability in plasma lipid concentrations. On both days, participants were asked to fast 
for 10-12 hours prior to their arrival to the Nutrition Laboratory at Arizona State 
University. On the first blood collection day for each timepoint, fasting blood was 
collected from the antecubital vein into evacuated tubes as follows: one serum separating 
tube (7 ml), two EDTA-containing tubes (10 ml each), one heparin-containing evacuated 
tubes (4 ml), and one EDTA and glycolysis inhibitor (potassium oxalate and sodium 
fluoride) tube (2ml). On the second blood collection day blood was collected into one 
EDTA-containing evacuated tube (7 ml). Blood was centrifuged at 1,100 x g at 4°C for 
20 minutes, and serum/plasma was separated, aliquoted, and stored at -70°C for future 
analysis. For vitamin C measurement, fresh EDTA plasma was mixed with an equal 
volume of 10% trichloroacetic acid before the supernatant was frozen. All samples were 
analyzed at once upon sample collection completion.  
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3.5 Measurements 
3.5.1  Socio-demographic Questionnaire 
At baseline after signing the consent form, participants answered a questionnaire 
about socio-demographic characteristics. The information collected included: gender, 
age, ethnicity, marital status, employment status, household income, education, and 
smoking status (Appendix I).   
3.5.2  Anthropometric Measurements 
Body weight was measured in kilograms using a calibrated scale and height was 
measured in centimeters using a wall-mounted stadiometer. Waist circumference was 
measured in centimeters using a flexible tape measure at the midpoint between the lowest 
rib and the iliac crest. Blood pressure was taken from the non-dominant arm (unless 
contraindicated) following a five minute rest using an Omron IntelliSense HEM-907XL 
automated blood pressure monitor (Omron Healthcare, Inc., Bannockburn, IL). All 
measurements were done in triplicate.  Body mass index (BMI) was calculated as weight 
divided by height squared (kg/m2). A Tanita body composition analyzer (model TBF-
300A, Tanita Corporation, Tokyo, Japan) was used to measured percent body fat.  
3.5.3  Cardiometabolic Risk Biomarkers 
A complete lipid panel (total cholesterol, HDL-c, LDL-c, and triglycerides) and 
glucose were measured in plasma using an automated chemistry analyzer (Cobas C111; 
Roche Diagnostics, Indianapolis, IN) using colorimetric enzymatic reagents. Glucose was 
measured in plasma that had potassium oxalate and sodium fluoride added as glycolysis 
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inhibitors. Plasma hsCRP was measured with a turbidimetric enzymatic assay using an 
automated chemistry analyzer (Cobas C111; Roche Diagnostics, Indianapolis, IN).  
The Lipoprint/Lipoware system (Quantimetrix Co., Redondo Beach, CA) was 
used to measure the cholesterol distribution in LDL and HDL subfractions and mean LDL 
particle size (163). Lipoprotein particles were separated from a plasma sample by 
nongradient polyacrylamide tube gel electrophoresis following the manufacturer 
instructions. The amount of cholesterol present in each of the different lipoprotein bands 
was quantified by densitometric analysis using the Lipoware computer software provided 
as part of the Lipoprint system.   This analysis resulted in the identification of seven LDL 
subfractions and ten HDL subfractions.  The relative percentage of total cholesterol in 
large and small LDL particles was calculated by adding the proportion of cholesterol in 
fractions LDL1 plus LDL2, and LDL3 through LDL7, respectively. Similarly, the relative 
percentage of HDL-cholesterol in large (HDL1 through HDL3), intermediate (HDL4 
through HDL6), and small HDL (HDL7 through HDL10) particles was calculated. In 
addition, LDL phenotype patterns were classified as LDL phenotypes A (predominantly 
large, buoyant LDL), B (predominantly small, dense LDL) or intermediate.  
Insulin was measured in serum using the ultra-sensitive human insulin 
radioimmunoassay kit (Millipore, Billerica, MA). Insulin sensitivity was assessed by 
calculating the homeostatic model assessment (HOMA) score (164):  
HOMA = glucose (mmol/L) x insulin (μU/ml)/22.5  
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LDL susceptibility to oxidation was measured by monitoring the formation of 
conjugated dienes catalyzed by incubating with Cu2+ after the isolation of LDL from 
plasma using density gradient ultracentrifugation, as previously described (165).  First, 
sample density was adjusted to 1.21 g/mL by adding potassium bromide. The adjusted 
samples were transferred to an ultracentrifuge tube (Quick-Seal Polyallomer tube, 
Beckman, Brea, CA). Samples were carefully overlayered with a 1.006 g/mL density 
solution. Samples were centrifuged for 3 hours at 80,000 rpm and 15°C using an Optima 
MAX-XP ultracentrifuge (Beckman, Brea, CA) with a fixed angle MLN 80 rotor 
(Beckman, Brea, CA). The LDL layer was removed and transferred to desalting columns 
(Econo-Pac 10DG columns, BioRad, Hercules, CA) for EDTA removal. The protein 
content of the LDL fractions was measured using the Modified Lowry Protein Assay Kit 
(Thermo Scientific, Waltham, MA), after which volume was adjusted with a phosphate 
buffered saline (PBS) solution to achieve 100 µg protein/1000 µl. The samples were 
incubated with 2.5 µM of copper sulfate at 37°C and the kinetics of conjugated dienes 
formation was assessed by continuous absorbance monitoring at 234 nm at 2-min 
intervals for 7 hours (165). The following measurements were acquired from the 
oxidation curve output: (1) lag time (min), the intercept of lines drawn through the linear 
portion of the propagation phase and the lag phase; and (2) oxidation rate (nmol diene x 
mg LDL protein x min-1), the slope of the linear portion of the propagation phase). 
 Oxidized LDL was measured in EDTA plasma using a commercially available 
ELISA kit (Mercodia AB, Uppsala Sweden) based on direct sandwich technique using the 
same specific murine monoclonal antibody mAb-4E6 as in the assay described by 
Holvoet et al (166).  
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Total antioxidant capacity (TAC) was measured in serum using a colorimetric 
assay kit (Cayman Chemical Company, Ann Arbor, MI) based on the generation of ABTS 
radical cation from the interaction between metmyoglobin and hydrogen peroxide, and 
was measured at 750 nm (167). 
Vitamin C was measured according to the method described by Omaye et al. 
(168).  Briefly, standards were made with 5% trichloroacetic acid (TCA) ranging from 0 
to 20 µg/ml. Samples and standards were incubated for 3 hours at 37°C after the addition 
of 100µl of 2,4-Dinitrophenylhydrazine/thiourea/copper (DTC) solution. Ice cold 65% 
sulfuric acid was added and samples were incubated at room temperature for 30 minutes. 
Samples and standards were measured at 520 nm spectrophotometrically. Vitamin C 
concentration was calculated using a linear regression equation.  
 
3.6  Sample Size Calculation   
A power analysis was performed to determine the sample size necessary to detect 
significant changes in total cholesterol. Using data from Frati-Munati (26), it was 
determined that to detect a minimum difference of 31 mg/dl change in total cholesterol 
(at a 0.05 significance level and power > 0.80) with a within-person standard deviation of 
40 mg/dL, a total of 16 subjects are needed (Appendix J). With an expected 20% dropout 
rate, target recruitment was 20 subjects.  Additional participants were enrolled to ensure 
study completion by 16 participants. 
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3.7  Statistical Analyses 
Untransformed data is reported as mean values ± standard deviation (mean ± SD). 
Mean values of both blood draws for lipids were used for statistical analysis. Prior to the 
analysis, normality of the outcome measurements was assessed. Baseline comparison 
between genders and test food satisfaction were analysed using an independent samples t-
test for normally distributed variables or a Mann-Whitney Test for non-normally 
distributed variables. For the other outcomes measured, a multivariate general linear 
model for repeated measures was used to determine significant treatment, time, or 
interactions effects. Non-normally distributed data were log-transformed or squared root 
transformed. A p value ≤ 0.05 was considered statistically significant. All analyses were 
conducted using SPSS (version 21, Chicago, IL). 
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CHAPTER 4 
RESULTS 
4.1 Participant Characteristics 
The sociodemographic characteristics of the study participants are presented in 
Table 2. A total of 16 participants completed the study. Participants’ mean age was 46.5 ± 
13.9 years. A majority of participants were female (68.8%). Participants identified 
themselves as Hispanic (43.8%), white (37.5%), or black (6.3%). About 44% of 
participants were single, 25% were married, and 12.5% were living together. Seventy five 
percent of participants were currently working, and about one-third of the participants 
reported a monthly household income of $3,000 or more (31%) and 44% had a monthly 
income below $2,000. The majority of participants had a college degree or higher 
(56.3%) or some college education (31.3%). None of the study participants reported 
smoking (data not shown). 
Table 3 shows participants’ physiologic characteristics at baseline. Participants’ 
mean BMI was 31.4 ± 5.7 kg/m2 and their mean percent body fat was 37.2 ± 9.0%.  
According the National Cholesterol Education Program Adult Treatment Panel (NCEP 
ATP) III criteria (7), mean waist circumference was within desirable girth for men (94.8 ± 
6.4; desired ≤ 102 cm) but not for women (105.0 ± 12.6 cm; desired ≤ 88 cm). Mean 
blood pressures were within the recommended levels (SBP = 123.3 ± 10.9 mm Hg; 
desired < 130 mm Hg, and DBP = 79.2 ± 10.8 mm Hg; desired < 85 mm Hg). Fasting 
glucose (99.2 ± 10.7 mg/dL, desired < 100 mg/dL) and total cholesterol (199.3 ± 24.6 
mg/dl; desired < 200 mg/dL) were very close to the upper limit for recommended 
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concentrations. Per study design, LDL-c concentrations were elevated (137.1 ± 20.5 
mg/dL, desired < 100mg/dL). HDL-c concentrations were slightly above minimum 
desirable values for women (50.9 ± 13.6 mg/dL; desired > 50 mg/dL) but not for men 
(33.1 ± 7.1 mg/dL; desired > 40 mg/dL, p=0.022). In addition, participants had 
triglyceride concentrations that were slightly above recommended levels (151.9 ± 84.9 
mg/dL; desired<150 mg/dL).  
Figure 3 shows the distribution of LDL subclass phenotype at baseline. Although 
participants had moderately high LDL-c concentrations, 44% of them were classified as 
having a LDL pattern A (the less atherogenic profile), 33% were classified as having an 
intermediate phenotype, and 25% presented the more atherogenic pattern B phenotype, 
which is characterized by having more of the small, dense LDL particles. 
 
4.2 Dietary Intake 
Dietary composition data before and during the consumption of both study foods 
is shown in Table 4. No significant treatment-by-time effect was observed for any of the 
dietary composition data. A significant time effect was observed for intakes of energy 
(pTime=0.026), total fat (pTime=0.003), monounsaturated fatty acid (MUFA; pTime=0.023), 
polyunsaturated fatty acid (PUFA; pTime=0.003) and vitamin E (pTime=0.026). Energy 
intake was not significantly different at pre-phases (cucumber, 1747 ± 565 kcal; nopales, 
1829 ± 600 kcal) and was decreased by 8.3% and 10.1% during the cucumber and 
nopales phases, respectively. Fat intake was the major contributor to the decrease in 
energy intake. During the cucumber and nopales phases, fat intake was decreased by 
16.2% and 14.4% respectively. The decrease in fat intake was mainly due to reduced 
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consumption of monounsaturated (cucumber, -13.2%; nopales -18.9%) and 
polyunsaturated fatty acids (cucumber, -13.7%; nopales -23.2%). Lastly, vitamin E intake 
was decreased by 35% in the cucumber phase and by 29% in the nopales phase. While no 
significant changes were observed in total and soluble fiber intake in both treatment 
phases. 
When evaluating dietary intake by food group (Table 5), a significant treatment-
by-time effect was observed for the intake of the nuts/avocado group (pInt=0.044). The 
intake of this food group was reduced in both treatments, but the reduction was greater in 
the nopales phase because at the beginning of this phase intake was greater than at the 
beginning of the cucumber phase. In addition, a significant time effect was observed for 
intake of vegetables, legumes, and refined grains. The intakes of vegetables were 
increased during both phases (pTime=0.003), while the consumption of legumes 
(pTime=0.002) and refined grains (pTime=0.029) were decreased. A significant treatment 
effect was observed for intakes of fruits and starchy vegetables that were higher during 
the cucumber phase compared to nopales phase (fruit, pTreat=0.028; starchy vegetables, 
pTreat=0.001).  
Prior to each intervention phase, participants were given a compliance calendar to 
keep a tally of the cups of test foods consumed. Compliance data were obtained for 75% 
of the participants. Among those participants, mean compliance was 92 ± 8% for the 
cucumber phase and 94 ± 6% for the nopales phase and did not significantly differ 
between the two groups (p=0.555).  The compliance of participants who did not return 
the calendars was verified by the inclusion of test foods in the 3-day food record. 
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Table 2. Descriptive characteristics of study participants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable All participants (n = 16) 
Age (years; mean ± SD) 46.5 ± 13.9 
Gender (%, n)  
     Male 31.2 (5) 
     Female 68.8 (11) 
Ethnicity (%, n)  
     White 37.5 (6) 
     Black 6.3 (1) 
     Hispanic 43.8 (7) 
     Other 12.5 (2) 
Marital Status (%, n)  
     Single 43.8 (7) 
     Married 25.0 (4) 
     Living together 12.5 (2) 
     Separated 6.3 (1) 
     Divorced 6.3 (1) 
     Widowed 6.3 (1) 
Currently working (%, n)  
     Yes 75 (12) 
     No 25 (4) 
Monthly Family Income (%, n)  
     $0 - $1000 12.5 (2) 
     $1001 - $2000 31.3 (5) 
     $2001 - $3000 6.3 (1) 
     $3001 - $4000 18.8 (3) 
     > $4000 12.5 (2) 
     Refused / Not sure 18.8 (3) 
Education (%, n)  
     Completed middle school 6.3 (1) 
     Completed high school 6.3 (1) 
     Some college 31.3 (5) 
     College graduate or higher 56.3 (9) 
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Table 3. Physiologic characteristics of study participants at baseline.a
Variable All participants 
(n=16) 
Men 
(n=5) 
Women 
(n=11) 
p Value 
BMI (kg/m2) b 31.4 ± 5.7 28.2 ± 3.2 32.9 ± 6.4 0.070 
Body fat (%) 37.2 ± 9.0 26.5 ± 3.9 42.1 ± 6.3 0.000 
Waist circumference (cm) c 101.8 ± 12.0 94.8 ± 7.1 105.0 ± 13.2 0.126 
Systolic blood pressure (mm Hg) 123.3 ± 10.9 123.1 ± 12.1 123.4 ± 11.4 0.968 
Diastolic blood pressure (mm Hg) c 79.2 ± 10.8 80.6 ± 14.1 78.6 ± 10.3 0.913 
Fasting lipids (mg/dL)     
     Total cholesterol 199.3 ± 24.6 208.9 ± 29.7 194.9 ± 23.5 0.326 
     LDL-cholesterol b 137.1 ± 20.5 145.1 ± 17.4 133.4 ± 22.4 0.321 
     HDL-cholesterol b 45.3 ± 14.6 33.1 ± 8.0 50.9 ± 14.3 0.022 
     Triglycerides 151.9 ± 84.9 216.0 ± 104 122.8 ± 64.5 0.044 
     LDL-c/HDL-c 3.4 ± 0.4 4.6 ± 1.5 2.9 ± 1.0 0.014 
Glucose (mg/dL) 99.2 ± 10.7 95.2 ± 4.9 101.0 ± 12.8 0.211 
Insulin (uU/mL) 19.1 ± 2.2 17.6 ± 7.8 19.7 ± 9.4 0.669 
HOMA 4.8 ± 0.7 4.2 ± 2.0 5.1 ± 2.9 0.536 
hsCRP (mg/dL) b 5.5 ± 5.8 2.0 ± 0.9 7.2 ± 6.7 0.030 
a 
Data shown as mean ± SD. Mean values for men and women were analysed using an independent samples 
t-test for normally distributed variables or a Mann-Whitney Test for non-normally distributed variables.  
b 
Abbreviations BMI – body mass index; HDL – high density lipoprotein; LDL – low density lipoprotein; 
HOMA - homeostasis model assessment ; hsCRP – high sensitivity C-reactive protein. 
c
 non-normally distributed.
 
Figure 3. LDL subclass phenotype at baseline 
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Table 4. Nutrient intake before and after each treatment.a  
  Cucumber Phase 
 
Nopales Phase 
 
p-value 
  Pre Post 
 
Pre Post 
 
Treat
 b
 Time
 
 Int
 b
 
Total grams per day 2287 ± 1070 2350 ± 1086  2538 ± 951 2131 ± 947  0.933 0.394 0.167 
Energy intake (kcal/d) 1747 ± 565 1602 ± 588 
 
1829 ± 600 1645 ± 526 
 
0.467 0.026 0.825 
Energy from carbohydrate 
(%) 
47.3 ± 6.4 49.9 ± 8.9 
 
44.3 ± 7.8 44.5 ± 6.8 
 
0.012 0.237 0.307 
   Carbohydrates (g) 210.2 ± 69.9 203.9 ± 76.5  203.6 ± 70.4 186.5 ± 65.9  0.331 0.196 0.649 
Energy from protein (%) 17.2 ± 3.3 16.9 ± 2.7 
 
17.5 ± 3.8 18.9 ± 5.5 
 
0.245 0.359 0.329 
   Protein (g) 73.1 ± 23.9 67.2 ± 23.6   75.9 ± 18.6 76.5 ± 25.1  0.269 0.431 0.262 
Energy from fat (%) 35.6 ± 7.4 32.9 ± 7.8 
 
36.4 ± 6.7 35.1 ± 5.4 
 
0.351 0.169 0.421 
   Fat (g) 72.6 ± 30.6 60.7 ± 30.2  76.6 ± 31.8 65.6 ± 24.1  0.331 0.003 0.588 
Energy from SFA (%)
b
 11.0 ± 2.4 10.2 ± 3.1 
 
11.3 ± 3.0 11.4 ± 3.3 
 
0.356 0.478 0.320 
   SFA (g)
 c
 22.3 ± 10.1 20.9 ± 12.5  25.1 ± 12.4 22.3 ± 12.6  0.240 0.062 0.459 
Energy from MUFA (%)
b
 13.2 ± 4.0 12.2 ± 3.8 
 
13.4 ± 3.4 12.7 ± 3.2 
 
0.579 0.373 0.721 
   MUFA (g)
 c
 27.3 ± 14.3 23.7 ± 12.9  28.1 ± 12.2 22.8 ± 7.7  0.458 0.023 0.650 
 Energy from PUFA (&)
b
 8.3 ± 2.4 7.5 ± 2.4 
 
8.6 ± 2.0 8.1 ± 2.5 
 
0.476 0.263 0.831 
   PUFA (g)
 c
 16.8 ± 6.0 14.5 ± 8.6  18.5 ± 7.0 14.2 ± 5.7  0.459 0.003 0.880 
Cholesterol (mg/d) 249 ± 147 269 ± 175 
 
284 ± 163 287 ± 123 
 
0.568 0.650 0.632 
Total sugars (g/d) 79.0 ± 34.0 86.9 ± 48.7 
 
83.0 ± 45.0 70.0 ± 34.7 
 
0.344 0.531 0.260 
a 
n = 15. Untransformed data shown as mean ± SD.  Effects of treatment, time, or interactions were assessed using a repeated measures 
ANOVA.  
b 
Abbreviations: SFA - saturated fatty acid; MUFA - monounsaturated fatty acid; PUFA - polyunsaturated fatty acid; Treat – treatment; 
Int –interaction.  
c
 Log-transformed prior to analysis. 
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Table 4. Nutrient intake before and after each treatment.a (continued)     
  Cucumber Phase  Nopales Phase  p-value 
  Pre Post 
 
Pre Post 
 
Treat
 b
 Time
 
 Int
 b
 
Total fiber (g/day)
c
 21.5 ± 10.5 18.6 ± 6.7  20.4 ± 8.8 19.2 ± 5.1  0.744 0.149 0.679 
Total fiber (g/1000kcal/day)  12.2 ± 3.6 12.1 ± 3.4  12.0 ± 3.9 12.5 ± 3.6  0.974 0.708 0.628 
   Soluble fiber (g/d)
c
 6.5 ± 3.0 5.8 ± 1.9 
 
6.6 ± 2.9 6.6 ± 1.6 
 
0.279 0.604 0.555 
   Soluble fiber (g/1000kcal/day) 3.7 ± 1.3 3.7 ± 1.0  3.9 ± 1.5 4.3 ± 1.3  0.250 0.331 0.466 
   Insoluble fiber (g/d)
c
 15.1 ± 7.9 12.8 ± 5.0 
 
13.6 ± 6.0 12.5 ± 3.7 
 
0.891 0.117 0.752 
   Insoluble fiber 
(g/1000kcal/day) 
8.5 ± 2.7 8.3 ± 2.6  8.0 ± 2.6 8.1 ± 2.4  0.571 0.949 0.699 
Vitamin C  (m/d)
c
 99 ± 62 102 ± 49 
 
108 ± 91 98 ± 81 
 
0.498 0.730 0.177 
Vitamin E  (mg/d)
c
 11.1 ± 11.1 7.2 ± 4.0 
 
9.7 ± 4.1 6.9 ± 3.2 
 
0.756 0.001 0.752 
Vitamin A (µg/d)
c
 970 ± 490 940 ± 414 
 
1275 ± 988 952 ± 375 
 
0.120 0.636 0.735 
α-carotene  (µg/d)c 486 ± 538 425 ± 741 
 
480 ± 558 591 ± 724 
 
0.009 0.893 0.176 
β-carotene  (µg/d)c 
3756 ± 
2658 
3108 ± 2238 
 
5027 ± 5258 
3239 ± 
2183  
0.210 0.362 0.912 
a 
n = 15. Untransformed data shown as mean ± SD.  Effects of treatment, time, or interactions were assessed using a repeated measures 
ANOVA.  
b 
Abbreviations: SFA - saturated fatty acid; MUFA - monounsaturated fatty acid; PUFA - polyunsaturated fatty acid; Treat – treatment; 
Int –interaction.  
c
 Log-transformed prior to analysis. 
 
 
 
 
  
5
9
 
Table 5. Intake of selected food groups before and after each treatment.a 
  Cucumber Phase   Nopales Phase   p-value 
Food Group (serving/day) Pre Post   Pre Post   Treat
b
 Time Int
b
 
Vegetable 
c
 3.21 ± 3.70 5.91 ± 1.72 
 
4.29 ± 3.40 5.37 ± 1.82 
 
0.646 0.003 0.221 
Fruit 
c
 2.42 ± 2.49 1.47 ± 1.77 
 
1.19 ± 1.62 0.83 ± 0.94 
 
0.028 0.171 0.252 
Legumes 
c
 0.38 ± 0.37 0.08 ± 0.26 
 
0.36 ± 0.34 0.20 ± 0.37 
 
0.581 0.002 0.29 
Starchy vegetables 
c
 0.25 ± 0.30 0.90 ± 1.22 
 
0.16 ± 0.29 0.20 ± 0.35 
 
0.001 0.052 0.207 
Whole Grain  1.33 ± 1.24 1.62 ± 1.31 
 
1.16 ± 1.14 1.23 ± 1.20 
 
0.299 0.446 0.531 
Refined Grain 
c
 4.28 ± 2.64 3.04 ± 2.39 
 
3.74 ± 1.52 3.34 ± 2.38 
 
0.899 0.029 0.436 
Eggs 
c
 0.54 ± 0.68 0.71 ± 0.76 
 
0.68 ± 0.59 0.71 ± 0.80 
 
0.619 0.554 0.359 
Nuts & Avocado 
c
 0.40 ± 0.57 0.16 ± 0.18 
 
1.34 ± 1.54 0.35 ± 0.63 
 
0.057 0.001 0.044 
Margarine 
c
 0.66 ± 1.13 0.69 ± 1.22 
 
0.78 ± 1.27 0.56 ± 1.04 
 
0.751 0.679 0.516 
Vegetable oil 
c
 1.39 ± 1.61 0.71 ± 1.81 
 
1.58 ± 2.20 1.52 ± 1.95 
 
0.226 0.118 0.207 
Butter/shortening 
c
 0.30 ± 0.35 0.49 ± 1.16 
 
0.53 ± 0.72 0.96 ± 1.22 
 
0.171 0.308 0.281 
Salad Dressing 
c
 0.42 ± 0.51 0.48 ± 0.66 
 
0.66 ± 0.56 0.38 ± 0.58 
 
0.503 0.168 0.113 
Sugar and sweets 
c
 1.42 ± 1.61 1.42 ± 1.93 
 
1.65 ± 1.72 1.29 ± 2.70 
 
0.780 0.320 0.864 
Sugar-sweetened drinks 
c
 0.35 ± 0.60 0.55 ± 0.90 
 
0.38 ± 0.51 0.35 ± 0.63 
 
0.861 0.963 0.153 
a 
n = 15. Untransformed data shown as mean ± SD.  Effects of treatment, time, or interactions were assessed using a 
repeated measures ANOVA.  
b 
Abbreviations: Treat – treatment; Int –interaction.  
c
 square-root-transformed prior to analysis.
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4.3 Cardiometabolic Risk Outcomes 
The intervention effects on cardiometabolic disease risk factors are shown in 
Table 6. No significant treatment-by-time effects were observed for the cardiometabolic 
outcomes measured. Weight, BMI and percent body fat remained constant throughout the 
study time. Comparable responses after the consumption of cucumber and nopales were 
observed. There was a non-significant trend for WC decrease after the consumption of 
both study foods (cucumber, -0.4%; nopales, -1.4%; pTime=0.053). There was also a non-
significant trend for a systolic blood pressure reduction after the consumption of 
cucumbers (-2.1%) and nopales (-2.6%, pTime=0.070). Consumption of both study foods 
resulted in a significant increase in triglycerides (cucumber, 14.8%; nopales, 15.2%; 
pTime=0.020). LDL-c at pre-phase was not significantly correlated with LDL-c change in 
both treatments (cucumber, r2=0.235 and p=0.381; nopales, r2=-0.283 and p=0.298). 
Results for cardiometabolic risk outcomes did not change when excluding 3 participants 
from the analysis that did not have LDL-c over 120 mg/dL at time point 1 (appendix K). 
Figure 4 denotes individual changes, relative to pre-treatment values after the 
consumption of both test foods for the major cardiometabolic outcomes. Great individual 
response variability was observed for all outcomes. For the primary outcome LDL-c, a 
decrease was observed in 7 (44%) and 10 (63%) participants after the cucumber and 
nopales phases respectively. Whereas not significant, the average decrease in LDL-c over 
time was 2.0 mg/dL (-1.4%) after the cucumber intake and 3.9 mg/dL (-2.9%) after the 
nopales intake (pTime=0.176).  
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Table 6. Effect of test food intake on cardiometabolic disease risk factorsa  
  Cucumber Phase   Nopales Phase   p-value 
  Pre Post % Change   Pre Post % Change   Treat
 b
 Time
 
 Int
 b
 
Weight (kg) 84.2 ± 13.3 84.5 ± 13.5 0.3 
 
84.1 ± 13.1 83.9 ± 13.1 -0.2 
 
0.237 0.637 0.155 
BMI (kg/m
2
) 
b
 31.5 ± 5.9 31.6 ± 5.9 0.3 
 
31.4 ± 5.8 31.3 ± 5.8 -0.3 
 
0.182 0.920 0.212 
Body Fat (%) 36.8 ± 9.6 36.8 ± 9.0 0 
 
36.7 ± 9.1 36.9 ± 9.2 0.5 
 
0.959 0.832 0.663 
WC (cm) 
b
 102.4 ± 11.9 102.0 ± 11.8 -0.4 
 
102.7 ± 12.3 101.3 ± 11.6 -1.4 
 
0.702 0.053 0.438 
BP (mm Hg) 
              Systolic 
c
 121.7 ± 11.9 119.1 ± 11.7 -2.1 
 
121.7 ± 11.3 118.5 ± 11.2 -2.6 
 
0.852 0.070 0.818 
   Diastolic 
c
 78.7 ± 10.0 77.7 ± 8.6 -1.3 
 
78.2 ± 10.8 78.9 ± 10.2 0.9 
 
0.796 0.950 0.459 
Lipids (mg/dL) 
              Total cholesterol 200.0 ± 26.9 201.0 ± 32.3 0.5 
 
199.2 ± 26.5 196.5 ± 26.6 -1.4 
 
0.440 0.745 0.319 
   HDL-c 
b
 45.4 ± 14.0 45.8 ± 15.8 0.9 
 
46.0 ± 15.9 44.4 ± 14.6 -3.5 
 
0.687 0.403 0.242 
   LDL-c 
b
 138.5 ± 22.3 136.5 ± 29.4 -1.4 
 
135.9 ± 21.5 132.0 ± 20.1 -2.9 
 
0.341 0.176 0.680 
   Triglycerides 
c
 150.2 ± 87.4 172.5 ± 108.3 14.8 
 
164.6 ± 124.4 189.7 ± 117.1 15.2 
 
0.090 0.020 0.435 
   LDL-c/HDL-c 3.39 ± 1.38 3.41 ± 1.72 0.6 3.36 ± 1.43 3.33 ± 1.37 -0.9 0.437 0.956 0.759 
Glucose (mg/dL) 97.9 ± 11.4 99.3 ± 8.1 1.4 
 
98.3 ± 10.1 97.4 ± 11.3 -0.9 
 
0.399 0.822 0.416 
Insulin (uU/mL) 19.6 ± 9.3 21.3 ± 10.0 8.7 
 
19.8 ± 9.2 20.4 ± 9.2 3.0 
 
0.709 0.387 0.245 
HOMA 
b
 4.9 ± 2.7 5.3 ± 2.6 8.2 
 
4.9 ± 2.1 5.0 ± 2.5 2.0 
 
0.516 0.469 0.268 
hsCRP (mg/dL) 
b, c
 5.5 ± 6.0 4.7 ± 4.7 -14.5   4.8 ± 5.0 4.8 ± 4.8 0.0   0.431 0.787 0.685 
a 
n = 16. Untransformed data shown as mean ± SD.  Effects of treatment, time, or interactions were assessed using a repeated measures ANOVA;  
b 
Abbreviations: BMI – body mass index; WC – waist circumferences; BP – blood pressure; HDL-c – high density lipoprotein cholesterol; LDL-c 
– low density lipoprotein cholesterol; HOMA - homeostasis model assessment ; hsCRP – high sensitivity C-reactive protein; Treat – treatment; 
Int –interaction;  
c
 Log-transformed prior to analysis. 
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Figure 4. Percent change of major biomarkers for each intervention phase 
   
   
n=16. Individual percent change according to treatment for a) Total Cholesterol; b) Low density-lipoprotein cholesterol (LDL-c);  
c) high-density lipoprotein cholesterol (HDL-c); d) Triglycerides; e) Glucose; f) Insulin 
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4.4 Lipoprotein subfractions 
The LDL particle size and cholesterol distribution in LDL and HDL subfractions 
are shown in Table 7. No significant treatment-by-time effect was observed for the 
distribution of cholesterol among any lipoprotein subfractions. Additionally, no 
significant treatment or time effects were observed in LDL size and the proportion of 
cholesterol in small LDL. The distribution of cholesterol in large LDL did not 
significantly change over time; however, it was modestly, but significantly higher during 
the cucumber phase (pTreat=0.037). No treatment effects were observed in the distribution 
of HDL cholesterol in HDL subfractions; however, similar pro-atherogenic changes were 
observed in both interventions over time. After the consumption of both study foods, the 
proportion of HDL cholesterol significantly decreased in large HDL (pTime=0.021) and 
significantly increased in small HDL (pTime=0.002).  
 
4.5 Oxidative Stress 
There were no significant treatment, time, or interactive effects for plasma, 
vitamin C, TAC, oxidized LDL and LDL oxidation (lag time and oxidation rate; Table 8). 
A time effect trend was observed for TAC (pTime=0.057), in which TAC increased 1.7% 
after the cucumber phase and 6.8% after the nopales phase. The observed mean values 
for oxidative stress markers were within the reference range for vitamin C (0.5 – 2.0 
mg/dL)(168), TAC (1.0 - 2.3 mM)(169), and oxidized LDL (26 - 117  U/L)(166). 
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Table 7. Effect of diet intervention on lipoprotein subfractions.a 
 
a 
n = 16. Untransformed data shown as mean ± SD.  Effects of treatment, time, or interactions were assessed using a repeated measures ANOVA.  
b 
Abbreviations: HDL – high density lipoprotein; HDL-c – high density lipoprotein cholesterol; LDL – low density lipoprotein; Treat – treatment; 
Int –interaction.  
c
 Log-transformed prior to analysis. 
 
 
 
 
 
 
 
  Cucumber Phase   Nopales Phase   p-value 
  Pre Post % Change   Pre Post % Change   
Treat
 b
 Time
 
 Int
 b
 
LDL peak diameter (Å) 267.5 ± 4.9 267.0 ± 5.4 -0.2 
 
267.3 ± 5.3 266.5 ± 5.9 -0.3 
 
0.323 0.175 0.665 
% cholesterol in large LDL 
b, c
 32.3 ± 4.0 31.6 ± 5.0 -2.0 
 
30.8 ± 5.7 30.0 ± 5.9 -2.8 
 
0.037 0.267 0.981 
% cholesterol in small LDL 
b, c
 4.1 ± 4.5 4.4 ± 5.1 8.0 
 
3.8 ± 4.0 4.4 ± 5.1 16.8 
 
0.573 0.679 0.117 
% HDL-c in large HDL 
b
 24.3 ± 12.4 23.1 ± 13.7 -5.1 
 
23.7 ± 13.1 22.4 ± 12.0 -5.9 
 
0.481 0.021 0.897 
% HDL-c in intermediate HDL 
b
 53.8 ± 5.1 54.2 ± 5.3 0.7 
 
54.2 ± 5.6 53.8 ± 4.9 -0.6 
 
0.980 0.962 0.581 
% HDL-c in small  HDL 
b
 21.7 ± 8.9 22.6 ± 9.9 4.1   21.9 ± 8.5 23.6 ± 8.9 7.9   0.455 0.002 0.358 
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Table 8. Effect of the diet interventions on oxidative stress markers.a  
  Cucumber Phase   Nopales Phase   p-value 
  Pre Post % Change   Pre Post % Change   Treat
 b
 Time
 
 Int
 b
 
Vitamin C (mg/dL) 1.17 ± 0.43 1.20 ± 0.42 2.6 
 
1.13 ± 0.47 1.14 ± 0.45 0.9 
 
0.099 0.634 0.744 
TAC (mM) 
c
 1.15 ± 0.41 1.17 ± 0.31 1.7 
 
1.18 ± 0.36 1.26 ± 0.32 6.8 
 
0.284 0.057 0.410 
Oxidized LDL (U/L) 83.2 ± 22.7 81.5 ± 21.3 -2.0 
 
81.0 ± 17.6 80.9 ± 18.2 -0.1 
 
0.600 0.546 0.592 
LDL oxidation 
b, d
 
           
   Lag time (min) 
d
 204.4 ± 39.1 194.1 ± 23.1 -5.0 
 
206.9 ± 37.7 
211.3 ± 
49.9 2.1 
 
0.472 0.624 0.258 
   Oxidation Rate 
c, e
 11.03 ± 2.7 11.04 ± 2.1 0.1 
 
11.21 ± 2.3 11.24  ± 1.9 0.3 
 
0.695 0.961 0.983 
a 
n = 16. Untransformed data shown as mean ± SD.  Effects of treatment, time, or interactions were assessed using a repeated measures ANOVA.  
b 
Abbreviations: TAC – total antioxidant capacity ; LDL – low density lipoprotein; G – group; Treat – treatment; Int –interaction.  
c
 Log-transformed prior to analysis.  
d
 n=14.   
e 
(nmol diene / mg LDL protein x min). 
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4.6 Side Effects and Test Food Outcomes 
The participants responded to a likert-type scale about gastrointestinal symptoms 
before and after each intervention phase to evaluate possible side effects of the test foods 
(Table 9). There was no significant treatment-by-time effect for gastrointestinal 
symptoms. No side effects were observed for abdominal pain, increased bowel 
movements, bloating, flatulence, fullness and increased liquids after the consumption of 
the test foods. The most common responses were “none” or “mild” for all categories. 
 
Table 9. Gastrointestinal symptoms by intervention and time point.a,b 
  Cucumber Phase   Nopales Phase   p-value 
  Pre Post   Pre Post   Treat Time Int 
Abdominal pain 0.1 ± 0.3 0.2 ± 0.6 
 
0.2 ± 0.8 0.2 ± 0.4 
 
0.791 0.791 0.423 
Increased bowel 
movements 
0.2 ± 0.5 
 
0.9 ± 0.8 
 
 
0.3 ± 0.6 
 
0.6 ± 0.8 
 
 
0.549 
 
0.016 
 
0.312 
 
Bloating 0.7 ± 0.9 0.2 ± 0.4 
 
0.2 ± 0.6 0.6 ± 0.6 
 
0.633 0.697 0.054 
Flatulence 0.7 ± 0.9  0.6 ± 0.7 
 
0.4 ±0.7 1.0 ± 1.2 
 
0.544 0.119 0.145 
Fullness 0.6 ± 0.7 0.9 ± 1.0 
 
0.6 ± 0.7 1.4 ± 1.1 
 
0.168 0.006 0.120 
Increased liquids 0.4 ± 0.8 0.4 ± 0.9   1.0 ± 1.2 0.9 ± 1.4  0.059 0.879 0.753 
a 
n = 16. Data shown as mean ± SD.  Effects of treatment, time, or interactions were assessed using a 
repeated measures ANOVA.  
b 
Likert-type scale: 0 = none; 1 = mild; 2 = moderate; 3 = high; 4 = severe. 
 
   
Participants also responded to a satisfaction and acceptability survey about the 
test foods, and the results are presented in Table 10. The cucumbers received 
significantly higher rates than the nopales for all acceptability and satisfaction 
components: appearance, consistency, flavor and overall satisfaction. Overall, cucumbers 
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were considered “good” and nopales “satisfactory”. Changes in the main outcome LDL-c 
were not associated with satisfaction of test foods (appendix K). 
 
Table 10. Acceptability and Satisfaction of test foods.a,b 
    Cucumber Phase   Nopales Phase   p-value 
    Post   Post     
Appearance  
 
3.8 ± 0.4  
 
2.9 ± 0.9 
 
0.005 
Consistency  
 
3.8 ± 0.4  
 
2.4 ± 1.1 
 
0.003 
Flavor  
 
3.6 ± 0.6 
 
2.5 ± 1.0 
 
0.002 
Overall Satisfaction   3.7 ± 0.6   2.8 ± 0.9   0.002 
a 
n = 16. Data shown as mean ± SD.  Mean values for post cucumber and nopales phases 
were analysed using Mann-Whitney Test due to non-normally distributed variables.  
b 
Likert-type scale: 0 = unsatisfactory; 1 = needs improvement; 2 = satisfactory; 3 = good; 4 
= excellent.  
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CHAPTER 5 
DISCUSSION 
 
Nopales have been used as complementary and alternative medicine for glycemic 
and cholesterol control by Mexicans and Native Americans, but evidence regarding their 
cardiometabolic health benefits is scarce. To date, human studies assessing the effects of 
nopales pads have been limited to one study that evaluated their effects on fasting lipids 
and glucose levels (26), and one study that evaluated postprandial glycemia (158). 
Additional studies have used other cactus-based products: cactus pads incorporated into 
tortillas (160), dehydrated cactus pads (156, 159, 170), and prickly pear fruit (27, 29, 171, 
172). The purported benefits of nopales are also based on animal studies using isolated 
pectin from cactus pads (173-175), and dehydrated cactus pads (176). Given the paucity 
of evidence regarding the effects of nopales intake, the present randomized crossover 
trial was designed to evaluate the effects of nopales intake compared to cucumbers on 
cardiometabolic risk factors in hyperlipidemic adults.  This is the first controlled study 
specifically designed to testing the effects of nopales in its most commonly consumed 
form (boiled) on cardiometabolic risk factors. Furthermore, this study adds to previous 
work by including measurements of the distribution of cholesterol among lipoprotein 
subfractions and biomarkers of oxidative stress as potential mechanisms involved in the 
purported effects of nopales intake.  
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5.1 Cardiometabolic risk factors: lipids and lipoproteins 
Limited evidence is available on the hypocholesterolemic effects of nopales from 
controlled trials. The present study did not show significant improvements on plasma 
lipids after the consumption of nopales compared to cucumbers. The only study that 
evaluated the effects of nopales on markers of cardiovascular risk was conducted by 
Frati-Munari et al. (26) showed in a quasi-experimental design with 8 non-obese, 14 
obese, and 7 diabetic hypercholesterolemic adult participants (28-65 years of age) that 
nopales intake resulted in a 31 mg/dL decrease in total cholesterol (p<0.001). This 
decrease was more pronounced in obese and diabetic participants compared to non-obese. 
In comparison to our study, Frati-Munari et al. (26) included participants with higher 
baseline total cholesterol (220 ± 52 mg/dL) and LDL-c (164 ± 43 mg/dL). In addition, 
significant weight loss (1.5 kg) was observed only in the obese and diabetic groups, 
which were the same groups that experienced greater improvements in lipids. It is 
possible that weight loss contributed to some of the changes observed. In contrast, 
participants from the present study remained weight-stable throughout the entire study. 
The dose utilized in our study (280 g/day for 14 days) was similar to the Frati-Munari 
study (300 g/day for 10 days).  However, in the present study nopales were provided 
boiled, instead of broiled.   
One of the proposed bioactive compounds from nopales is dietary fiber.  The 
current study was designed to provide an additional 2.5 g/day of soluble fiber. Boiling 
nopales has been shown not to interfere with soluble fiber content, although the viscosity 
and gel consistency may be compromised (177). According to a meta-analysis conducted 
by Brown et al. (22), increasing soluble fiber intake (oat β-glucan, psyllium, and pectin) 
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by 3 g/day is associated with a 5 mg/dL decrease in both total cholesterol and LDL-c. 
Although not statistically significant, we observed that after the nopales phase plasma 
total cholesterol and LDL-c concentrations were 4.5 mg/dL lower than after the cucumber 
phase.  Nevertheless, we observed large individual response variability in LDL-c 
concentrations to both treatments. It has been proposed that the heterogeneity in the lipid 
response to dietary interventions is related to genetic polymorphisms, including 
variations in the genes encoding apoproteins, CETP, LCAT, LDL receptor, and 
cholesterol 7α-hydroxylase (178, 179). 
Due to the scarcity of studies with cactus pads, studies evaluating prickly pear 
fruit will also be discussed. It is important to note that the nutritional composition of 
prickly pears (fruit) and nopales (pads) is not the same, and that the effects may not be 
comparable. Budinsky et al. (27) evaluated the effects of 250 g of prickly pear pulp 
consumption for four weeks compared to a healthy diet in hypercholesterolemic 
individuals.  Prickly pear pulp intake led to a reduction in total cholesterol (-22.5 mg/dL, 
p<0.01) and LDL-c (-16.5 mg/dL, p<0.04), while triglycerides and HDL-c did not change 
with the intervention. In contrast to the current study, Budinsky et al. (27) included 
participants with a higher baseline LDL-c (226 ± 26 mg/dL), and provided the entire diet 
to participants keeping energy and macronutrients constant throughout the study. In the 
present study participants had mild hypercholesterolemia (LDL-c = 137 ± 20 mg/dL) and 
although they were asked to maintain their habitual diet, they may have displaced other 
fiber rich foods when adding the test foods. In a parallel study that included 68 women 
from 20 to 55 years of age with metabolic syndrome, the effects of dehydrated cactus 
pads capsules three times a day after meals for 6 weeks on lipids was evaluated. In 
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agreement with our study, no significant changes in total cholesterol, LDL-c, HDL-c and 
triglycerides were observed (170).  
From studies with guinea pigs, the main proposed mechanism for the 
hypocholesterolemic effect of prickly pears or prickly pear pectin is associated with a 
decrease in intestinal cholesterol absorption coupled with an increase in the expression of 
Apo B/E receptors in the liver (171, 173, 175).  This would result in increased bile acid 
excretion and the interruption of the enterohepatic circulation of cholesterol and bile 
acids (173, 175). Similarly, in individuals with familial hypercholesterolemia 
consumption of 250 g/day prickly pear for six weeks, a 16% decrease in LDL-c was 
accompanied by a 27% increase in LDL uptake by the liver (171).  
Lipoproteins are heterogeneous according to particle size, density and 
composition. Therefore, assessing the distribution of cholesterol among different 
lipoprotein subfractions may provide information on anti- or pro-atherogenic effects of 
dietary interventions beyond traditional lipids measures (57). Few studies have evaluated 
the effects of soluble fiber on lipoprotein remodeling. The addition of 3 g of β-glucagon 
from barley to a National Cholesterol Education Step I diet (low fat, low cholesterol diet) 
in mildly hypercholesterolemic subjects led to a 14% lower LDL-c concentration. 
However, the amount of cholesterol in large LDL particles were also lower compared to 
control, while no change was observed for small LDL particles (180). In contrast, Davy et 
al. (181) showed that the addition of oat cereal for twelve weeks not only reduced LDL-c 
(-2.5%), but also the concentrations of small, dense LDL-c (-17.3%) and the number of 
LDL particles (-5%) compared to wheat cereal. In another study, a one month diet therapy 
that included 7 g of psyllium and 2 g of plant sterols significantly reduced LDL-c 
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concentration and increased LDL peak size in hypercholesterolemic individuals. This 
resulted in the lower prevalence of the more proatherogenic LDL pattern B from 27 to 
18% (182).  
Studies have shown that small, dense LDL particles are strongly associated with 
increased triglycerides concentration (63, 183). An increased pool of triglyceride-rich and 
cholesterol-poor VLDL leads to the production of LDL with fewer lipids in its core, 
resulting in smaller, denser particles. Furthermore, LDL particle size is reduced as 
particles become triglyceride-enriched and cholesterol-depleted by the action of hepatic 
lipase and CETP producing small, dense LDL particles. (51, 66, 67). In the present study, 
triglycerides concentration increased after the consumption of both test foods 
(pTime=0.020) and tended to be higher after the nopales phase (pTreat=0.090). However, no 
differences were observed for LDL size and LDL lipoprotein subfractions over time or 
between treatments. In contrast, pro-atherogenic changes in HDL subfractions were 
observed after the consumption of both study foods by decreasing the proportion HDL 
cholesterol in large HDL and increasing the proportion in small HDL. Elevations in 
triglycerides have been observed when dietary fat is replaced by carbohydrates (184-
186). The suggested mechanism for carbohydrate-induced triglyceride elevation is by 
reducing triglycerides clearance rather than increasing its production (187). However, it is 
unlikely that this was the underlying cause for an increase in triglycerides as two cups of 
the test food offered only adds 10 g of carbohydrates. In addition, according to 
participants’ reported food intake, the contribution of each macronutrient to total energy 
intake was not altered throughout the study.  Conversely, the displacement of other food 
sources when incorporating the test foods to the habitual diet cannot be ignored. The 
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dietary assessment has shown a decrease in the overall consumption of monounsaturated 
and polyunsaturated fatty acids with the addition of both test foods. Studies have reported 
that decreasing the consumption of unsaturated fatty acids increases triglycerides levels 
(188-190). 
 
5.2 Cardiometabolic risk factors: glucose and insulin 
The most studied health outcome of prickly pear consumption has been on its 
hypoglycemic effects (26, 28, 158, 191). In the present study, the consumption of 
nopales, relative to cucumber intake, did not result in significant effects on fasting 
glucose, insulin or HOMA.  In contrast, other studies have documented a reduction in 
fasting glucose concentrations after the consumption of nopales or nopales products.  In a 
study by Frati-Munari et al. (26) the consumption of nopales decreased glucose 
concentrations by 63.4 ± 27.1 mg/dL (p<0.001) among participants with diabetes. The 
decrease observed in non-diabetic individuals, albeit statistically significant, was of a 
much lower magnitude (3.5 ± 1.5 mg/dL) (26). Similarly, in a crossover study including 
28 healthy adults, the consumption of 200 g of tortillas made with nopales for three 
weeks decreased glucose concentrations by 17 mg/dL (17.5%) (160).  
In the postprandial period, the effects of nopales on postprandial glycemia have 
been investigated in individuals with type 2 diabetes. The consumption of different 
breakfast menus containing nopales, compared to the same breakfast without nopales, 
resulted in a decrease in the incremental area under the curve for the glycemic response. 
The extent of the reduction differed from 20 to 48% depending on the breakfast 
preparation (chilaquiles, burritos, or quesadillas), suggesting that changes are also related 
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to the macronutrient content and other components of the mixed meal (158).  In a parallel 
study with 29 participants the supplementation with 200 mg of capsules containing cactus 
pads and fruit extract in pre-diabetic individuals have shown to decrease glucose 
postprandially. However, after 16 weeks of supplementation no significant changes were 
observed in fasting glucose, insulin, lipids and CRP compared to the placebo (191). There 
are two hypothesized mechanisms underlying the hypoglycemic effects of nopales. The 
first mechanism is related to lower postprandial sugar absorption due to the soluble fiber 
content of the nopales. The second mechanism is related to improved cellular sensitivity 
to insulin due to the presence of bioactive components. However, the exact mechanisms 
remain unclear (25).   
 
5.3 Oxidative stress 
It has been suggested that oxidative stress is involved in the development and 
progression of chronic diseases, such as diabetes and atherosclerosis. Few studies have 
examined the effects of prickly pear fruit on oxidative stress outcomes; however, to date 
the effects of nopales pads on markers of oxidative stress have not been investigated. In 
the current study, measurements of oxidized LDL, LDL susceptibility to oxidation, 
vitamin C and total antioxidant capacity were used as markers of oxidative stress. 
Emphasis was given to lipid peroxidation markers due to its role on the atherosclerotic 
process (17, 101, 102). Our study provided no support that the consumption of nopales 
decreased oxidative stress. 
The lack of improvement in markers of oxidative stress in the present study may 
be explained by a combination of factors. First, nopales did not significantly reduce 
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substrates for oxidation such as LDL-c or small, dense LDL-c concentrations. The 
development of oxidized LDL is dependent not only on ROS formation and antioxidant 
capacity but also on substrate concentration availability, more specifically of lipids (136). 
In fact, it has been shown that oxidized LDL is positively associated with LDL-c 
concentrations and inversely associated with HDL-c concentrations (192-194). LDL size 
also influences LDL susceptibility to oxidation. Several studies have shown an inverse 
association between LDL size and oxidized LDL concentrations (193, 195, 196). Small, 
dense LDL particles have a lower affinity for LDL receptors, prolonging its residence 
time in the circulation and increasing its susceptibility to oxidation and glycation (67, 
68). Therefore, the lack of significant changes in LDL-c concentrations and LDL size 
may partially explain the absence of improvements in lipid peroxidation markers. 
Second, some phytochemicals present in other functional foods may not be 
present in the nopales pads.  It has been previously reported that the consumption of 
prickly pear fruit decreases urinary and plasma isoprostanes in individuals with familial 
hypercholesterolemia. The effects observed were more pronounced in females than males 
and isoprostanes were positively related to LDL-c concentrations (27). Similarly, 
Tesorieri et al. (29) observed in healthy adults significant decreases in isoprostanes, 
malondialdehyde and conjugated dienes lipid hydroperoxide after prickly pear fruit intake 
for two weeks compared to vitamin C. Interestingly, plasma vitamins C and E were 
significantly increased in both groups; however, oxidative markers were only decreased 
with prickly pear fruit intake. This would suggest that prickly pear fruit has other 
antioxidants or bioactive components that prevented oxidative damage. The authors 
suggested that the presence of betalains could be responsible for the positive findings 
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(29). The same group observed a postprandial increase in the distribution of betalain 
pigments in red blood cells after prickly pear fruit intake, conferring protection to the 
cells (172). Unlike the fruit, nopales pads used in the present study do not contain 
betalains.  
Finally, it is also possible that thermal treatment (i.e. boiling) may have attenuated 
bioactive components thus decreasing the antioxidant activity potential of nopales. 
Ramirez-Moreno et al. (177) evaluated the effects of boiling cactus pads (Opuntia spp of 
two different cultivars) for 20 minutes on nutritional composition and antioxidant 
capacity. Boiling caused losses mostly of soluble compounds, such as vitamin C and 
soluble sugars (glucose and fructose), with retention values between 49 to 67%. The 
retention of β-carotene varied from 54 to 84% depending on the cultivar. Another study 
evaluating the thermal treatment effects on antioxidant activity of cactus pads identified 
three types of carotenoids, lutein, β-carotene, and α-cryptoxanthin. The thermal treatment 
actually increased the extractability of carotenoids, improving their bioavailability. 
Despite the fact that the phenolic compounds were decreased, the antioxidant activity was 
significantly increased. This suggests that carotenoids are the main known antioxidant 
compounds in cactus pads (197). This is in agreement with another study evaluating the 
effects of boiling on vegetables, such as carrots and broccoli, where an increase in TAC 
was observed. The authors suggested that the increase in antioxidant activity is due to the 
matrix softening and increased extractability of the compounds (198). Therefore, the 
modifications related to boiling could potentially lead to positive or negative changes in 
the metabolic effects after nopales ingestion.  
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5.4 Dietary Intake  
Feeding studies can help establish causal relationships between diet and disease 
risk factors due to its controlled nature (199). In the present study participants received 
the test foods weekly and were advised to maintain their habitual diet. Dietary assessment 
before and during each intervention was performed to evaluate if other changes besides 
the inclusion of the test foods were made to the diet. A significant decrease in energy 
intake was observed during both treatment phases. This change is probably related to the 
increased satiety as the increased intake of low energy-dense foods can displace high 
energy-dense foods. Despite the fact that the contribution of each macronutrient to the 
total energy intake did not change throughout the treatments, a significant decrease in the 
total amount of fat was observed with the introduction of both test foods. While this may 
appear to be a beneficial shift, the decrease in total fat was mostly due to reductions in 
mono and polyunsaturated fatty acids provided by nuts and avocados. Previous studies 
have shown that increased intake of unsaturated fatty acids have a major impact on lipids 
by decreasing the ratio of total to HDL cholesterol and decreasing triglycerides (188-
190).  
We observed no significant change in total, soluble or insoluble fiber intakes with 
the addition of the test foods to the participant’s habitual diet. Participants were 
encouraged to not change their diet when adding the test foods. If that would hold true, an 
increase of 2.9 g and 5.6 g of total fiber and of 0.5 g and 2.5 g of soluble fiber would be 
expected in the cucumber and nopales phases respectively. However, a non-significant 
decrease in fiber intake was observed during both treatment phases. When adjusting for 
calorie intake, it was noted that fiber intake remained the same throughout the study. The 
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3-day food records were checked to confirm the consumption of 2 cups/day of test foods, 
which were described. The analysis of dietary intake by food group showed that 
vegetables intake was increased on average by 2.7 servings/day during the cucumber 
phase. Since cucumbers are not a rich source of fiber, it did not reflect an increased fiber 
intake. Conversely, during the nopales phase, vegetable intake was increased on average 
by 1 serving/day, suggesting that participants displaced other vegetables when adding 
nopales. Since this was a new food for several participants, it is possible that a greater 
shift took place in order to incorporate nopales into their habitual diet.  
The displacement of nutrients due to the addition of functional foods has not been 
extensively studied. This process may blunt the actual functional food metabolic 
responses or in some cases overestimate its effect size. For instance, the extent of soy 
protein health benefits has been contested as recent trials showed only a modest 
cholesterol-lowering effect of isoflavone supplementation compared to older trials. 
Jenkins et al. (200) has shown that the intrinsic cholesterol-lowering effects of soy 
protein contributed to a 4.3% LDL-c reduction while the displacement from the diet of 
saturated fat and cholesterol-rich foods contributed a 3.6 to 6% LDL-c reduction. Thus, 
extrinsic effects must also be considered when evaluating the effects of functional foods 
on metabolic responses. 
 
5.5 Limitations and Strengths  
There are some limitations to our study. It is possible that our study may have 
lacked statistical power to detect changes in outcomes of interest.  The sample size 
calculation estimated that at least 16 subjects would be necessary for this study to have 
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enough statistical power for detecting changes in total cholesterol. Recruitment was 
increased in order to assure that the minimum sample size was achieved. The sample size 
calculation was based on Frati-Munari et al. (26) study, the only study available about 
humans using nopales. It is possible that the effect size based on that study may have 
been overestimated because of its quasi-experimental design, it included participants with 
higher total- and LDL-c concentrations, and participants lost weight during the study. 
When using actual LDL-c changes from the present study to conduct a power analysis, 
the suggested sample size for having a statistical power (at a 0.05 significance level and 
power > 0.80) was 42 participants. The attrition rate (41%) was higher than anticipated 
(20%). In part, this was attributed to the participants dropping out of the study before 
starting the actual intervention.  However, since some participants dropped out because of 
their dislike of nopales, implementing a taste test during the recruitment phase may have 
helped exclude participants that disliked the test food. Although at least two weeks are 
necessary in order to observe lipoprotein metabolism changes (201), it is possible that 
greater effects would have been observed if the test food intake phases had been longer. A 
longer intervention time would have also provided information regarding the 
sustainability of adding nopales to a habitual diet. We relied on self-report data to 
estimate dietary intake using 3-day food records. This method has fewer problems with 
omission of foods compared to other methods since it does not rely on memory (202). 
However, estimating portion sizes can be a source of error and underestimation of energy 
intake has been reported (202). Improved dietary adherence and avoidance of nutrients 
displacement may have been achieved by providing the complete diet to participants. 
 80 
 
Although this approach would control participant’s energy and nutrients intake, it would 
also lose its applicability to free-living individuals and such studies are highly costly. 
The present study has a number of strengths worth discussing. The randomized 
crossover design allows each participant to serve as their own control, minimizing 
individual variation. In order to reduce treatment effect variability and the interference of 
external factors, participants were recruited based on the presence of moderately high 
LDL-c and were otherwise healthy. Study inclusion criteria were stringent. Participants 
were non-smoking, sedentary, with low habitual fruit and vegetable consumption and not 
taking drugs or supplements known to interfere with the study’s outcomes. Another 
strength from this study is that the participants’ body weight was maintained during the 
study, minimizing the effects of weight loss on the measured outcomes. Finally, extra 
care was taken to measure the lipids to provide accurate values. The LDL-c concentration 
was directly measured in plasma rather than using the Friedewald formula (203), which is 
known to underestimate LDL-c in the presence of increased triglyceride concentrations. 
Also, all lipids were measured in two separate days at the beginning and end of each 
phase to decrease the effect of day-to-day variability by about 3% (204).  
 
5.6 Future research 
The present study was conducted to evaluate the short-term effect of nopales 
consumption on cardiometabolic risk factors under free-living condition. Future research 
evaluating nopales should include a larger sample size and opt for a tightly controlled 
study design under metabolic conditions. In this approach it is possible to monitor 
participants more closely, assuring adherence to the diet and consistency throughout the 
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study.  This would allow a more accurate assessment of nopales’ intrinsic effects by 
ruling out the extrinsic effects of food displacement. In addition, a longer study duration 
of at least four weeks may be necessary to show greater changes in the lipoprotein 
profile.  
A decrease in energy intake was observed with the addition of both test foods to 
the diet. Vegetables are low energy density foods and a good source of fiber which may 
have caused an increase in satiety levels and a consequent shift in eating patterns. It 
would be interesting to evaluate changes in hormones that are related to satiety. For 
example, ghrelin is known to stimulate appetite, whereas other hormones, such as leptin, 
cholescystokinin (CCK), and peptide YY (PYY), are known to inhibit appetite. These 
biomarkers could help assess the satiating effects of foods provided as well as clarify 
food intake regulation (205).   
People spend most of their day in a postprandial state causing transient elevations 
in glucose and lipids that can lead to oxidative stress, inflammatory response and 
endothelial dysfunction. Studies have shown that increased postprandial triglycerides are 
associated with incident cardiovascular events and cardiovascular mortality (206-208). 
Previous studies only evaluated the effects of nopales and dehydrated prickly pear on 
postprandial glycemia (158, 191). Therefore, future studies should investigate the effects 
of isocaloric meals with and without nopales on postprandial lipemia.  
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CHAPTER 6 
CONCLUSION 
 
 Research assessing strategies to decrease CVD risk are in growing need as CVD 
continues to be the leading cause of morbidity and mortality among Americans. The 
present study was designed to evaluate the effects of adding nopales to a participant’s 
habitual diet on markers of cardiometabolic disease risk. This test food was selected 
based on its nutritional composition and purported hypocholesterolemic effects. Previous 
studies have shown that prickly pear pads and fruits can help reduce fasting and 
postprandial glucose, as well as fasting LDL-c. We elected prickly pear pads in its most 
common preparation (boiled) as this would better reflect how this vegetable is normally 
consumed, and results would be more applicable to the general population. The primary 
aim of the study was to evaluate the effects of nopales on lipoprotein metabolism as 
literature is scarce in this topic. To our knowledge, this is the first study to examine the 
effects of nopales on lipoprotein subfractions. In addition, two exploratory analyses were 
conducted in order to evaluate the effects of nopales on cardiometabolic risk factors and 
oxidative stress.  
 This study did not confirm the main hypothesis that nopales intake compared to 
control would improve the lipid profile of adults with moderate hypercholesterolemia. No 
significant treatment-by-time effect was observed for total cholesterol, LDL-c, HDL-c, 
triglycerides or any of the lipoprotein subfractions. In addition, the other cardiometabolic 
risk factors (glucose, insulin, HOMA, blood pressure, and CRP) and oxidative stress 
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(total antioxidant capacity, plasma vitamin C, oxidized LDL, and LDL oxidation) were 
not improved in the nopales phase compared to control. Reasons for the lack of the effect 
of nopales intake on the outcomes measured may be related to the study small sample 
size, treatment duration, lack of compliance to treatment, and the displacement of other 
foods. The latter is an area that deserves further attention as shifts in eating patterns due 
to the addition of function foods may have detrimental effects on health. More research is 
needed to better understand the effects of food displacement and the best strategies to 
introduce a new food to an individual’s habitual diet. Incorporating functional foods into 
a diet is appealing because one simple change may be able to mitigate disease risk and 
promote health. However, by modifying only one aspect of the diet modest improvements 
should be expected. Greater effects can be achieved by modifying the overall dietary 
pattern but long term compliance may be a challenge. 
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SCREENING FORM 
 
Screening ID#: ____________ Date of Phone Call: _____________ Recruiter: _____________ 
 
Recruiter: Obtain verbal consent to ask eligibility criteria questions by reading and asking 
the following: 
 
In order to determine whether you qualify or not for the study I need to ask a few questions about 
you and some general health information. This will take about 15 minutes. Can I ask these 
questions at this time? 
         YES   NO  
 
If YES, continue asking eligibility verification questions. 
If NO, inform participant that you cannot proceed and thank him/her for their time. (STOP) 
 
(Do not read) Participant’s gender:         
       MALE    FEMALE  
 
ELIGIBILITY VERIFICATION  
 
How old are you?  _______________ 
 
(Do not read) Is age between 18 and 70 years?    YES   NO  
 
Do you live in the Phoenix area?     YES  N NO  
 
If the answer to any of these questions is NO, read:    (STOP) 
 
At this point you do not qualify for this study.  Thank you very much for your time. 
 
If the answer to all of these questions is YES, continue. 
 
Are you afraid of needles or blood drawing?    YES   NO  
Do you faint when you have your blood drawn?    YES   NO  
Is it usually hard for medical personnel to draw your blood?  YES   NO  
 
If participant is a woman <50 y old please ask:  
 
Are you Pregnant?      YES   NO  
  Breastfeeding?      YES   NO  
 Are you planning to become pregnant in the next 3 months? YES   NO  
 
Are you following any of the following diets?  
 Vegan        YES   NO  
 Very low carbohydrate      YES   NO  
 Atkins        YES   NO  
 Are you following any other specific diet? What type? _______________________ 
 
(Do not read) Is this a restrictive diet?     YES   NO  
Recruiter: consider any extreme diet or any diet that restricts a major food group, except for 
regular vegetarian diets, as a restrictive diet.  
 
Do you eat 4 or more servings/day of fruits and vegetables  YES   NO  
 106 
 
Do you take supplements such as antioxidants, fiber or botanicals? YES   NO  
Do you exercise for 30 minutes or more a day, 5 times or more per week? YES  NO  
Are you allergic to LATEX, nopales, or cucumber?     YES  NO  
Has a doctor or health care provider ever told you that you have any of the following: 
  Heart disease? Diabetes? High blood pressure?     
  Kidney disease? Liver disease? Cancer ?       
  Hepatitis? Thyroid disease? HIV? Arthritis?     
         YES   NO  
 
Are you taking any of the following medications? 
  Cholesterol-lowering 
  Blood pressure 
  Diabetes or blood sugar control    YES   NO  
 
Has a doctor or health care provider ever told you that you have any other medical condition I did 
not mention?           
         YES   NO  
 
Are you enrolled in any other research study anywhere?    YES   NO  
 
If the answer to any of these questions is YES, read:   (STOP) 
 
At this point you do not qualify for this study.  Thank you very much for your time. 
 
 
Is patient eligible for screening?  YES   NO  (STOP) 
 
 
If YES, continue explaining the study procedures. 
 
Do you know your LDL cholesterol level? YES   NO   NOT SURE  
 
If yes, what is it? _____________ 
 
Will you be able to maintain your current diet and physical activity for a consecutive 7 weeks? 
YES   NO   NOT SURE  
 
Prior to starting the study we will ask you to attend a preliminary screening visit to verify you have 
moderately high cholesterol.  If you qualify for the study, you will be asked to provide written 
informed consent for all study-related procedures. You will be randomly assigned to 
supplementation for 16 days with 2 cups/day of nopales or 2 cups/day of cucumbers. After 2-3 
weeks of no intervention, you will receive the alternative treatment for an additional 16 days. We 
would then ask you to come for two study visits before and after each dietary intervention for a 
total of 8 visits, in which we will measure your height, weight, waist, blood pressure, and we will 
draw your blood. You will have to fast for 12 hours before your study visits. Before each visit we 
will ask you to keep record of your food intake for three days and to bring that information with 
you at the time of your appointment.  Are you willing to participate in this study?  
  YES   NO 
 
If YES, continue explaining the screening procedures. 
 
As part of this research study we will ask you to come to our ASU study site for a preliminary visit 
to explain the study to you, ask you to sign a screening procedures consent form and we will 
collect your blood draw (about 5 ml or 1 teaspoon) to check your blood cholesterol. You will need 
to fast for 12 hours prior to your study visit. This means you that you should not eat or drink 
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anything but water starting 12 hours before your appointment. This appointment will be scheduled 
early in the morning so that you can come before you have breakfast. We will give you a light 
snack after the blood draw. 
 
Which of the following would you prefer? 
 
 A. Meet first to sign the screening consent form and subsequently schedule your formal 
screening visit. 
Recruiter: Fill out A. and B. in the box below. 
 
 B. Consent now to fast prior to attending the screening visit at which I will sign the screening 
consent form before any other procedure takes place. 
Recruiter: Only fill out B. in the box below. 
 
Have you donated blood in the past 4 weeks?    YES   NO  
 
If YES, when?    
 _________________________________________ 
 
Recruiter: Schedule screening visit at least 4 weeks after the blood donation date. 
 
Where did you hear about this study? _________________________________________ 
 
 
 
A. Meeting to sign screening consent form date and time: ____________________________ 
 
B. Screening visit date and time: 
__________________________________________________ 
 
 
Recruiter: Read the following: 
Thank you for your time.  
 
LDL ELIGIBILITY 
 
Screening LDL-Cholesterol: ____________________________  
 
Is LDL-C ≥ 130 mg/dL? YES   NO (Ineligible participant)  
 
Is LDL-C ≥ 190 mg/dL? YES   NO   
 
If YES, refer to PCP for care.  Enroll only if participant refuses medication use or if based on prior 
use participant is intolerant to hypolipidemic medications. 
 
If NO, participant is eligible to participate.    Study ID: 
_______________ 
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ARIZONA STATE UNIVERSITY 
PREADMISSION SCREENING INFORMED CONSENT FORM 
 
The Effect Of Nopales (Opuntia Spp) On Lipoprotein Profile And Oxidative Stress 
Among Moderately Hypercholesterolemic Adults 
 
Principal Investigator:  Sonia Vega-López 
 
Co-Investigator:  Giselle Pereira Pignotti  
 
 
INTRODUCTION 
  
 The purpose of this form is to record the consent of those who agree to be involved in the 
screening process to assess your eligibility to participate in this research study. If you are found 
to be eligible you will be asked to sign a separate informed consent for the actual research study. 
 
RESEARCHERS 
  
 Dr. Sonia Vega-López, Assistant Professor, School of Nutrition and Health Promotion at 
Arizona State University and her co-investigators have invited your participation in a research 
study. 
 
STUDY PURPOSE 
 
 The overall purpose of the research is to determine the effects of eating nopales pads 
(cactus pads) and cucumber on factors that increase the risk for developing heart disease and 
diabetes among adults with moderately elevated blood cholesterol.  The purpose of the screening 
process is to find out if you are eligible to be part of the study. 
 
DESCRIPTION OF SCREENING PROCESS 
 
You have participated in some pre-screening procedures by answering a questionnaire about 
your health, medications and lifestyle either using a web-based survey (Survey Monkey) or via a 
telephone interview. Based on your responses, you may qualify for the study if your blood 
cholesterol is slightly high.  You have now been asked to participate in a preliminary blood draw 
screening to assess your blood cholesterol. If you have given verbal consent to come to the 
laboratory in a fasted state (no food for 12 hours; nothing but water to drink for the past 12 hours) 
for the blood draw screening, this blood draw will take place today.  If you have not given verbal 
consent to fast for this blood draw, or if you are not fasting, your screening visit will be scheduled 
once you sign this consent form. 
 
You will have 5 ml (about 1 teaspoon) of blood drawn from the vein in your arm to verify the 
presence of moderately high blood cholesterol (LDL- [“bad”] cholesterol ≥ 120 mg/dL). The results 
of the LDL-cholesterol test will be made available to you.  If your LDL-cholesterol is high (≥ 190 
mg/dL) you will be advised to contact your primary care provider for proper medical care for high 
cholesterol.  In this case, you will only be admitted to the study if after consulting with your 
primary care provider you do not want to take cholesterol lowering medications, or if in the past 
you have had side effects to those medications. 
If you agree to participate in the screening procedures to learn if you qualify for the study, the 
screening procedures will last for up to 1 hour and will involve a fasting blood draw at the ASU 
Downtown campus.  Approximately 120 people from the Phoenix area will be screened to 
participate in this study. 
 
 
RISKS 
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If you decide to participate in this screening visit, there is a small risk that you will feel 
uncomfortable from hunger, dizzy, or lightheaded due to fasting.  You may face a risk of bruising 
and discomfort, dizziness, and fainting associated with blood drawing.  However, this risk is small. 
The research team will minimize these risks by using trained personnel to draw your blood and by 
giving you a snack after the blood draw. 
 
BENEFITS  
  
 There are no direct benefits from participating in this screening process.  The results of 
this screening procedure may or may not qualify you to be admitted into the research study.  The 
results of the LDL-cholesterol test will be made available to you. 
 
NEW INFORMATION 
  
 If the researchers find new information during the study that would reasonably change 
your decision about participating, then they will provide this information to you. 
 
CONFIDENTIALITY 
  
 All information obtained in this study is strictly confidential unless disclosure is required 
by law.  Your name or identity will not be revealed. In order to maintain confidentiality of your 
records, Dr. Vega-López will code all the data and blood samples so that they do not contain any 
information that could identify you.  All confidential information will be kept in a locked filing 
cabinet in Dr. Vega-López' office or in a password-protected computer, and will only be available 
to members of the research team. All samples and study materials will be destroyed 10 years 
after the study has been completed or upon your withdrawal from the study. At this point, blood 
samples will be discarded and study-related documents will be shredded.  
 
WITHDRAWAL PRIVILEGE 
 
 Taking part in this research study is totally your choice. It is ok for you to say no. Even if 
you say yes now, you are free to say no later, and withdraw from the study at any time. You can 
decide to stop taking part in this study at any time for any reason. 
 
COSTS AND COMPENSATION 
 
 The researchers want your decision about participating in the screening process to be 
absolutely voluntary. There will be no monetary compensation for participating in the screening 
process. You will be offered a copy of the LDL-cholesterol exam. 
 
COMPENSATION FOR ILLNESS AND INJURY 
 
 If you agree to participate in the study, then your consent does not waive any of your 
legal rights. However, no funds have been set aside to compensate you in the event of injury.  
 
 
 
 
 
 
VOLUNTARY CONSENT 
 
 Any questions you have concerning the research study or your participation in the study, 
before or after your consent, will be answered by Dr. Vega-López, 500 N 3
rd
 ST, Phoenix, AZ 
85004; (602) 827-2268; sonia.vega.lopez@asu.edu . 
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 If you have questions about your rights as a subject/participant in this research, or is you 
feel you have been placed at risk, you can contact the Chair of the Humans Subjects Institutional 
Review Board, through the ASU Office of Research Integrity and Assurance, at (480) 965-6788. 
 
 This form explains the nature, demands, benefits and any risks of the project.  By signing 
this form you agree knowingly to assume any risks involved. Remember, your participation is 
voluntary.  You may choose not to participate or withdraw your consent and discontinue 
participation at any time without penalty or loss of benefit. In signing this consent form, you are 
not waiving any legal claims, rights, or remedies.  A copy of this consent form will be given 
(offered) to you.   
 
 
Your signature below indicates that you consent to participate in the above study 
 
 
 
 
___________________________ ___________________________ ____________ 
Subject's Signature   Printed Name    Date 
 
 
 
 
___________________________ _________________________________________       
Contact phone number                        E-mail 
 
 
INVESTIGATOR’S STATEMENT 
 
"I certify that I have explained to the above individual the nature and purpose, the potential 
benefits and possible risks associated with participation in this research study, have answered 
any questions that have been raised, and have witnessed the above signature. These elements 
of Informed Consent conform to the Assurance given by Arizona State University to the Office for 
Human Research Protections to protect the rights of human subjects. I have provided the 
subject/participant a copy of this signed consent document." 
 
 
 
 
Signature of Investigator______________________________________    Date_____________ 
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ARIZONA STATE UNIVERSITY 
FINAL STUDY INFORMED CONSENT FORM 
The Effect of Nopales (Opuntia Spp) on Lipoprotein Profile and Oxidative Stress among 
Moderately Hypercholesterolemic Adults 
 
Principal investigator: Sonia Vega-López 
Co-investigator:  Giselle Pereira Pignotti  
 
INTRODUCTION 
 The purposes of this form are to provide you (as a prospective research study participant) 
information that may affect your decision as to whether or not to participate in this research and to 
record the consent of those who agree to be involved in the study. You have participated in some 
screening procedures as outlined in the screening consent form.  You have now been invited to 
participate in the study, since you are in reasonable health and you qualify for the research study. 
 
RESEARCHERS 
 Dr. Sonia Vega-López, Assistant Professor, School of Nutrition and Health Promotion at 
Arizona State University and her co-investigators have invited your participation in a research 
study. 
 
STUDY PURPOSE 
 The purpose of the research is to determine the effects of eating nopales pads (cactus 
pads) and cucumber on factors that increase the risk for developing heart disease and diabetes 
among adults with moderately high blood cholesterol (LDL- [“bad”] cholesterol ≥ 120 mg/dL) but 
otherwise healthy. 
 
DESCRIPTION OF RESEARCH STUDY 
 If you decide to participate in this research study, it will involve a commitment of 
approximately seven weeks in which there will be two 16-day test phases. During these test 
phases you will be provided with either one of the test foods: nopales or cucumbers, and you will 
be asked to consume 2 cups/day of the test food (divided into two 1-cup daily doses with each of 
two main meals).  The order in which you consume the test foods will be assigned to you 
randomly (by chance, like a toss coin). There will be a 2 to 3 week break in between the two diet 
phases. All study procedures described below will be done for research purposes only. 
All test foods (nopales or cucumbers) will be provided to you by our study personnel. You 
will be asked to attend the study site twice per week to pick up the study during each intervention 
phase. The test foods (nopales and cucumber) will be purchased from a local produce distributor. 
The nopales will be cooked in our metabolic kitchen, and will be packed in sealable plastic bags 
containing the daily amount you will have to consume (2 cups each).  You will receive 3 to 4 bags 
every time you come to the study site to get your study foods.  When you are consuming 
cucumbers, you will get them whole in enough amount to provide the daily dose (2 cups), and you 
will be given detailed instructions for rinsing, chopping and measuring the appropriate amount of 
cucumbers (using a study provided measuring cup) for daily consumption.  You will have to keep 
all study foods (nopales or cucumbers) refrigerated and will have to refrain from sharing these 
foods with others.  You will also have to maintain your usual level of physical activity and usual 
diet throughout the research study period and to keep tally of servings of test foods per day. 
We will ask you to fill a 3-day food record form in which you will record everything that 
you eat and drink for three days (two weekdays and one weekend) before and during the last 
week of each testing phase. You will be asked to complete this questionnaire and bring it to the 
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next study visit. Our study personnel will be available to assist you if you have any questions or 
need help filling out the questionnaire.  
 
All testing will be completed during 2 separate days (A and B) at the beginning (days 1 
and 2) and 2 separate days at the end (days 15 and 16) of each intervention phase, for a total of 
8 test visits. All testing visits will involve a blood draw.  We need to draw your blood on 2 separate 
days so that we can average your blood lipid values (cholesterol and other fats) as they normally 
vary on a day-to-day basis. 
You will need to fast for 12 hours prior to your study visits. This means you that you 
should not eat or drink anything but water starting 12 hours before your appointment. This 
appointment will be scheduled early in the morning so that you can come before you have 
breakfast. We will give you a light snack after each blood draw. 
 
Test day A - You will be asked to use the restroom to empty your bladder after which 
measurements of height, weight and waist circumference will be taken 3 times.  You will be asked 
to sit down for a few minutes after which we will measure your blood pressure 3 times.  
We will collect a blood sample to measure your blood lipids (cholesterol and other fats), 
sugar, indicators of risk for heart disease and diabetes, indicators of how cholesterol and sugar 
are processed in your body, and indicators of inflammation, response to oxidation, and dietary 
quality.  The total amount of blood that we will draw will be 38 ml (about 3 tablespoons). 
We will store some of the blood we collect (15 ml or about 1 tablespoon) for the future 
measurement of additional markers of diabetes and heart disease risk, inflammation, response to 
oxidation, and dietary quality.  You will be given the option to decide whether you want us to store 
your blood for future use.  If you agree to have your blood stored for future use, you give us 
permission to share this blood with other investigators without notifying you.  No genetic analysis 
will be performed on any blood collected. 
During the first visit we will also measure your body composition by estimating the 
relative amounts of fat and lean tissue using an FDA-approved bone density measurement 
machine (Dual-Energy X-Ray Absorptiometry or DEXA).  For this, you will lie face up in the DEXA 
bed for 7 minutes while the DEXA arm passes over your entire body.  If you are a woman, we will 
ask you to provide a urine sample to conduct a pregnancy test in our laboratory prior to the DEXA 
measurement.  A negative test is required before the DEXA can take place.  If the pregnancy test 
shows a positive result, you will no longer be able to continue in the study, and will ask you to go 
to your regular health care provider for appropriate follow-up procedures.  
 
  Test day B – We will collect an additional blood sample (7 ml, about ½ tablespoon) to 
measure your blood lipids and account for how they vary on a day-to-day basis, and vitamin C.  
You will be asked to complete a survey with the help of an interviewer to ask information 
about any gastrointestinal discomfort, the acceptability of the test foods, and your satisfaction with 
the study.  On the first survey you will also be asked to give information about your 
sociodemographic characteristics. 
 
If you agree to be part of the study, then your participation will last for approximately 7 
weeks and will consist of 8 test visits to the Downtown campus of ASU, each lasting about 60 
min, and no more than 2 hours, plus biweekly visits to pick up your study foods during the test 
phases.  Each test visit will include a fasting blood draw.  Approximately 60 people from the 
Phoenix area will be participating in this study. 
RISKS 
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 If you decide to participate in this study, then you may face a risk of bruising and 
discomfort, dizziness and fainting associated with blood drawing.  However, this risk is small. 
There is also a small risk that you will feel uncomfortable from hunger, dizzy, or lightheaded due 
to fasting. The research team will minimize these risks by using trained personnel to draw your 
blood and by giving you a snack after the blood draw. 
You might experience mild discomfort during blood pressure testing as the cuff inflates. 
However, the risk is small, and discomfort will go away after the cuff is deflated. 
For the body composition measurement, you will be exposed to minimal radiation (1-4 
microSieverts) that is within an acceptable range as provided by the US FDA. The amount of 
radiation (1-4 microSieverts) that you would be exposed to is quite minimal.  For example, you 
would receive radiation exposure of approximately 30 to 40 microSieverts during a typical chest 
x-ray.  If you are a woman, you will be asked to provide a urine sample to conduct a pregnancy 
test before the DEXA to avoid fetus exposure to radiation. If a pregnancy test is positive, you will 
no longer be able to take part of the study.  There is a small risk that the pregnancy test will be 
negative when you are in fact pregnant (false negative; tests are 99% accurate), which could lead 
to radiation exposure to a fetus. 
There is no known risk of consuming two cups per day of nopales (cactus pads) or 
cucumber.  There is a small possibility of having an allergic reaction to the test foods.  Other 
possible side effects include nausea and headaches.  It is possible that you may experience 
increased stool volume and more frequent bowel movements associated with increased fiber 
intake. 
It is possible that study foods may spoil if they are not kept refrigerated.  As with most 
vegetables, there is a small risk of food poisoning if the test foods are not refrigerated, although 
this risk is smaller than that of foods becoming spoiled.  To minimize this risk, we will ask you to 
keep the test foods refrigerated, to pick up the test foods twice per week (so that you only have a 
small amount of foods at once), and to pick up the test foods closer to the time when you will be 
going home to ensure you can place them in the refrigerator promptly. 
As with any research, there is some possibility that you may be subject to risks that have 
not yet been identified.  There are no feasible alternative procedures available for this study.  You 
can ask your doctor for a health exam.  
 
BENEFITS  
 There are no direct benefits from participating in this study.  However, knowledge may be 
gained from your participation, which may benefit the health of others. You will be offered a copy 
of select results (e.g. serum lipids, blood pressure, weight status) from the beginning and end of 
treatment assessments.     
 
NEW INFORMATION 
 If the researchers find new information during the study that would reasonably change 
your decision about participating, then they will provide this information to you. 
 
CONFIDENTIALITY 
 All information obtained in this study is strictly confidential unless disclosure is required 
by law.  The results of this research study may be used in reports, presentations, and 
publications, but your name or identity will not be revealed. In order to maintain confidentiality of 
your records, Dr. Vega-López will code all the data and blood samples so that they do not contain 
any information that could identify you.  All confidential information will be kept in a locked filing 
cabinet in Dr. Vega-López' office or in a password-protected computer, and will only be available 
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to members of the research team.  All samples and study materials will be destroyed 10 years 
after the study has been completed or upon your withdrawal from the study. Blood samples will 
be discarded and study-related documents will be shredded.  
 
WITHDRAWAL PRIVILEGE 
Taking part in this research study is totally your choice. It is ok for you to say no. Even if 
you say yes now, you are free to say no later, and withdraw from the study at any time. You can 
decide to stop taking part in this study at any time for any reason.  
 
COSTS AND COMPENSATION 
 The researchers want your decision about participating in the study to be absolutely 
voluntary. Yet they recognize that your participation may pose some inconveniences due to the 
time needed to complete the research activities and because we will draw a blood sample from 
you in each visit. In order to compensate for your time and discomfort, you will receive a total of 
$100 in gift cards, a set of ear phones, and a pen drive for completing the entire study.  
 
You will receive compensation as follows:  
Visit 1 A - $15 
Visit 1 B - $10 
Visit 2 A - $15 
Visit 2 B - $10 and one set of ear phones 
Visit 3 A - $15 
Visit 3 B - $10 
Visit 4 A - $15 
Visit 4 B - $10 and one pen drive.  
 
COMPENSATION FOR ILLNESS AND INJURY 
 If you agree to participate in the study, then your consent does not waive any of your 
legal rights. However, no funds have been set aside to compensate you in the event of injury.  
 
VOLUNTARY CONSENT 
 Any questions you have concerning the research study or your participation in the study, 
before or after your consent, will be answered by Dr. Vega-López, 500 N 3
rd
 ST, Phoenix, AZ 
85004; (602) 827-2268; sonia.vega.lopez@asu.edu .  
 If you have questions about your rights as a subject/participant in this research, or if you 
feel you have been placed at risk, you can contact the Chair of the Humans Subjects Institutional 
Review Board, through the ASU Office of Research Integrity and Assurance, at (480) 965-6788. 
 This form explains the nature, demands, benefits and any risks of the project.  By signing 
this form you agree knowingly to assume any risks involved. Remember, your participation is 
voluntary.  You may choose not to participate or withdraw your consent and discontinue 
participation at any time without penalty or loss of benefit. In signing this consent form, you are 
not waiving any legal claims, rights, or remedies.  A copy of this consent form will be given 
(offered) to you.   
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Your signature below indicates that you consent to participate in the above study 
 
 
___________________________ ___________________________ ____________ 
Subject's Signature   Printed Name    Date 
 
 
___________________________ _________________________________________       
Contact phone number                        E-mail 
 
Your initials here indicate whether you give us permission to store 15 ml (1 tablespoon) of 
your blood for future use for the measurement of additional markers of diabetes and heart 
disease risk, inflammation, response to oxidation, and dietary quality. 
 
I  DO consent to have my blood stored for future analyses. 
 
I  DO NOT consent to have my blood stored for future analyses. ___________ 
          Subject’s initials 
 
INVESTIGATOR’S STATEMENT 
"I certify that I have explained to the above individual the nature and purpose, the potential 
benefits and possible risks associated with participation in this research study, have answered 
any questions that have been raised, and have witnessed the above signature. These elements 
of Informed Consent conform to the Assurance given by Arizona State University to the Office for 
Human Research Protections to protect the rights of human subjects. I have provided the 
subject/participant a copy of this signed consent document." 
 
 
Signature of Investigator______________________________________    Date_____________ 
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FOOD RECORD FORM 
 
 A food record form is used to record the amounts and types of foods you eat and drink 
each day. Please record your food intake for three random days (e.g. Tuesday, Thursday, 
Sunday, etc.), including one weekend day. In recording the foods/beverages you consume each 
day, try to be as precise as possible with the amounts and descriptions of each food/beverage 
consumed. 
 
 Attached you will find a blank food record form. Below are instructions for completing the 
form. 
 
 Record everything, forget nothing. Do not forget to write down everything that you eat and 
drink, including foods consumed for both meals and snacks. 
 Include condiments and oils used for cooking. 
 Be accurate with food descriptions. Write down clear descriptions of the food or beverage 
that you consume. In addition, it is important to mention how the food was prepared. For 
example: baked chicken, toasted wheat bread, boiled carrots. 
 Record the amount of food/beverage consumed. You can use household measures such 
as cups, tablespoons, teaspoons, etc., or weight and volume measures such as ounces, 
pounds, grams, etc. 
 Record everything immediately after eating. Carry the food record with you everywhere so 
that you don’t forget to write down anything you’ve eaten. 
 Ask the assistance of the person who prepared the food. The person who prepares your 
meals or snacks, if it is not yourself, may have better idea of what was in the food you ate 
than you do. 
 Include all supplements. Include vitamins, minerals, Tums, Fibercon, etc. 
 Use more than one form per day if needed. 
 
Example of a Food Record: 
 
Day of the week: Monday 
 
Place and Time Amount Portion 
Size 
Description of Foods and 
Beverages 
Brand 
Home 9:00 am 2 Large Eggs, scrambled N/A 
Home 9:00 am 1 teaspoon Canola oil Crisco 
Home 9:00 am 1 cup whole milk Hood 
Home 9:00 am 1 Large wheat bagel Lenders 
Home 9:00 am 2 slices baked ham Boar’s Head 
Home 9:00 am 1 ounce Cheddar cheese Stella 
  
 120 
 
FOOD RECORD FORM 
 
 
 Day of the week ________________________ Date __________________ 
 
Place and Time Amount  Portion Size Description of Foods and Beverages Brand 
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CALENDAR – EXPERIMENTAL FOODS 
 
Experimental Food:   Cactus Pads   Cucumber 
Place an “X” on the calendar for each day you ate 1 cup of the experimental food. If you forget to 
eat the experimental food, do not mark “X” in the calendar.  
 
JUL 
 
SUN MON TUE WED THUR FRI SAT 
 
 
 
 
1 
 
 
 
2 
 
 
 
 
3 
 
 
 
 
4 
 
 
 
5 
 
 
 
6 
 
 
 
7 
 
 
 
8 
 
 
 
9 
 
 
 
 
10 
 
 
 
 
11 
 
 
 
12 
 
 
 
13 
 
 
 
14 
 
 
 
15 
 
 
 
16 
 
 
 
 
17 
 
 
 
 
18 
 
 
 
19 
 
 
 
20 
 
 
 
21 
 
 
 
22 
 
 
 
23 
 
 
 
 
24 
 
 
 
 
25 
 
 
 
26 
 
 
 
27 
 
 
 
28 
 
 
 
29 
 
 
 
 
30 
 
 
 
31 
 
 
 
   
 
 
AUG 
 
SUN MON TUE WED THUR FRI SAT 
 
 
 
 
   1 
 
 
 
2 
 
 
 
 
3 
 
 
 
 
4 
 
 
 
5 
 
 
 
6 
 
 
 
7 
 
 
 
8 
 
 
 
9 
 
 
 
 
10 
 
 
 
 
11 
 
 
 
12 
 
 
 
13 
 
 
 
14 
 
 
 
15 
 
 
 
16 
 
 
 
 
17 
 
 
 
 
18 
 
 
 
19 
 
 
 
20 
 
 
 
21 
 
 
 
22 
 
 
 
23 
 
 
 
 
24 
 
 
 
 
25 
 
 
 
26 
 
 
 
27 
 
 
 
28 
 
 
 
29 
 
 
 
 
30 
 
 
 
31 
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GASTROINTESTINAL SYMPTOMS SURVEY 
 
 
Test food:   Nopales  Cucumber 
 Pre      Post 
Did you experience in the last 2 weeks: 
 None Mild  Moderat
e 
High Severe 
1. Abdominal pain      
2. Increased bowel 
movements 
     
3. Bloating      
4. Flatulence      
5. Fullness      
6. Increased liquids      
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ACCEPTABILITY AND SATISFACTION OF TEST FOOD SURVEY 
 
Test food:   Nopales  Cucumber  
    
 Excellent Good Satisfactory Needs 
Improvement 
Unsatisfactory 
1. Appearance      
2. Consistency / Texture      
3. Flavor      
4. Overall Satisfaction      
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INTERVIEW INFORMATION 
 
Study ID _____________________________________________    Date ________________ 
 
1) Interviewer name: ____________________________________     
 
 
SOCIODEMOGRAPHIC CHARACTERISTICS/ PERSONAL INFORMATION  
 
2) Gender:  1 Male  2Female  
 
 
3) How old are you? _________    
 
 
4) Do you identify yourself as any of the following?  
(Interviewer, please read the options) 
 
1 White  
2 Black  
3 Hispanic or Latino 
4 Native American 
77 Other (please specify):_______________________     
99 Refuse  
 
 
5) What is your current marital status?  (Interviewer, please read all options; make sure single 
means “never been married” ) 
 
1 Single/No partner             
2 Married  
3 Living together (not married)  
4 Separated  
5 Divorced  
6 Widowed  
77 Other, please specify: _____________ 
99 Refused                                                  
 
6) Are you currently working?  
 
1 Yes  2 No, go to question # 8 
 
7) Which of the following best describes your current employment status? 
 
1 Working full-time, 35 hours per week or more  
2 Working part-time, less than 35 hours per week  
Skip to question 9 
 
8) Which of the following best describes your current employment status? 
 
(Interviewer please read all options and check only one box.) 
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3 Unemployed or laid off and looking for work 
4 Unemployed and not looking for work  
5 Homemaker  
6 In school  
7 Retired  
8 Disabled, not able to work  
9 Other?  (Please specify):____________________ 
 
9) Including money from all salaries/work, government assistance and (if applicable) 
unemployment, what is the total amount of money your household receives PER MONTH?   
 
(Interviewer, if participant is not sure read all the options; make sure answer includes 
food stamps, alimony, and foster care)  
 
1 $0-1000  
2 $1001-2000 
3 $2001-3000 
 4 $3001-4000 
 5 >$4000 
77 Other amount, (specify) ____________ 
 88 DK  
 99 Refused  
 
10) Last grade you completed in school  
 
1 Less than 6
th
 grade  
2 Completed elementary school (6
th
 grade)  
3 Completed middle school (9
th
 grade)  
 4 Completed high school (12
th
 grade)  
 5 Some college  
 6 College graduate or higher  
77 Other, (specify) ____________ 
 88 DK  
 99 Refused  
 
 
11) Have you ever smoked cigarettes?  
 
1 Yes  2 No, go to question # 14 
 
12) Do you currently smoke cigarettes?  
 
1 Yes  2 No, go to question # 14 
 
13) How many cigarettes do you smoke per day? _________ 
 
 
 
 
 
 
 
Please indicate if any of your family members have been diagnosed with the following: 
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Chronic diseases 
 
Family members 
 
 
1Both parents 2Father/mother 3Sibling(s) 4Children 
14) Diabetes 
 
    
15) Heart disease 
 
    
16) Cancer 
 
    
17) High cholesterol 
 
    
18) High blood pressure 
 
    
 
 
DIETARY HABITS 
 
 
19) Are you usually the main person cooking the meals in your home?   
 
1 Yes   
2 No, Who does it?  _______________________________________ 
3 Share cooking with another person in household. Who? ________________________ 
99 Refused                                                                                                         
 
 
How often do you eat each of the main meals during a typical week? 
 
Meals 
 
During a typical week, how 
many times do you eat…? 
Where do you usually 
eat…? 
Reason for 
skipping… 
20) Breakfast 
 
   
21) Lunch 
 
   
22) Dinner 
 
   
 
 
23) Do you eat foods OR snacks between your meals? 
  
     1 Yes,       
     2  No 
99 Refused    
 
 
 
 
 
 
 
24) How often do you eat foods OR snacks between your meals? # times________ 
1 daily  
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2 weekly  
3 monthly  
4 yearly  
5 never  
99 Refused  
 
25) What type of foods do you usually eat between your meals? 
 
_______________________________________________________________________ 
 
_______________________________________________________________________ 
 
26) How often do you eat snacks in place of a main meal (such as breakfast, lunch and 
dinner)? 
1 Never  
2 Once a week  
3 Twice a week  
4 3 to 4 times per week  
5 5 or 6 times per week  
6 7 or more times per week  
99 Refused  
 
 
PHYSICAL ACTIVITY 
 
27) Select the option that best describes your on-the-job activities during the past year: 
 
1 I have no job or regular work 
  
2 I spent most of the day sitting or standing. When I was at work, I did such things as 
writing, typing, talking on the telephone, assembling small parts, or operating a machine 
that takes very little exertion or strength. If I drove a car or truck while at work, I did not lift 
or carry anything for more than a few minutes each day. 
  
3 I spent most of the day walking or using my hands and arms in work that required    
moderate exertion. When I was at work, I did such things as delivering mail, patrolling on 
guard duty, doing mechanical work on automobiles or other large machines, house 
painting, or operating a machine that requires some moderate-activity work of me. If I 
drove a truck or lift, my job required me to lift and carry things frequently. 
  
4 I spent most of the day lifting or carrying heavy objects or moving most of my body in 
some other way. When I was at work, I did such things as stacking cargo or inventory, 
handling parts or materials, or doing work like that of a carpenter who builds structures or 
a gardener who does most of the work without machines. 
  
5 I spent most of the day doing hard physical labor. When I was at work, I did such things 
as digging or chopping with heavy tools or carrying heavy loads (bricks, for example) to 
the place where they were to be used. If I drove a truck or operated equipment, my job 
also required me to do hard physical work most of the day with only short breaks. 
  
 
 
 
28) Select the option that best describes your leisure-time activities during the past year: 
 
 132 
 
1 Most of my leisure time was spent without very much physical activity. I mostly did things 
like watching television, reading, or playing cards. If I did anything else, it was likely to be 
light chores around the house or yard or some easy-going game like bowling or catch. 
Only occasionally, no more than once or twice a month, did I do anything more vigorous, 
like jogging, playing tennis, or active gardening. 
  
2 Weekdays, when I got home from work, I did few active things, but most weekends I was 
able to get outdoors for some light exercise—going for walks, playing a round of golf 
(without motorized carts), or doing some active chores around the house. 
 . 
3 Three times per week, on average, I engaged in some moderate activity, such as brisk 
walking or slow jogging, swimming, or riding a bike for 15–20 minutes or more, or I spent 
45 minutes to an hour or more doing moderately difficult chores, such as raking or 
washing windows, mowing the lawn or vacuuming, or playing games such a doubles 
tennis or basketball. 
 
4 During my leisure time over the past year, I engaged in a regular program of physical 
fitness involving some kind of heavy physical activity at least three times per week. 
Examples of heavy physical activity are jogging, running, or riding fast on a bicycle for 30 
minutes or more; heavy gardening or other chores for an hour or more; active games or 
sports such as handball or tennis for an hour or more; or a regular program involving 
calisthenics and jogging or the equivalent for 30 minute or more. 
 
5 Over the past year, I engaged in a regular program of physical fitness along the lines 
described in the last paragraph (I), but I did it almost daily—five or more times per week. 
 
END OF INTERVIEW 
 
Interviewer: Read… 
Thank you so much for your time.  
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1. Power Analysis based on Frati-Munari (1983) study  
 
[1] -- Tuesday, October 15, 2013 -- 11:55:09 
t tests - Means: Difference between two dependent means (matched pairs) 
Analysis: A priori: Compute required sample size  
Input: Tail(s) = Two 
 Effect size dz = 0.7750000 
 α err prob = 0.05 
 Power (1-β err prob) = 0.80 
Output: Noncentrality parameter δ = 3.1000000 
 Critical t = 2.1314495 
 Df = 15 
 Total sample size = 16 
 Actual power = 0.8255337 
 
2. Power analysis based on the current study effect size 
 
[1] -- Tuesday, October 15, 2013 -- 10:34:56 
t tests - Means: Difference between two dependent means (matched pairs) 
Analysis: A priori: Compute required sample size  
Input: Tail(s) = Two 
 Effect size dz = 0.4465102 
 α err prob = 0.05 
 Power (1-β err prob) = 0.80 
Output: Noncentrality parameter δ = 2.8937168 
 Critical t = 2.0195410 
 Df = 41 
 Total sample size = 42 
 Actual power = 0.8065830 
 
[2] -- Tuesday, October 15, 2013 -- 10:35:00 
t tests - Means: Difference between two dependent means (matched pairs) 
Analysis: A priori: Compute required sample size  
Input: Tail(s) = Two 
 Effect size dz = 0.4465102 
 α err prob = 0.05 
 Power (1-β err prob) = 0.85 
Output: Noncentrality parameter δ = 3.0611197 
 Critical t = 2.0128956 
 Df = 46 
 Total sample size = 47 
 Actual power = 0.8500538 
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[3] -- Tuesday, October 15, 2013 -- 10:35:04 
t tests - Means: Difference between two dependent means (matched pairs) 
Analysis: A priori: Compute required sample size  
Input: Tail(s) = Two 
 Effect size dz = 0.4465102 
 α err prob = 0.05 
 Power (1-β err prob) = 0.90 
Output: Noncentrality parameter δ = 3.3114083 
 Critical t = 2.0048793 
 Df = 54 
 Total sample size = 55 
 Actual power = 0.9018217 
 
[4] -- Tuesday, October 15, 2013 -- 10:35:07 
t tests - Means: Difference between two dependent means (matched pairs) 
Analysis: A priori: Compute required sample size  
Input: Tail(s) = Two 
 Effect size dz = 0.4465102 
 α err prob = 0.05 
 Power (1-β err prob) = 0.95 
Output: Noncentrality parameter δ = 3.6820174 
 Critical t = 1.9960084 
 Df = 67 
 Total sample size = 68 
 Actual power = 0.9524195 
 
[5] -- Tuesday, October 15, 2013 -- 10:35:10 
t tests - Means: Difference between two dependent means (matched pairs) 
Analysis: A priori: Compute required sample size  
Input: Tail(s) = Two 
 Effect size dz = 0.4465102 
 α err prob = 0.05 
 Power (1-β err prob) = 0.99 
Output: Noncentrality parameter δ = 4.3520431 
 Critical t = 1.9855234 
 Df = 94 
 Total sample size = 95 
 Actual power = 0.9905428 
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APPENDIX K 
ADDITIONAL RESULTS 
  
  
 
 1
3
7
 
Table 11. Effect of test food intake on cardiometabolic disease risk factorsa  
  Cucumber Phase   Nopales Phase   p-value 
  Pre Post % Change   Pre Post % Change   Treat
 b
 Time
 
 Int
 b
 
Weight (kg) 84.1 ± 12.9 84.6 ± 13.2 0.6 
 
84.2 ± 12.8 84.1 ± 12.8 -0.1 
 
0.671 0.366 0.155 
BMI (kg/m
2
) 
b
 30.9 ± 5.8 31.0 ± 5.8 0.3 
 
30.9 ± 5.7 30.8 ± 5.7 -0.3 
 
0.604 0.419 0.213 
Body Fat (%) 36.0 ± 9.4 36.1 ± 9.0 0.3 
 
36.0 ± 9.1 36.3 ± 9.2 0.8 
 
0.861 0.552 0.804 
WC (cm) 
b
 103.0 ± 11.8 102.6 ± 11.9 -0.4 
 
103.3 ± 12.1 102.0 ± 11.4 -1.3 
 
0.767 0.102 0.551 
BP (mm Hg) 
              Systolic 
c
 122.0 ± 13.1 120.0 ± 12.3 -1.6 
 
121.7 ± 12.3 119.3 ± 12.1 -2.0 
 
0.772 0.225 0.870 
   Diastolic 
c
 78.5 ± 10.8 77.2 ± 9.6 -1.7 
 
78.3 ± 11.9 79.2 ± 11.1 1.1 
 
0.742 0.847 0.568 
Lipids (mg/dL) 
              Total cholesterol 206.6 ± 25.3 208.4 ± 29.9 0.9 
 
204.4 ± 26.5 203.2 ± 24.7 -0.6 
 
0.372 0.909 0.463 
   HDL-c 
b
 44.2 ± 14.6 44.1 ± 16.4 -0.1 
 
43.4 ± 15.8 42.4 ± 14.7 -2.3 
 
0.258 0.542 0.665 
   LDL-c 
b
 145.3 ± 18.7 143.2 ± 27.9 -1.4 
 
141.5 ± 19.9 137.7 ± 18.4 -2.7 
 
0.310 0.253 0.767 
   Triglycerides 
c
 155.7 ± 94.3 187.9 ± 114.0 20.7 
 
177.3 ± 134.5 201.2 ± 124.8 13.5 
 
0.138 0.022 0.984 
   LDL-c/HDL-c 3.67 ± 1.39 3.73 ± 1.77 1.6  3.68 ± 1.40 3.62 ± 1.35 -1.6  0.586 0.941 0.514 
Glucose (mg/dL) 96.2 ± 8.7 98.9 ± 7.7 2.8 
 
97.1 ± 7.4 95.7 ± 9.3 -1.4 
 
0.164 0.649 0.227 
Insulin (uU/mL) 20.0 ± 8.6 21.6 ± 10.6 8.0 
 
19.8 ± 8.0 21.6 ± 9.8 9.1 
 
0.609 0.080 0.389 
HOMA 
b
 4.5 ± 2.1 5.3 ± 2.8 17.8 
 
4.8 ± 2.0 5.2 ± 2.6 8.3 
 
0.856 0.053 0.282 
hsCRP (mg/dL) 
b, c
 6.3 ± 6.4 5.3 ± 4.9 -15.9   5.6 ± 5.2 5.7 ± 5.0 1.8   0.763 0.970 0.741 
a 
n = 13. Untransformed data shown as mean ± SD.  Effects of treatment, time, or interactions were assessed using a repeated measures ANOVA;  
b 
Abbreviations: BMI – body mass index; WC – waist circumferences; BP – blood pressure; HDL-c – high density lipoprotein cholesterol; LDL-c – low 
density lipoprotein cholesterol; HOMA - homeostasis model assessment ; hsCRP – high sensitivity C-reactive protein; Treat – treatment; Int –
interaction;                         
c
 Log-transformed prior to analysis. 
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Table 12. Correlation of changes in dietary factors and changes in fating plasma lipids 
during nopales phase 
 
Change in total 
cholesterol 
Change in 
LDL 
Change in 
HDL 
Change in TG 
Change in  
Dietary intake 
r2 
p-
value 
r2 
p-
value 
r2 
p-
value 
r2 
p-
value 
Energy  -0.098 0.718 0.184 0.498 0.057 0.835 -0.222 0.408 
SFA -0.248 0.353 -0.248 0.353 0.065 0.811 0.018 0.946 
MUFA 0.151 0.576 0.075 0.782 0.548 0.028 0.000 0.999 
PUFA -0.118 0.663 -0.049 0.857 0.307 0.247 -0.242 0.366 
Soluble Fiber 0.286 0.282 0.405 0.120 -0.088 0.746 0.052 0.848 
 
 
Table 13. Correlation of changes in LDL-c, LDL baseline values, gastrointestinal 
symptoms and acceptability of test foods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Change in LDL 
Cucumber 
Change in LDL 
Nopales 
 Dietary intake r
2
 p-value r2 p-value 
Pre phase LDL  0.235 0.381 -0.283 0.298 
Increased bowel movements -0.190 0.481 0.258 0.334 
Fullness 0.125 0.644 0.321 0.226 
Overall test food acceptability 0.048 0.859 -0.044 0.872 
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Figure 5. Changes in LDL-c ranked by changes in soluble fiber intake during nopales 
phase 
 
 
Change in Soluble Fiber Nopales Phase 
Change in LDL-c Nopales Phase 
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APPENDIX L 
DATA SHEETS 
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ID Gender 
Age 
(y) 
Ethnicity 
Marital 
Status 
Employment 
Status 
Monthly 
Income 
Education 
1 Female 55 White Single Working refused 
college or 
higher 
3 Male 29 White Single Working $0-$1000 
college or 
higher 
4 Female 29 Hispanic Single Working 
$1001-
$2000 
college or 
higher 
5 Male 32 White Married Working 
$3001-
$4000 
college or 
higher 
6 Female 40 Hispanic Single Not working refused some college 
9 Female 62 White Divorced Working 
$1001-
$2000 
college or 
higher 
10 Female 42 
White 
/Asian 
Married Working 
$1001-
$2000 
college or 
higher 
11 Female 46 Hispanic Widowed Working 
$1001-
$2000 
some college 
12 Female 68 Hispanic Married Working 
$3001-
$4000 
college or 
higher 
14 Female 64 White Single Not working 
$1001-
$2000 
some college 
16 Female 48 Hispanic Separated Working $0-$1000 
completed 
high school 
20 Female 48 Black Married Working >$4000 
college or 
higher 
21 Female 54 Asian 
Living 
together 
Not working 
Do not 
know 
completed 
middle school 
23 Male 66 White 
Living 
together 
Working 
$2001-
$3000 
some college 
25 Male 36 Hispanic Single Working 
$3001-
$4000 
college or 
higher 
26 Male 26 Hispanic Single Not working >$4000 some college 
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ID 
Pre Cucumber 
 
Weight 
(kg) 
BMI 
(kg/m2) 
Body Fat 
(%) 
WC 
(cm) 
SBP 
(mm Hg) 
DBP 
(mm Hg) 
 
1 68.7 25.1 30.7 80.3 105.0 64.0 
 
3 98.4 32.1 33.4 97.2 122.7 78.0 
 
4 98.5 40.2 48.2 110.5 116.0 88.0 
 
5 81.4 25.1 21.9 94.6 121.0 74.3 
 
6 82 30.7 43.6 110.6 116.0 77.7 
 
9 67.7 26.4 39.5 99.0 127.3 75.0 
 
10 107.1 40.6 48.6 118.5 141.0 104.7 
 
11 99.8 41.0 50.7 124.5 99.3 69.7 
 
12 91.5 35.9 45.9 104.9 126.3 77.0 
 
14 92.9 37.6 41 116.0 144.3 75.0 
 
16 65.3 26.6 35.1 94.3 119.0 72.3 
 
20 82.9 32.4 43.7 101.2 122.3 78.7 
 
21 64.1 26.3 27.6 83.1 119.3 74.0 
 
23 76.8 24.7 24.6 96.6 108.0 71.0 
 
25 87.6 27.7 23.9 103.5 129.7 87.7 
 
26 82.7 31.6 31.2 103.3 130.7 92.7 
 
BMI – body mass index; WC – waist circumference; SBP – systolic blood pressure; DBP – diastolic 
blood pressure 
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ID 
Post Cucumber 
 
Weight 
(kg) 
BMI 
(kg/m2) 
Body Fat 
(%) 
WC 
(cm) 
SBP 
(mm Hg) 
DBP 
(mm Hg) 
 
1 67.4 24.5 30.0 78.4 109.33 65.3 
 
3 99.1 32.4 33.2 96.8 123.00 77.7 
 
4 98.6 40.0 47.2 107.3 106.00 80.3 
 
5 81.2 25.1 22.2 96.1 117.67 69.3 
 
6 83.8 31.4 43.9 110.6 110.33 77.7 
 
9 66.9 26.0 37.8 96.9 128.00 73.0 
 
10 107.8 40.8 47.3 118.6 145.67 98.0 
 
11 100.6 41.3 50.6 123.7 94.67 71.7 
 
12 90.5 35.5 43.8 107.2 114.00 76.0 
 
14 91.8 37.2 41.6 114.5 128.33 76.0 
 
16 66.0 26.9 35.7 94.3 124.67 81.3 
 
20 82.7 32.3 43.4 104.7 115.33 73.0 
 
21 64.0 26.3 28.3 83.6 125.33 75.3 
 
23 78.6 25.3 30.5 97.9 112.33 69.0 
 
25 89.3 28.2 22.5 99.3 125.33 88.3 
 
26 84.1 32.1 30.8 101.8 126.00 91.3 
 
BMI – body mass index; WC – waist circumference; SBP – systolic blood pressure; DBP – diastolic 
blood pressure 
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ID 
Pre Nopales 
 
Weight 
(kg) 
BMI 
(kg/m2) 
Body Fat 
(%) 
WC 
(cm) 
SBP 
(mm Hg) 
DBP 
(mm Hg) 
 
1 67.8 24.7 33.3 78.3 110.0 63.3 
 
3 96.6 31.5 32.5 96.6 116.3 80.3 
 
4 97.2 39.6 47.6 112.1 116.7 83.3 
 
5 83.5 25.8 23.2 98.0 118.0 62.0 
 
6 85.7 32.1 43.7 111.2 113.0 80.0 
 
9 67.4 26.2 37.9 100.2 121.3 74.3 
 
10 107.2 40.6 47.8 119.8 150.0 104.3 
 
11 99.7 41.0 51.1 122.2 114.0 78.0 
 
12 89.0 34.9 43.9 105.1 119.3 74.0 
 
14 91.5 37.0 40.2 116.7 133.3 75.3 
 
16 65.3 26.6 35.1 94.2 120.0 75.0 
 
20 82.4 32.2 44.1 108.6 113.0 74.3 
 
21 63.6 26.1 28.3 82.3 129.3 76.7 
 
23 76.5 24.6 24.7 97.0 110.7 73.7 
 
25 89.1 28.1 23.8 100.3 121.3 77.7 
 
26 82.4 31.5 30.4 100.1 141.0 99.3 
 
BMI – body mass index; WC – waist circumference; SBP – systolic blood pressure; DBP – diastolic 
blood pressure 
  
 145 
 
 
ID 
Post Nopales 
 
Weight 
(kg) 
BMI 
(kg/m2) 
Body Fat 
(%) 
WC 
(cm) 
SBP 
(mm Hg) 
DBP 
(mm Hg) 
 
1 67.8 24.7 32.5 79.43 106.7 66.7 
 
3 97.3 31.8 32.8 95.53 123.0 78.3 
 
4 97.0 39.4 47.0 111.33 115.0 85.0 
 
5 81.5 25.2 23.7 98.27 116.0 71.7 
 
6 86.3 32.1 45.0 102.33 106.3 74.0 
 
9 67.4 26.2 37.5 101.00 126.0 72.7 
 
10 107.2 40.6 47.0 118.60 134.7 97.0 
 
11 98.4 40.4 51.8 125.30 95.7 71.0 
 
12 88.3 34.7 44.1 101.50 108.7 76.3 
 
14 92.1 37.3 43.5 110.77 120.7 67.0 
 
16 65.4 26.6 34.9 94.77 112.7 73.3 
 
20 82.9 32.4 43.1 100.00 129.0 84.3 
 
21 63.5 26.1 27.9 82.23 121.3 73.0 
 
23 76.3 24.5 24.6 96.67 117.0 82.0 
 
25 88.4 27.9 24.3 100.17 124.3 90.0 
 
26 82.6 31.6 30.6 103.33 139.3 101.0 
 
BMI – body mass index; WC – waist circumference; SBP – systolic blood pressure; DBP – diastolic 
blood pressure 
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ID 
Pre Cucumber 
 
TC 
(mg/dL) 
LDL-c 
(mg/dL) 
HDL-c 
(mg/dL) 
TG 
(mg/dL) 
Glucose 
(mg/dL) 
Insulin 
(uU/mL) 
HOMA 
CRP 
(mg/dL) 
 
1 197.3 139.2 64.5 43.9 87.0 7.3 1.6 0.9 
 
3 229.8 167.0 24.8 267.1 102.5 26.3 6.7 4.1 
 
4 163.0 103.6 40.3 186.3 126.5 37.6 11.8 4.2 
 
5 169.8 116.4 48.5 90.8 97.0 19.2 4.6 0.3 
 
6 169.0 120.5 24.0 193.4 103.0 23.5 6.0 11.4 
 
9 240.5 181.7 61.8 70.7 90.0 9.6 2.1 3.6 
 
10 211.8 150.0 42.5 199.2 111.0 28.8 7.9 6.1 
 
11 209.8 147.1 55.5 112.0 106.0 13.0 3.4 9.7 
 
12 169.8 112.4 48.0 104.3 103.5 18.8 4.8 1.9 
 
14 187.3 128.7 52.3 78.2 95.0 16.7 3.9 19.7 
 
16 210.5 151.2 35.0 215.3 88.5 18.6 4.1 2.1 
 
20 216.8 147.5 64.3 53.6 88.5 25.1 5.5 17.2 
 
21 181.8 111.4 63.8 87.8 85.5 11.1 2.4 0.2 
 
23 208.0 149.8 36.5 164.0 107.0 9.2 2.4 0.8 
 
25 251.8 161.9 30.8 367.8 87.0 13.1 2.8 2.9 
 
26 183.3 128.4 33.8 168.0 88.0 36.1 7.9 2.8 
 
TC – total cholesterol; LDL-c – low density lipoprotein cholesterol; HDL-c – high density lipoprotein 
cholesterol; TG – triglycerides; HOMA – homeostasis model assessment; CRP – c-reactive protein 
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ID 
Post Cucumber 
 
TC 
(mg/dL) 
LDL-c 
(mg/dL) 
HDL-c 
(mg/dL) 
TG 
(mg/dL) 
Glucose 
(mg/dL) 
Insulin 
(uU/mL) 
HOMA 
CRP 
(mg/dL) 
 
1 204.0 139.6 68.0 63.1 89.5 6.5 1.4 1.1 
 
3 257.8 193.8 23.5 311.0 102.0 29.8 7.5 3.4 
 
4 144.0 89.0 43.3 143.2 113.5 26.1 7.3 3.0 
 
5 154.0 84.5 39.0 226.3 88.5 23.1 5.0 1.2 
 
6 171.8 108.3 18.5 356.7 102.5 32.0 8.1 5.0 
 
9 230.5 171.7 59.3 51.5 94.0 9.6 2.2 2.3 
 
10 203.0 148.8 42.8 158.0 111.5 33.5 9.2 7.3 
 
11 218.5 146.2 67.3 123.6 105.5 20.7 5.4 10.8 
 
12 175.3 117.4 50.3 108.9 100.5 22.7 5.6 2.0 
 
14 205.3 142.2 55.8 96.7 97.0 18.2 4.4 14.6 
 
16 223.5 167.3 38.8 208.2 110.5 20.9 5.7 2.4 
 
20 223.0 155.8 60.5 53.1 88.5 21.7 4.8 14.8 
 
21 186.5 115.6 67.0 64.3 90.0 11.1 2.5 0.2 
 
23 185.5 131.3 33.0 195.7 101.5 10.3 2.6 1.4 
 
25 250.3 147.8 31.3 399.2 97.0 12.4 3.0 2.8 
 
26 182.8 124.5 35.3 200.0 97.5 42.6 10.3 2.4 
 
TC – total cholesterol; LDL-c – low density lipoprotein cholesterol; HDL-c – high density lipoprotein 
cholesterol; TG – triglycerides; HOMA – homeostasis model assessment; CRP – c-reactive protein   
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ID 
Pre Nopales 
 
TC 
(mg/dL) 
LDL-c 
(mg/dL) 
HDL-c 
(mg/dL) 
TG 
(mg/dL) 
Glucose 
(mg/dL) 
Insulin 
(uU/mL) 
HOMA 
CRP 
(mg/dL) 
 
1 187.8 130.3 59.3 45.1 86.5 8.1 1.7 0.8 
 
3 228.0 164.9 23.8 253.7 100.0 22.0 5.4 2.8 
 
4 165.3 106.5 47.5 159.1 126.0 27.5 8.6 2.3 
 
5 189.5 140.9 45.8 87.1 96.0 16.2 3.8 0.8 
 
6 163.8 113.5 21.3 252.3 101.0 24.3 6.1 8.7 
 
9 253.8 189.6 64.0 82.6 95.0 11.6 2.7 2.2 
 
10 193.5 144.5 40.5 133.1 99.0 33.4 8.2 7.3 
 
11 194.0 126.4 58.0 129.7 113.0 14.5 4.0 10.1 
 
12 175.8 113.3 53.3 95.7 95.0 22.7 5.3 2.1 
 
14 214.5 147.1 56.8 121.6 97.5 24.6 5.9 12.6 
 
16 213.5 154.3 35.8 215.1 106.0 21.5 5.6 3.2 
 
20 214.3 143.7 66.0 54.3 86.5 28.5 6.1 17.7 
 
21 189.5 115.6 71.8 73.5 90.0 9.4 2.1 0.2 
 
23 170.0 129.2 33.3 163.6 96.0 8.4 2.0 1.6 
 
25 242.3 126.1 28.0 559.4 88.5 15.9 3.5 3.2 
 
26 192.5 128.7 31.8 207.9 97.0 28.4 6.8 2.0 
 
TC – total cholesterol; LDL-c – low density lipoprotein cholesterol; HDL-c – high density lipoprotein 
cholesterol; TG – triglycerides; HOMA – homeostasis model assessment; CRP – c-reactive protein   
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ID 
Post Nopales 
 
TC 
(mg/dL) 
LDL-c 
(mg/dL) 
HDL-c 
(mg/dL) 
TG 
(mg/dL) 
Glucose 
(mg/dL) 
Insulin 
(uU/mL) 
HOMA 
CRP 
(mg/dL) 
 
1 199.5 135.9 57.8 94.9 85.5 8.7 1.8 1.6 
 
3 244.8 155.4 22.3 421.9 100.5 32.3 8.0 2.6 
 
4 157.5 96.4 42.0 217.3 126.0 16.2 5.0 1.5 
 
5 185.3 134.2 46.0 100.6 88.5 16.1 3.5 0.6 
 
6 175.0 113.6 21.5 321.9 102.0 32.7 8.2 12.2 
 
9 235.3 179.0 58.3 81.3 90.0 11.7 2.6 2.2 
 
10 204.3 149.9 43.8 158.4 116.5 36.1 10.4 6.1 
 
11 208.3 142.3 49.5 150.2 103.5 22.6 5.8 7.6 
 
12 172.0 114.2 50.0 116.4 97.5 18.7 4.5 2.2 
 
14 202.8 137.0 62.0 99.8 96.0 21.1 5.0 13.7 
 
16 212.8 149.6 38.5 239.9 98.0 16.0 3.9 1.5 
 
20 199.3 131.2 61.0 73.1 81.0 22.2 4.4 12.7 
 
21 172.5 111.0 67.0 85.6 91.0 10.6 2.4 0.2 
 
23 159.5 118.2 30.5 174.7 98.0 10.4 2.5 0.5 
 
25 233.5 132.6 30.3 422.4 96.5 14.9 3.6 10.3 
 
26 182.0 111.8 30.3 276.3 88.0 35.8 7.8 2.1 
 
TC – total cholesterol; LDL-c – low density lipoprotein cholesterol; HDL-c – high density lipoprotein 
cholesterol; TG – triglycerides; HOMA – homeostasis model assessment; CRP – c-reactive protein 
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ID 
Pre Cucumber 
 
LDL 
size (Å) 
% C 
small 
LDL 
% C 
large 
LDL 
LDL 
pattern 
% HDL-c 
small 
HDL 
% HDL-c 
interm 
HDL 
% HDL-c 
large  
HDL 
 
1 270.0 2.7 35.4 A 11.2 41.8 47.0 
 
3 263.0 9.0 31.9 B 36.6 58.0 2.3 
 
4 267.0 2.7 31.4 intermed. 22.5 62.2 15.3 
 
5 273.0 0.0 34.0 A 15.6 50.0 34.4 
 
6 265.0 4.4 34.6 intermed. 25.3 59.3 15.4 
 
9 272.0 0.0 39.3 A 18.3 55.5 26.3 
 
10 267.0 3.2 33.4 intermed. 25.7 51.7 22.6 
 
11 267.0 2.9 39.1 intermed. 21.6 58.7 19.6 
 
12 271.0 0.0 28.7 A 16.2 54.6 29.2 
 
14 273.0 0.5 33.4 A 11.9 54.1 34.0 
 
16 262.0 9.3 29.8 B 33.3 48.4 18.3 
 
20 274.0 0.0 31.1 A 9.0 49.0 42.0 
 
21 272.0 0.0 30.0 A 10.9 50.0 39.1 
 
23 261.0 11.4 28.5 B 23.7 56.4 19.9 
 
25 258.0 13.4 23.0 B 32.9 57.6 9.4 
 
26 265.0 6.2 33.2 intermed. 32.3 53.6 14.1 
 
LDL – low density lipoprotein; C – cholesterol; HDL-c – high density lipoprotein cholesterol 
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ID 
Post Cucumber 
 
LDL 
size (Å) 
% C 
small 
LDL 
% C 
large 
LDL 
LDL 
pattern 
% HDL-c 
small 
HDL 
% HDL-c 
interm 
HDL 
% HDL-c 
large  
HDL 
 
1 270.0 1.2 36.8 A 8.9 42.8 48.3 
 
3 259.0 13.1 27.3 B 35.5 64.5 0.0 
 
4 270.0 1.2 30.6 A 23.4 56.4 20.2 
 
5 270.0 0.0 30.8 A 14.7 49.4 35.9 
 
6 265.0 3.5 28.7 intermed. 26.6 61.6 11.8 
 
9 273.0 0.0 39.5 A 18.7 53.9 27.4 
 
10 266.0 4.7 33.1 intermed. 26.9 51.7 21.4 
 
11 267.0 3.4 37.5 intermed. 27.5 54.2 18.3 
 
12 269.0 1.2 33.6 A 15.6 52.5 31.9 
 
14 272.0 0.6 34.2 A 12.1 55.2 32.7 
 
16 263.0 9.8 34.0 B 38.0 48.7 13.3 
 
20 273.0 0.0 35.2 A 9.5 51.5 39.0 
 
21 274.0 0.0 31.8 A 9.1 52.9 37.5 
 
23 259.0 13.0 24.5 B 29.9 53.6 16.6 
 
25 257.0 13.2 19.8 B 34.3 60.2 2.9 
 
26 265.0 6.2 28.9 B 30.4 57.5 12.0 
 
LDL – low density lipoprotein; C – cholesterol; HDL-c – high density lipoprotein cholesterol 
  
 152 
 
 
ID 
Pre Nopales 
 
LDL 
size (Å) 
% C 
small 
LDL 
% C 
large 
LDL 
LDL 
pattern 
% HDL-c 
small 
HDL 
% HDL-c 
interm 
HDL 
% HDL-c 
large  
HDL 
 
1 269.0 2.7 35.2 A 11.5 48.6 40.0 
 
3 262.0 8.3 27.7 B 28.4 64.0 5.6 
 
4 268.0 2.3 33.4 intermed. 23.3 62.3 14.4 
 
5 271.0 0.0 36.7 A 20.8 46.8 32.3 
 
6 264.0 5.5 32.1 B 29.3 58.8 11.9 
 
9 270.0 1.2 39.0 A 21.4 50.4 28.2 
 
10 268.0 1.8 35.8 A 26.3 52.9 20.8 
 
11 267.0 3.0 33.2 intermed. 23.4 57.6 19.0 
 
12 272.0 0.0 29.8 A 13.2 54.4 32.4 
 
14 271.0 1.0 31.9 A 15.1 53.7 31.2 
 
16 264.0 7.9 30.7 B 34.3 52.5 13.1 
 
20 274.0 0.0 30.3 A 8.9 45.5 45.6 
 
21 274.0 0.0 26.7 A 8.9 48.9 42.3 
 
23 265.0 6.7 29.6 B 20.1 52.7 27.2 
 
25 253.0 13.7 14.2 B 33.6 62.1 2.5 
 
26 264.0 6.7 26.9 B 31.4 55.3 13.3 
 
LDL – low density lipoprotein; C – cholesterol; HDL-c – high density lipoprotein cholesterol 
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ID 
Post Nopales 
 
LDL 
size (Å) 
% C 
small 
LDL 
% C 
large 
LDL 
LDL 
pattern 
% HDL-c 
small 
HDL 
% HDL-c 
interm 
HDL 
% HDL-c 
large  
HDL 
 
1 269.0 2.1 34.2 A 14.2 47.4 38.4 
 
3 256.0 16.3 23.8 B 34.3 60.2 3.1 
 
4 269.0 1.3 31.4 A 22.8 61.8 15.4 
 
5 272.0 0.0 35.7 A 20.8 46.1 33.1 
 
6 262.0 9.0 26.2 B 31.3 58.4 10.2 
 
9 270.0 1.0 43.9 A 22.9 53.1 24.0 
 
10 267.0 3.0 35.9 intermed. 27.5 52.6 19.9 
 
11 266.0 3.4 30.9 intermed. 26.3 58.7 15.0 
 
12 270.0 0.0 28.8 A 15.7 52.9 31.4 
 
14 273.0 0.0 34.1 A 14.6 56.6 28.9 
 
16 262.0 9.2 26.4 B 35.5 47.5 17.0 
 
20 273.0 0.0 31.5 A 11.9 50.9 37.2 
 
21 274.0 0.0 22.8 A 9.2 47.9 42.1 
 
23 260.0 12.0 25.7 B 20.6 55.0 24.4 
 
25 256.0 14.9 20.9 B 33.5 58.2 8.2 
 
26 265.0 5.6 27.3 B 36.5 54.2 9.3 
 
LDL – low density lipoprotein; C – cholesterol; HDL-c – high density lipoprotein cholesterol 
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ID 
Pre Cucumber 
 
Plasma 
Vitamin C 
(mg/dL) 
Total 
Antioxidant 
Capacity (mM) 
Oxidized LDL 
(U/L) 
Lag time 
(min) 
Oxidation Rate 
(mmol diene/mg 
LDL ptn * min) 
 
1 1.96 0.81 61.20 224.00 13.25 
 
3 1.17 1.06 103.12 162.00 11.05 
 
4 0.71 0.87 60.54   
 
5 1.38 0.86 72.12 229.00 10.50 
 
6 1.20 1.02 85.93 208.00 8.95 
 
9 1.58 1.05 83.74 259.00 12.35 
 
10 0.59 0.91 105.51 198.00 9.95 
 
11 0.70 0.69 88.29 175.00 14.55 
 
12 1.17 0.88 61.94 234.00 5.50 
 
14 1.95 0.91 62.15 189.00 7.65 
 
16 1.22 1.79 122.77 174.00 14.55 
 
20 0.97 1.10 71.02 174.00 12.80 
 
21 1.28 1.82 49.88 292.00 10.25 
 
23 1.05 1.48 98.75 185.00 13.95 
 
25 1.22 2.06 124.67 158.00 9.15 
 
26 0.49 1.18 79.25   
 
LDL – low density lipoprotein; ptn - protein 
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ID 
Post Cucumber 
 
Plasma 
Vitamin C 
(mg/dL) 
Total 
Antioxidant 
Capacity (mM) 
Oxidized LDL 
(U/L) 
Lag time 
(min) 
Oxidation Rate 
(mmol diene/mg 
LDL ptn * min) 
 
1 2.10 0.96 66.96 222.00 12.75 
 
3 0.88 0.95 119.02 157.00 11.20 
 
4 0.84 1.09 48.76 287.00 9.30 
 
5 0.85 0.81 58.50 174.00 8.25 
 
6 1.26 1.11 89.65 201.00 11.85 
 
9 1.71 1.24 82.22 228.00 9.65 
 
10 0.59 1.19 93.20 186.00 11.50 
 
11 1.45 0.71 88.33 163.00 15.65 
 
12 1.55 0.96 58.62 239.00 8.40 
 
14 1.72 1.00 72.62 189.00 9.25 
 
16 1.25 1.57 114.68 185.00 13.90 
 
20 0.95 1.12 76.58 197.00 8.80 
 
21 1.30 1.43 54.50 192.00 10.95 
 
23 1.20 1.37 91.14 192.00 12.00 
 
25 1.02 1.99 109.87 192.00 10.40 
 
26 0.66 1.16 79.58 339.00 12.25 
 
LDL – low density lipoprotein; ptn - protein 
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ID 
Pre Nopales 
 
Plasma 
Vitamin C 
(mg/dL) 
Total 
Antioxidant 
Capacity (mM) 
Oxidized LDL 
(U/L) 
Lag time 
(min) 
Oxidation Rate 
(mmol diene/mg 
LDL ptn * min) 
 
1 1.85 0.99 67.84 205.00 9.25 
 
3 0.86 1.15 100.21 314.00 9.05 
 
4 0.79 0.96 55.58 214.00 15.70 
 
5 0.78 1.02 85.79 186.00 10.75 
 
6 1.09 0.93 79.15 226.00 10.80 
 
9 1.68 0.83 92.14 235.00 10.30 
 
10 0.62 1.13 90.68 202.00 12.35 
 
11 0.92 0.65 65.60 184.00 12.30 
 
12 1.34 0.81 62.48 209.00 6.75 
 
14 1.94 0.81 73.85 167.00 10.80 
 
16 1.27 1.60 117.00 164.00 15.10 
 
20 0.83 1.36 78.25 198.00 11.35 
 
21 1.41 1.76 52.22 230.00 10.90 
 
23 1.44 1.68 88.48 180.00 15.50 
 
25 1.11 1.73 99.22 196.00 11.80 
 
26 0.18 1.40 87.67 237.00 10.85 
 
LDL – low density lipoprotein; ptn - protein 
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ID 
Post Nopales 
 
Plasma 
Vitamin C 
(mg/dL) 
Total 
Antioxidant 
Capacity (mM) 
Oxidized LDL 
(U/L) 
Lag time 
(min) 
Oxidation Rate 
(mmol diene/mg 
LDL ptn * min) 
 
1 2.26 1.20 61.13 222.00 10.10 
 
3 0.91 1.55 103.26 349.00 10.55 
 
4 0.48 0.90 53.48 205.00 11.60 
 
5 1.07 1.34 88.78 184.00 12.35 
 
6 1.42 0.94 84.07 215.00 9.00 
 
9 1.38 0.88 100.84 229.00 14.80 
 
10 0.67 0.95 92.07 184.00 12.65 
 
11 1.30 1.07 77.67 135.00 12.35 
 
12 1.32 0.93 65.03 255.00 7.45 
 
14 1.54 0.99 74.28 188.00 10.45 
 
16 0.86 1.34 110.79 177.00 12.25 
 
20 0.77 1.43 63.12 232.00 10.95 
 
21 1.48 1.73 55.29 220.00 9.60 
 
23 1.05 1.60 84.60 183.00 13.60 
 
25 1.17 1.87 103.48 185.00 11.25 
 
26 0.58 1.39 77.73 312.00 12.50 
 
LDL – low density lipoprotein; ptn - protein 
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ID 
Pre Cucumber 
 
Total 
(g) 
Energy 
(kcal) 
Fat 
 (g) 
CHO 
(g) 
Ptn 
(g) 
SFA 
(g) 
MUFA 
(g) 
PUFA 
(g) 
Cholest 
(mg) 
 
1 1358 1076 51.2 104.5 57.7 12.5 20.1 14.7 131.4 
 
3 2431 2550 122.1 308.7 72.4 34.3 58.7 18.5 358.5 
 
4 1791 1348 55.3 164.3 53.0 19.7 18.3 12.0 160.5 
 
5 965 1384 51.2 185.8 56.3 17.3 17.5 12.9 67.6 
 
6 1443 1381 69.5 134.6 58.2 19.0 24.1 20.2 344.1 
 
9 3313 2181 106.9 245.0 81.9 29.9 46.9 22.4 148.2 
 
10 1161 1261 58.2 146.8 42.8 17.7 18.1 17.7 84.4 
 
11          
 
12 2551 1287 55.0 157.9 51.3 14.9 24.6 9.8 139.3 
 
14 1494 1774 74.5 196.5 84.3 21.0 26.1 20.7 368.4 
 
16 3488 1434 38.4 197.9 80.3 10.3 13.5 10.4 279.1 
 
20 2012 1798 67.7 235.1 71.0 22.6 20.2 19.5 273.0 
 
21 2237 1584 49.6 226.5 63.3 21.9 15.2 7.1 262.8 
 
23 3124 1860 45.5 283.8 92.5 12.1 16.7 13.6 131.2 
 
25 1997 2105 106.6 199.4 93.4 33.1 41.4 23.3 611.1 
 
26 4954 3179 136.7 366.7 138.7 47.8 48.3 29.2 373.5 
 
CHO – carbohydrate; Ptn – protein; SFA – saturated fatty acid; MUFA – monounsaturated fatty acid; 
PUFA – polyunsaturated fatty acid; Cholest – cholesterol 
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ID 
Post Cucumber 
 
Total 
(g) 
Energy 
(kcal) 
Fat 
 (g) 
CHO 
(g) 
Ptn 
(g) 
SFA 
(g) 
MUFA 
(g) 
PUFA 
(g) 
Cholest 
(mg) 
 
1 1592 1421 61.0 149.2 63.2 20.1 24.4 11.9 199.8 
 
3 1953 2062 82.6 260.1 82.9 25.0 23.2 27.6 234.9 
 
4 2225 1575 52.6 223.7 60.0 19.4 19.2 8.4 204.8 
 
5 918 1116 33.4 173.1 37.0 8.8 13.5 8.5 33.7 
 
6 1856 911 46.6 93.1 36.7 14.6 20.8 6.7 368.8 
 
9 2830 1479 60.6 185.7 64.2 15.3 21.9 18.6 250.7 
 
10 1079 1286 52.1 146.8 61.3 18.7 18.6 9.9 266.0 
 
11 2276 2491 127.4 167.5 166.3 53.0 46.3 16.0 681.7 
 
12 2749 1034 36.4 151.0 33.4 7.8 14.0 11.0 123.7 
 
14 1380 1208 52.4 135.1 51.6 18.9 19.4 8.5 453.5 
 
16 4369 1305 29.7 193.0 70.8 10.4 10.3 4.6 236.0 
 
20 2903 1944 54.5 290.7 88.9 14.7 19.1 16.2 151.5 
 
21 1946 1308 38.6 180.1 63.1 13.1 14.1 7.5 145.3 
 
23 3540 2307 69.1 362.0 77.7 18.8 19.1 25.1 130.1 
 
25 1573 1920 91.3 180.2 97.4 31.6 35.9 15.6 648.7 
 
26 4343 3152 150.6 335.3 119.4 44.6 59.3 35.5 590.5 
 
CHO – carbohydrate; Ptn – protein; SFA – saturated fatty acid; MUFA – monounsaturated fatty acid; 
PUFA – polyunsaturated fatty acid; Cholest - cholesterol 
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ID 
Pre Nopales 
 
Total 
(g) 
Energy 
(kcal) 
Fat 
 (g) 
CHO 
(g) 
Ptn 
(g) 
SFA 
(g) 
MUFA 
(g) 
PUFA 
(g) 
Cholest 
(mg) 
 
1 1938 1437 65.1 137.2 86.9 16.8 22.9 20.5 245.2 
 
3 1685 2452 134.0 215.6 98.3 49.9 54.0 21.2 618.4 
 
4 2195 1561 70.0 166.4 70.5 19.6 25.4 18.6 259.7 
 
5 4317 2066 88.1 246.0 89.0 29.0 31.4 20.7 242.4 
 
6 1934 1292 39.6 137.4 41.0 12.9 16.3 7.4 84.4 
 
9 2751 2202 113.3 213.6 80.8 34.9 46.2 23.2 326.5 
 
10 1923 930 37.9 100.9 46.4 12.8 12.8 7.6 320.5 
 
11 1741 2282 100.2 171.7 88.8 39.9 30.1 22.1 377.7 
 
12 2632 1125 48.4 120.8 52.0 12.8 21.4 9.4 308.0 
 
14 1187 1924 71.2 259.6 68.7 21.0 22.8 22.9 189.5 
 
16 3159 1237 31.7 179.7 64.6 8.7 9.9 10.0 157.4 
 
20 2506 1918 58.2 295.8 76.4 18.5 18.1 16.1 179.2 
 
21 1840 1655 73.5 161.7 90.2 21.7 24.6 20.5 443.2 
 
23 3740 2423 96.2 328.2 83.6 24.5 37.9 28.6 56.8 
 
25 1985 2018 96.7 187.8 103.8 34.7 35.9 16.9 596.0 
 
26 4289 3191 125.6 303.5 86.6 44.5 39.5 30.6 226.2 
 
CHO – carbohydrate; Ptn – protein; SFA – saturated fatty acid; MUFA – monounsaturated fatty acid; 
PUFA – polyunsaturated fatty acid; Cholest - cholesterol 
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ID 
Post Nopales 
 
Total 
(g) 
Energy 
(kcal) 
Fat 
 (g) 
CHO 
(g) 
Ptn 
(g) 
SFA 
(g) 
MUFA 
(g) 
PUFA 
(g) 
Cholest 
(mg) 
 
1 1778 1148 48.1 81.4 101.9 11.9 21.9 9.9 323.6 
 
3 1800 2499 112.2 253.8 119.8 48.2 41.3 12.8 456.7 
 
4 2699 1507 56.1 184.8 60.9 19.3 17.1 14.1 355.8 
 
5 845 1172 45.4 150.9 44.7 12.3 19.2 10.4 70.9 
 
6 1687 1135 57.8 128.6 35.7 15.8 27.8 10.3 79.3 
 
9 2477 2430 111.1 263.2 107.9 55.7 29.0 16.2 526.1 
 
10 740 776 32.8 76.0 45.8 12.0 11.4 5.5 320.8 
 
11 2836 1659 54.6 220.8 81.2 21.4 16.1 11.0 371.9 
 
12 2665 1203 48.7 140.4 50.1 12.8 18.9 13.0 350.9 
 
14 1412 1986 93.0 207.8 86.5 28.9 35.3 21.9 234.2 
 
16 4396 1294 45.4 160.2 66.9 12.6 17.6 11.2 223.8 
 
20 2139 2098 61.5 299.7 93.5 18.7 17.0 21.5 226.6 
 
21 2131 1748 52.7 235.7 85.8 19.9 18.9 8.6 321.1 
 
23 3024 1880 83.4 203.4 80.1 23.8 27.3 27.1 178.6 
 
25 2918 2206 67.1 243.8 90.7 22.3 23.5 16.0 297.2 
 
26 1266 1586 69.5 167.3 77.0 21.9 23.2 18.8 340.5 
 
CHO – carbohydrate; Ptn – protein; SFA – saturated fatty acid; MUFA – monounsaturated fatty acid; 
PUFA – polyunsaturated fatty acid; Cholest - cholesterol 
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ID 
Pre Cucumber 
 
Total 
Sugars
(g) 
Total 
Fiber 
(g) 
Sol. 
Fiber 
(g) 
Insol. 
Fiber 
(g) 
Vit E 
(mg) 
Vit C 
(mg) 
Vit A 
(µg) 
α-
carotene 
(µg)  
β-
carotene 
(µg) 
 
1 47.0 17.0 6.0 11.0 5.3 60.1 639.5 39.2 2531.4 
 
3 141.6 35.4 10.1 25.4 16.7 254.8 2100.1 1488.3 10097.5 
 
4 66.6 10.9 3.5 7.4 4.4 20.7 294.9 23.5 256.4 
 
5 62.9 20.2 4.6 15.6 5.2 68.7 917.3 1023.3 2573.2 
 
6 31.7 13.7 5.2 8.5 8.5 25.2 451.9 85.7 1602.0 
 
9 127.1 34.9 9.2 25.8 29.9 150.7 961.3 424.4 3312.1 
 
10 55.1 14.7 4.1 10.6 5.6 107.0 540.0 371.2 2238.5 
 
11          
 
12 65.6 22.6 7.9 14.7 5.2 99.0 547.1 338.2 2477.8 
 
14 112.3 13.4 3.0 10.3 8.2 105.6 1731.5 1339.7 8586.0 
 
16 101.9 13.7 4.5 9.2 5.8 183.5 938.3 202.7 3680.0 
 
20 99.1 13.7 4.6 9.2 8.6 92.7 1146.4 65.1 4939.9 
 
21 24.6 22.2 9.5 12.9 4.5 53.1 1300.6 1401.8 5378.6 
 
23 101.5 28.0 5.4 22.7 9.1 95.0 729.8 186.3 1647.7 
 
25 74.0 15.6 6.1 9.6 6.6 53.3 968.9 261.9 2327.7 
 
26 74.0 46.9 13.6 33.1 43.4 127.7 1290.5 44.9 4701.9 
 
Sol. – soluble; Insol. – insoluble; vit – vitamin;   
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ID 
Post Cucumber 
 
Total 
Sugars
(g) 
Total 
Fiber 
(g) 
Sol. 
Fiber 
(g) 
Insol. 
Fiber 
(g) 
Vit E 
(mg) 
Vit C 
(mg) 
Vit A 
(µg) 
α-
carotene 
(µg)  
β-
carotene 
(µg) 
 
1 59.8 20.6 6.1 14.5 8.8 66.4 879.9 43.4 3276.8 
 
3 124.5 24.1 6.5 17.3 11.4 138.0 627.9 150.8 1268.8 
 
4 114.4 16.0 4.5 11.5 5.0 67.3 806.6 55.0 1599.0 
 
5 55.7 16.1 5.1 11.0 6.2 53.9 590.2 75.5 570.0 
 
6 30.2 14.1 5.4 8.7 3.9 51.7 328.3 60.9 639.8 
 
9 80.9 24.0 5.5 18.5 15.7 111.2 958.9 374.5 2791.5 
 
10 40.5 12.8 3.7 9.0 4.6 72.2 853.2 50.8 2892.3 
 
11 55.2 16.0 6.0 9.9 5.4 74.1 2035.7 2875.0 8133.1 
 
12 74.9 17.4 4.7 12.8 4.6 205.7 912.3 413.8 4264.5 
 
14 94.2 8.1 2.7 5.4 4.2 109.1 913.3 53.9 2671.2 
 
16 99.4 16.0 4.6 11.2 4.3 141.6 1046.6 732.6 4087.6 
 
20 165.4 18.6 7.6 11.0 4.1 99.7 668.8 125.3 1879.8 
 
21 9.9 18.0 6.1 11.9 6.2 108.9 1526.6 1373.0 7655.7 
 
23 190.8 35.8 11.0 24.8 12.3 190.1 1281.9 282.1 4549.3 
 
25 64.6 12.4 5.0 7.4 3.8 31.0 1104.5 41.5 2435.9 
 
26 98.6 27.8 8.2 19.5 14.6 115.9 519.9 102.7 1026.5 
 
Sol. – soluble; Insol. – insoluble; vit – vitamin; 
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ID 
Pre Nopales 
 
Total 
Sugars
(g) 
Total 
Fiber 
(g) 
Sol. 
Fiber 
(g) 
Insol. 
Fiber 
(g) 
Vit E 
(mg) 
Vit C 
(mg) 
Vit A 
(µg) 
α-
carotene 
(µg)  
β-
carotene 
(µg) 
 
1 73.7 22.9 7.9 15.2 9.7 167.3 689.8 218.9 2350.6 
 
3 98.8 12.9 4.3 8.5 9.9 24.4 1283.9 757.0 3379.9 
 
4 33.5 17.2 5.6 11.6 7.1 21.7 217.5 60.9 351.9 
 
5 101.8 22.2 7.2 15.0 17.0 191.9 4186.8 736.9 21660.9 
 
6 40.0 16.6 6.0 10.5 4.9 47.2 561.8 650.4 1823.5 
 
9 91.0 26.0 7.2 18.8 16.3 97.3 1396.4 688.2 5467.3 
 
10 26.0 10.4 2.5 7.8 3.1 44.2 422.4 13.0 1091.0 
 
11 75.6 10.3 3.4 6.9 7.3 37.3 758.6 33.5 1929.0 
 
12 28.2 17.9 6.6 11.0 7.6 86.6 997.9 245.2 4615.6 
 
14 126.8 15.0 6.7 7.9 8.3 65.5 1962.4 71.4 6999.9 
 
16 85.7 16.4 4.6 10.9 5.8 131.0 792.4 636.3 3635.4 
 
20 167.9 35.0 12.5 21.8 9.4 164.7 793.1 281.2 3103.8 
 
21 34.5 20.9 5.8 15.1 12.4 197.3 2384.0 2234.9 11127.5 
 
23 142.5 43.9 13.8 29.7 16.3 365.3 1986.0 848.0 7912.9 
 
25 69.5 16.5 5.6 10.7 9.3 55.0 604.2 31.0 1314.8 
 
26 126.4 22.1 5.3 16.5 11.0 42.5 1367.3 177.7 3674.5 
 
Sol. – soluble; Insol. – insoluble; vit – vitamin; 
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ID 
Post Nopales 
 
Total 
Sugars
(g) 
Total 
Fiber 
(g) 
Sol. 
Fiber 
(g) 
Insol. 
Fiber 
(g) 
Vit E 
(mg) 
Vit C 
(mg) 
Vit A 
(µg) 
α-
carotene 
(µg)  
β-
carotene 
(µg) 
 
1 42.9 17.5 6.0 11.5 11.6 106.2 848.5 146.5 2656.6 
 
3 113.4 17.5 5.4 11.8 5.4 25.3 584.8 183.9 722.1 
 
4 64.3 21.3 7.6 13.7 6.2 37.5 635.5 206.7 1178.7 
 
5 60.3 11.2 3.4 7.8 5.2 61.7 546.1 383.5 1229.4 
 
6 49.1 19.2 7.6 11.6 8.6 283.5 674.5 361.6 2657.1 
 
9 123.5 29.6 9.4 20.4 14.8 64.2 1163.6 374.2 3161.8 
 
10 15.9 13.5 4.4 9.1 2.2 22.7 1637.6 3022.7 7169.6 
 
11 109.8 18.5 6.8 11.7 4.0 263.8 573.8 216.7 1234.3 
 
12 52.9 18.4 6.7 11.7 5.6 86.4 1099.8 320.4 4664.3 
 
14 147.2 13.9 5.4 8.3 5.0 70.1 1229.2 780.3 2323.8 
 
16 55.2 19.0 6.6 12.1 4.7 171.7 1276.8 1339.9 5887.3 
 
20 92.1 21.3 8.0 13.4 4.4 41.9 780.7 917.3 2721.0 
 
21 45.4 24.2 7.4 16.9 6.8 51.3 1408.4 240.6 6900.8 
 
23 56.2 29.0 8.8 20.2 10.7 160.6 1499.5 364.9 5998.2 
 
25 72.4 17.8 7.1 10.6 7.7 78.3 788.9 450.6 2201.3 
 
26 59.6 15.8 5.9 9.9 8.1 38.3 498.9 149.9 1124.7 
 
Sol. – soluble; Insol. – insoluble; vit – vitamin  
 
